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Abstract
The thesis focuses on characterisation of two different protein families, kinesins and ubiquitin
ligases, that are involved in different biological processes. Kinesins constitute a superfamily
of microtubule-based motor proteins, fulfilling important cellular functions, ranging from
intracellular transport to cell division. They also play a role in primary cilia and Hedgehog
signalling. Ubiquitin ligases are enzymes that catalyse the transfer of ubiquitin to the lysine
residues of the substrate. Marking protein substrates with ubiquitin alters their functions
and fates. With nearly 700 different ubiquitin ligases in humans, they control a vast array of
cellular processes.
The first part of this thesis summarises results relating to kinesins. Protocols for creation of
a panel of kinesin motor domains, a useful tool for anti-mitotic inhibitors specificity testing
are presented. Furthermore, biochemical, kinetic and structural features of a poorly described
kinesin motor protein — Kif15 are reported. Kif15’s motor domain structure is described and
compared to Eg5’s catalytic core. Moreover, the influence of Eg5 inhibitors on Kif15 ATPase
activity is investigated. Scouting for small molecules targeting Kif15 is also performed. Kif15
interaction with microtubules in various nucleotide-bound states is characterised. The possi-
bility of a secondary microtubule binding site in the tail of Kif15 is examined. The binding
of Kif15 with partner proteins is also investigated. Additionally the high-resolution structure
of the human Kif7 motor domain is presented, providing the first step towards structural
characterisation of this Kinesin-4 family member.
The second part of this thesis concerns a ubiquitin ligase, Trim28. Trim28 was first reported
as a transcription corepressor, working by recruiting proteins that drive the heterochromatin
state, whilst its mechanism of action as a ubiquitin ligase remains elusive. Attempts to crys-
tallise and determine the three-dimensional structure of Trim28 are described. Additionally,
Trim28 functioning as an E3 ubiquitin ligase, and its interactions with E2s, KRAB domains
of various zinc finger proteins and with the Mage-C2 protein are investigated. The results
provide the foundation for future studies on Trim28.
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Preface
This thesis comprises two distinct parts. The first concerns molecular motors — kinesins and
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Structural and biochemical insights
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Chapter 1
Introduction
1.1 Kinesin superfamily overview
Movements within cells, including transport of cellular components, muscle contraction and
cell division, are essential in eukaryotes. This is carried out by three families of molecular
motors: myosins, dyneins and kinesins (Figure 1.1) (Mallik and Gross, 2004).
Figure 1.1: Overall architecture of three molecular motor types. From left: kinesin, myosin
and dynein. All of them contain a catalytic site (green) followed by a stalk domain (blue).
Protrusions emanating from the dynein head provide the microtubule binding site (in the
case of the other motors, this is an integral part of the motor domain). The kinesin tail
(yellow) and associated peptides (pink) are also presented. Figure adapted from Woehlke
and Schliwa (2000).
In order to move, all cellular motors utilise specific cytoskeletal tracks — actin, in the case of
myosins, and microtubules, used by dyneins and kinesins. Microtubules (MTs) are biopoly-
mers of α and β-tubulin dimers, which exist in a state of “dynamic instability” — enabling
2
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them to rapidly switch from growing to shrinking phase. Tubulin heterodimers form linear
protofilaments in a GTP-dependent manner. In mammalian cells, thirteen protofilaments
create a cylinder with a diameter of 24 nm (Figure 1.2). MTs are polar entities due to the
“head to tail” tubulin dimer (α-β) linkage, and possess an α-monomer on the minus MT end
(slow growing), and β-tubulin on the plus end (fast growing) (Conde and Caceres, 2009).
 – end + end
24 nm
β-Tubulin
Tubulin dimer
γ-Tubulin
α-Tubulin
Figure 1.2: Structure of microtubules. Microtubules are polar biopolymers of α- and
β-tubulin dimers. Figure adapted from Conde and Caceres (2009).
The discovery of the kinesin superfamily was initiated following the observation of cellular
particle transport in the axoplasm extracted from the Loligo pealei squid (Allen et al., 1985).
This movement along the MT filaments was detected for organelles, beads and MTs (Vale
et al., 1985b). A 110–120 kDa translocation protein was identified and named kinesin, from
the Greek kinein — to move (Brady, 1985; Vale et al., 1985a). It had the ability to associate
with MTs in the presence of AMP-PNP, a non-hydrolysable ATP analogue. In addition it
was detected in solution only when ATP was present in the experimental setup (Vale et al.,
1985a).
Since conventional kinesin, the founding member of the kinesin superfamily was discovered,
several other representatives have been described. Originally they were divided into 3 groups
based on the position of the motor domain within their amino acid sequence. Kinesins with
the motor domain at the N-terminus, middle or C-terminus of the protein were named KinN,
KinI or KinC, respectively (Vale and Fletterick, 1997). The KinN family was then subdivided
into 12 families (Kinesin-1 to Kinesin-12) while KinI was renamed as Kinesin-13 and KinC as
Kinesin-14 family (Kinesin-14A and Kinesin-14B) (Figure 1.3) (Miki et al., 2005). These that
could not be classified into any family (some nematode kinesin-like proteins) were categorised
as orphan kinesins (Lawrence et al., 2004; Miki et al., 2001). A more robust analysis of kinesin
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sequences was possible with growing availability of complete eukaryotic genomes. This led to
identification of 17 kinesin families (Wickstead and Gull, 2006).
Figure 1.3: Phylogeny of human kinesins. Figure adapted from Hirokawa et al. (2009), Miki
et al. (2001).
1.1.1 Organisation of the kinesin molecule
A conventional kinesin consists of a heavy chain (KHC) dimer and two associated kinesin
light chains (KLC) that are involved in substrate recognition and binding. The heavy chain
comprises an N-terminal motor domain (MD) followed by an elongated stalk and a small,
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intrinsically disordered C-terminal tail domain (Figure 1.4) (Hirokawa et al., 1989; Seeger et
al., 2012; Yang et al., 1989).
 Neck
 Hinge
 Motor domains
Stalk domain
Tail domains
Figure 1.4: Overall structural design of conventional kinesin heavy chain. Figure adapted
from Woehlke and Schliwa (2000).
The motor domain is the catalytic core of the kinesin, comprising the ATP binding pocket and
the nucleotide-dependent MT binding site (Yang et al., 1989). This part is highly conserved
among kinesins and to an even higher degree within any single kinesin family (Miki et al.,
2005). Conservation of α and β secondary structure elements is prominent in motor domains,
with loop regions providing the distinct features of each kinesin family (e.g. loop L5 in Eg5,
K-loop in Kif1A) (Marx et al., 2009). The crystal structure of the human conventional kinesin,
Kif5B (Figure 1.5), revealed the overall fold of the motor domain — eight-stranded β-sheet
surrounded by six α-helices (Kull et al., 1996). This structural organisation strongly resembles
the core region of the myosin head fold, despite lacking amino acid sequence conservation.
Figure 1.5: Conventional kinesin catalytic core fold. Architecture of the conventional kinesin
catalytic core, presenting α-helices in teal, β-sheets in pink and loops in grey (PDB ID: 1BG2
(Kull et al., 1996)). Mg2`ADP is shown as a ball and stick model. Secondary structure
elements are labelled on the front or back-view of the motor domain.
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The Kif5B structure contained Mg2`ADP bound in the the P-loop (Walker motif (Walker et
al., 1982)), the short loop between β3 and α2 (stabilising the α- and β-phosphate of ADP).
The magnesium ion is vital for the stabilisation of the nucleotide and cannot be substituted
by any other cation (Cross, 2004). The globular motor domain is followed by the neck region,
containing a neck linker (two short β-strands) and a neck coiled-coil (Kozielski et al., 1997).
This region is implicated in the process of motor domain dimerisation of conventional kinesin
and is thought to play a key role in promoting kinesin movement and maintaining association
with MT tracks (Case et al., 2000; Grummt et al., 1998; Romberg et al., 1998). The neck
linker region is responsible for communicating subtle changes that occur in the motor domain
(depending on its nucleotide bound state) to the rest of the kinesin molecule (Woehlke and
Schliwa, 2000).
It has been noted that not all kinesins move in the same direction. Furthermore, this di-
rectionality is linked to the position of the motor domain in the primary sequence. Thus,
kinesins have been subdivided into three groups (Figure 1.6), N-type kinesins (KinN, Kinesin-
1 to Kinesin-12) that move in the plus-direction of the MTs and contain a motor domain
at the amino-end of the molecule and C-type kinesins (KinC, Kinesin-14A and Kinesin-14B)
moving towards the minus-end of the MTs, with a carboxy-terminal motor domain (Hirokawa
et al., 2009; Woehlke and Schliwa, 2000). The third group, M-type kinesins (KinI, Kinesin-
13), which unlike others, contain a motor in the middle of the polypeptide chain and do not
move directionally along MT tracks, instead these kinesins can depolymerise and modulate
the dynamics of MTs (Friel and Howard, 2011; Kobayashi et al., 2011).
N-type
C-type
M-type
Figure 1.6: Kinesin classification due to the motor domain position. Position of the kinesin
motor domain in its general architecture determines its mode of action and directionality.
Figure adapted from Hirokawa et al. (2009).
The conventional kinesin and ncd motor domain share a typical fold of kinesin catalytic core
(Figure 1.7). The structures of a dimeric conventional kinesin heavy chain (Kozielski et al.,
1997) and a representative C-type kinesin, Drosophila melanogaster ncd (minus-end directed
motor) (Figure 1.8) revealed differences in orientation of the neck linker of the conventional
kinesin and neck region of ncd with respect to the motor domains. Plus-end directed motors
dimerise through perpendicular positioned neck linkers. The ncd coiled-coil neck region stays
in close contact and aligns with the globular motor domain (Sablin et al., 1996). Deletion
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studies and investigation of chimeric constructs confirmed that the neck region is responsible
for motor directionality and the mode of movement (Case et al., 2000; Grummt et al., 1998;
Romberg et al., 1998).
Figure 1.7: Structure overlay of Kif5B and ncd motor domain. Front and back view of
overlaid Kif5B (beige) (PDB ID: 1BG2 (Kull et al., 1996)) and ncd (green) (PDB ID: 2NCD
(Sablin et al., 1996)) reveals similarity of their catalytic cores. Mg2`ADP is shown as a ball
and stick model.
Figure 1.8: Influence of neck region orientation on kinesin directionality. Differently oriented
neck region in the structures of rat conventional kinesin dimer (on the left) (PDB ID: 3KIN
(Kozielski et al., 1997)) and in ncd C-type motor (on the right) (PDB ID: 2NCD (Sablin et
al., 1996)). Neck linker of the conventional kinesin and neck region of ncd are highlighted
with red arrows.
Sequence conservation is not retained outside of the catalytic core of the kinesins. After the
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hinge region that connects the motor and neck linker with the rest of the kinesin body, there is
an elongated stalk with one or more regions with the potential of coiled-coil structure creation
that supports oligomerisation into dimers or higher oligomers. The conventional kinesin heavy
chain ends with a small tail domain that facilitates binding to cargoes (Figure 1.4) (Yang et
al., 1989).
Conventional kinesins perform their mode of action as tetramers with KHC and KLC ho-
modimers. The Kinesin-2 family works as heterotrimers (two complementary motors and an
auxiliary protein). Eg5, a member of Kinesin-5 family, has the ability to form homotetramers.
A representative of the Kinesin-3 subfamily, Kif1A, utilises the specialised K-loop to perform
movement as a monomeric motor (Okada and Hirokawa, 2000).
1.1.2 Mechanism of conventional kinesin movement
What makes kinesin not only an allosteric enzyme, but also a motor protein, is its processive
movement. This feature allows conventional kinesin dimers to perform over a hundred steps
before dissociating from MT. As kinesins are ATPases that convert the chemical energy
of ATP hydrolysis into mechanical movement, their speed depends on the rates of their
enzymatic turnover. The process of kinesin movement can be observed from two perspectives.
First, by looking into chemical kinetic events driven by the enzyme, and secondly, by looking
at structural changes occurring in the kinesin dimer, in relation to MTs, upon each of the
enzymatic steps (Woehlke and Schliwa, 2000).
The state of the motor domain can be referred to as open, closed or trapped, depending on
its nucleotide loading state. In the MT-free environment the majority of kinesins exist in the
ADP-bound state (trapped state). The ADP release is a rate-limiting step in ATP turnover.
ADP-bound kinesin motor domain possess low affinity for MTs. Binding to MTs changes
the motor domain conformation to open, stimulating rapid ADP release. This nucleotide
free state of kinesin (open) is stably bound to MTs. Once the nucleotide-binding site is free,
ATP binding causes the motor domain conformation to change from open to closed. The
kinetics of ADP and ATP binding is similar. The change from the open to closed state of
the motor domain upon ATP binding leads to structural changes in the catalytic core active
site. Two motor domain elements are rearranged when ATP is present in the active site:
the switch I element (SSRSH) and switch II element (DLAGSE). In the closed conformation,
they come together to create a salt bridge enabling γ-phosphate hydrolysis by positioning the
water molecule, crucial for the process. This was shown by Parke et al. (2009), in their Eg5-
AMPPNP structure. The γ-phosphate hydrolysis occurs in the closed state, with the kinesin
head attached to the MT and does not result in any structural changes in the motor domain.
However, γ-phosphate release returns the cycle to the open state. Kinesins can perform their
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catalytic action both in the presence and absence of MTs, although their presence speeds
up the process significantly (about 104 fold) (Cross, 2004). The cycle of kinesin enzymatic
turnover is summarised in Figure 1.9.
K -ADP
TRAPPED
D
MT+K +ATP
CLOSED
T
MT+K +ADP+P
CLOSED i
DP
MT+K +ADP
CLOSED
D
MT+K +ADP
OPEN
D
MT-K -ADP
TRAPPED
D
MT+K
OPEN
MT+K +ATP
OPEN
T
Figure 1.9: Influence of the nucleotide state of the motor domain on kinesin enzymatic
turnover. Kinesin enzymatic turnover in the various nucleotide states (D-ADP, T-ATP, Pi)
in the presence of MTs. Figure adapted from Cross (2004).
Kinesin movement cannot be considered independently of MTs. Although crystal structures
of the motor domains allow a detailed insight into the catalytic core fold, they do not pro-
vide information about the mechanism of kinesin movement, parts of the motor contacting
MTs and the secondary structure elements rearrangement during the enzymatic cycle. The
visualisation of kinesins and their tracks was possible by applying cryo-electron microscopy
(cryo-EM). The MT-interacting region of the kinesin is composed of helices α4, α5 and α6.
All of these helices are placed on the same side of the eight-stranded β-sheet. On the opposite
side, several loops (loop L7 — the P loop, loop 9 — switch I, loop 11 — switch II) create
the nucleotide-binding site. Binding of the MTs and the nucleotide leads to conformational
changes, which are further amplified and result in a neck linker movement. Once bound to
MTs, switch II helix (α4) is extended by an ordered part of loop L11. The presence of ATP
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causes helix α6 extension and consequently the neck linker docks onto the motor domain
(Sindelar and Downing, 2007). A recent crystal structure report of a kinesin motor domain
bound to tubulin dimer (Figure 1.10) stays in line with all cryo-EM data and allowed an
additional, atomic level insight into the interaction between the kinesin and MTs (Gigant et
al., 2013).
Figure 1.10: Overall structure of kinesin-tubulin complex (PDB ID: 4HNA (Gigant et al.,
2013)). The tubulin heterodimer is coloured in orange for α- and blue for β-tubulin. The
conventional kinesin is shown in green. Part of the motor involved in the tubulin-heterodimer
binding (L8, β5a, α4, L12, α6) and the neck linker (ball and stick model) are coloured in red.
Mg2`ADP is shown in magenta as a ball and stick model.
The relative conformation between the motor domain and the neck linker can be linked
with the nucleotide bound in the active site of the catalytic core. The ADP-bound state is
associated with the neck linker in an undocked (disordered) position, whereas in the ATP-
bound state the neck linker is docked (ordered) to the motor domain. The shift between these
two locations creates a power stroke by switching from disordered to ordered conformation,
causing the whole motor domain to exert force and move forward (Figure 1.11) (Woehlke and
Schliwa, 2000). It is worth mentioning that the correlation between the neck linker position
and bound nucleotide is genuine only in the presence of MTs (Sindelar et al., 2002).
Although the exact model of how conventional kinesins processively move along MTs is still
not entirely understood, the asymmetric hand-over-hand is the most common and accepted
one (Figure 1.12). In this model, each kinesin head undergoes a different conformational
change as it moves forward and therefore the final motor domain conformation is different
from the initial one. The active domains that create dimer through their neck regions al-
ternately hydrolyse a single ATP molecule, causing one head to stay bound to the MT, and
the other to dissociate (Asbury et al., 2003). The sequential ADP release occurring in both
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ADP ATP
Figure 1.11: Diagram of differences in the kinesin motor domain in different nucleotide-bound
states in the presence of MTs. The ADP-bound state is correlated with the switch II cluster
(yellow) in the down position and an undocked neck linker (pink). ATP binding induces
switch II cluster to move upwards and allows neck linker docking onto the motor domain.
kinesin heads produces a “stepping” type of kinesin movement (Hackney, 1994). This type
of motion requires a head-to-head coordination, in order to keep the processivity, and this
type of communication has been termed as a “gating mechanism”, where the changes in one
motor domain enable the occurrence of the catalytic steps in the partner head (Gennerich
and Vale, 2009).
ADP
ADP
A B C
FED
ADP ADP ADP
ADP
ADP
ADPADPD·Pi
ATP ATP
ATPATP
ATP
ATP
β β β βα α α α α β β β βα α α α α β β β βα α α α α
β β β βα α α α αβ β β βα α α α αβ β β βα α α α α
Figure 1.12: Illustration of the hand-over-hand kinesin mechanism of movement. (A) One
of the kinesin dimer motor domains is stimulated by MTs, releases ADP, and binds ATP.
(B) ATP binding causes docking of the neck linker to the catalytic core of the kinesin, neck
docking generates the power stroke. (C) The ADP bound head is now presented in front of
the ATP bound one. (D) ATP is hydrolysed, Pi released, the ADP bound head exchanges
the nucleotide. (E) The second head undergoes a process analogous to the one described in
point B, the neck linker docks, the power stroke occurs. (F) Kinesin performs a second step,
analogous to the one in step C. Figure adapted from Toprak et al. (2009).
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1.1.3 Functions of kinesins
Kinesins fulfil a variety of functions within eukaryotic cells (summarised in Table 1.1). They
transport synaptic proteins, the Golgi apparatus, endoplasmic reticulum, endosomes, lyso-
somes and mitochondria, promote neuron polarity and elongation. They have also been
shown to participate in axonal and dendritic transport (Hirokawa et al., 2009; Seog et al.,
2004).
Kinesin family Function
Kinesin-1 Transport of vesicles, organelles and mRNA
Kinesin-2 Transport of vesicles, melanosomes, intraflagellar transport
Kinesin-3 Transport of vesicles
Kinesin-4 Positioning of chromosomes, intraflagellar transport
Kinesin-5 Organisation and separation of mitotic spindle
Kinesin-6 Assembly of spindle midzone and cytokinesis
Kinesin-7 Attachment of chromosomes and kinetochore
Kinesin-8 Congression of chromosomes
Kinesin-9 Intraflagellar transport
Kinesin-10 Positioning of chromosomes
Kinesin-11 Function poorly understood
Kinesin-12 Organisation and maintenance of mitotic spindle
Kinesin-13 Correction of kinetochore-MT errors
Kinesin-14A Organisation of spindle poles, transport
Kinesin-14B Organisation of spindle poles, transport
Table 1.1: Kinesin families and their functions (Verhey and Hammond, 2009).
Another scenario where kinesin activity is crucial is cilia formation. Primary cilia are a place
of various signalling events crucial for cellular homeostasis (Verhey et al., 2011). Proper
execution of mitosis also relies on kinesin activity. To date, sixteen human kinesins have
been implicated in various stages of cell division from bipolar spindle initiation, elongation
and maintenance, MT dynamic modulation, accommodating MT and kinetochore interac-
tion, regulating chromosome structure, dynamics and congression to cytokinesis (Rath and
Kozielski, 2012). Figure 1.13 (top) depicts kinesin function in cellular division. Figure 1.13
(bottom) shows specific functions fulfilled by different motors. Frequently a single kinesin
can perform multiple functions, e.g. in mitosis and in neuronal development or intracellular
transport (Kif2A (Hirokawa et al., 2009; Ishikawa et al., 2008), Kif4A and Kif4B (Martinez
et al., 2008; Zhu and Jiang, 2005), Eg5 (Blangy et al., 1995; Ferhat et al., 1998a), Kif15
(Boleti et al., 1996; Buster et al., 2003), Mklp1 (Ferhat et al., 1998b; Nislow et al., 1992)).
CHAPTER 1. INTRODUCTION 13
Figure 1.13: Kinesins in mitotic cell division. Top figure depicts kinesin functioning in cellular
division. The bottom one shows specific functions fulfilled by different motors. Adapted by
permission from Macmillan Publishers Ltd: [Marta Klejnot] (Rath and Kozielski, 2012),
copyright (2012).
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1.1.4 Regulation of kinesins
Kinesins possess control mechanisms allowing them to manage their activity and ensure en-
ergy efficiency. Although the process by which a kinesin switches on and off is not well
characterised, it is believed that the presence / absence of cargo induces an active or inhib-
ited state. Autoinhibition has been reported for Kinesin-1, Kinesin-2 and Kinesin-3 families
(Verhey and Hammond, 2009). The structure of the autoinhibited Drosophila melanogaster
Kinesin-1 dimer revealed a mechanism for this process, showing that a single tail peptide
binds between two dimer heads, stabilising the ADP bound conformation, and precluding
the advancement of the catalytic cycle (Kaan et al., 2011). The other question is how ki-
nesins are targeted to their zone of action, for example the bipolar spindle in the case of
mitosis. Phosphorylation has been implicated as a modification used in kinesin targeting
(Verhey and Hammond, 2009).
1.1.5 Kinesins as targets in anti-mitotic therapies
In order to successfully divide, the genome of the dividing cell has to be properly segregated
and separated. Since cancer cells divide rapidly, the mitotic spindle is an appealing drug
target. Several anti-proliferative drugs targeting MTs have been developed, like taxanes
(stabilising MTs) and vinca alkaloids (depolymerising MTs) (Rath and Kozielski, 2012).
These agents, though effective, have several drawbacks, mostly because MT polymers are not
exclusively vital in the process of cell division but also fulfil roles during neuronal transport
and other non-neuronal transport events. This type of treatment may lead to acute side
effects. Moreover, prolonged treatment leads to drug resistance (Miyamoto et al., 2003).
The requirement for kinesin activity in mitosis makes them attractive candidates as drug
targets that may circumvent problems associated with MT targeting drugs. The first selective
kinesin inhibitor was discovered in a phenotype-based screen scouting for small molecules
inhibiting the bipolar spindle assembly (Mayer et al., 1999). The identified compound did not
affect MT stability, but it specifically targeted Eg5 and led to the formation of monoastral
spindle (Figure 1.14). Based on this characteristic phenotype the compound was named
monastrol. This small molecule was then commonly used in various biochemical, functional
and mechanistic studies of Eg5 (Liu et al., 2011).
The 1.9 A˚ structure of Eg5-ADP plus monastrol complex provides insight into the inhibitor-
binding pocket (Figure 1.15) (Yan et al., 2004). The inhibitor-binding pocket is restricted by
helix α3, loop L5 and helix α2, with about 20 residues contributing to monastrol stabilisation.
Since its binding pocket is placed 12 A˚ away from the nucleotide-binding site, monastrol is
considered an ATP-noncompetitive inhibitor (Yan et al., 2004). The comparison of the
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Figure 1.14: Monastrol leads to formation of monoastral spindles in dividing cells. Two
pictures show the normal bipolar spindle of the control cells treated with DMSO (left) and
the monastrol treated cells with a rosette-like spindle morphology (right). From Mayer et al.
(1999). Reprinted with permission from AAAS.
Figure 1.15: Eg5-ADP in a complex with monastrol. The overall Eg5 structure (green) with
Mg2` (white ball), ADP and monastrol (balls and sticks: C — orange, N — blue, S — yellow,
O — red). The electron densities of ADP and monastrol are presented. Reprinted from Yan
et al. (2004). Copyright (2014), with permission from Elsevier.
native and monastrol-bound structure (Turner et al., 2001), several conformational changes
were detected. Starting from Arg112 (helix α2) and Tyr211 (helix α3) moving outwards,
to Trp127 (loop L5) that swings down from the solvent-exposed area (7 A˚) and forms a pi-
interaction with the Tyr211 ring (Figure 1.16). These changes in Eg5 conformation close the
entrance of the induced-fit binding pocket (Yan et al., 2004). Additionally the γ-phosphate
sensor (switch I) moves outward in the solvent exposed direction (6 A˚). Changes occur around
the inhibitor-binding pocket leading to the rearrangements of helix α4 and α5 (switch II, move
upwards) and the neck linker (docked, aligned with the motor domain) (Figure 1.17) (Yan et
al., 2004). The structural insight into the allosteric inhibitor-binding pocket of Eg5 enabled
structure-based drug design and development of others potent Eg5 inhibitors. Another kinesin
targeted in anti-mitotic therapies is CENPE. Several Eg5 and CENPE targeting drugs are
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currently undergoing testing in multiple phase I and II clinical trials (Rath and Kozielski,
2012).
Figure 1.16: A stereo view of the monastrol-binding pocket, before (red) and after (green)
monastrol binding to Eg5-ADP. Residues R119, W127 and Y211 are highlighted to emphasise
their movement upon inhibitor binding. Reprinted from Yan et al. (2004). Copyright (2014),
with permission from Elsevier.
Figure 1.17: Differences in switch I, switch II and neck linker regions upon monastrol binding.
Eg5 structures before and after inhibitor binding are coloured in red and green respectively.
The circled parts of the structure are magnified. Reprinted from Yan et al. (2004), Copyright
(2014), with permission from Elsevier.
1.2 Human mitotic kinesin — Kif15
Kif15 (KIF15, Hklp2, Kinesin-12 family) was first identified in the Xenopus laevis genome,
along with three other kinesin-like proteins, and has been named Xklp2 — Xenopus kinesin-
like protein 2 (Vernos et al., 1993). After Xklp2 was detected in the Xenopus system, ho-
mologous genes were detected in mice, though the architecture, or protein function was not
assigned in this case (Nakagawa et al., 1997).
The elucidated gene encodes a 159 kDa protein, comprising an N-terminal motor domain,
followed by a long stalk with several coiled-coil regions. The analysis of the Xklp2 sequence
revealed unusual feature of its C-terminal tail, which consists of coiled-coil (Figure 1.18).
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Figure 1.18: Probability of coiled-coil content in human Kif15 sequence. The plot was gen-
erated using COILS software. The program compares the query sequence with a database
of reported coiled-coils and assigns a similarity factor, which is then compared to the dis-
tribution of scores in globular and coiled-coil proteins. Finally, the probability of coiled-coil
formation is computed. Three lines correlate to the sequence fragment lengths that were used
when scanning the database (green — 14, blue — 21, red — 28 residues) (Lupas et al., 1991).
This feature makes the overall protein design resemble the topography of myosin II, rather
than that of a typical kinesin. It has also been pointed out that the stalk (500 amino acids)
shares about 20% sequence identity with myosin (Boleti et al., 1996). A typical consensus
phosphorylation site for Cdc2 in Xklp2 was found (Thr666), however unlike in other super-
family members, it is not located in the tail domain. Instead, it is situated in the stalk, in
the region where the coiled-coil is interrupted (Boleti et al., 1996). Phosphorylation of this
conserved motif in Eg5 (Thr927) is known to be responsible for its targeting to spindle MTs
in the mitotic prophase, and a loss of this modification causes a failure of Eg5 localisation
(Sawin and Mitchison, 1995). The role of this site in Kif15 has not been addressed yet,
though it is possible that it is analogous to this feature of Eg5. The C-terminal tail domain
was assigned as residues 1137–1387. Moreover the presence of a leucine zipper (four leucine
residues with six amino acids separating each of them, a common structural protein motif,
often involved in oligomerisation) was detected at the very end of the tail domain. Initial
protein characterisation revealed that the protein moves along MTs in the plus-end direction
with rather low velocity (3.2˘1.2 µm/min), therefore it is a slow kinesin (Boleti et al., 1996).
In comparison, conventional kinesin, considered as a fast motor protein, moves 10 to 60 times
faster (Woehlke and Schliwa, 2000).
MD Coiled Coil Tail
19 375 13881149Cdc2
Neck
Figure 1.19: Overall Kif15 architecture. The motor domain (MD) shown in green is fol-
lowed by a neck region and stalk domain with coiled-coil regions and a putative tail (blue).
The leucine zipper is presented in yellow. Residue numbering relates to the human Kif15
representative.
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Hklp2      -  59MAP L V P AI VFV I PPA A L L VL LGC T S TNGQSNQ SN G SGS G QN C S SSTSK R K R R RE E D E D E
KIF15      -  59MAP L V P AI VFV I PA A A L L VL ALGC S N TNSHSNQ SN G S G QS C S SQTK R K R R RE EDD EE D E
Xklp2      60 MPP P V PLP LP A AI VFV I PPV L V L L AL IGT G SN TQ C S GT TG G QG C T SSTTK K R RD EED E D E
KRP-180    -------- ---  49M L AA A AI VFV V P A AAF L V LP IS Q N S G S SH GQC TKK K K R R RE D E D E D D E D
KLP-18     ---------------------- ------ -  31M I V P A L AP LFV VVSQY CYG S G S S G GK R R R RE
Hklp2       119R K K KL P P F F VA V VFA VA IV M IFA F MHSN T T H TTQ S T S SC SGYNGT YGQTGSG T TE D D D E E
KIF15       119R K K KL P P FVF VA M VF VA IV M IFA F MHSN T Y G TTQ S ST S SC SGYNGT YGQTGSG T TD D D E E
Xklp2       120R K K K KL P P MF F VA V VF VA IV M IFA F MHS T H N TNQ S SS N SC NGYNGT YGQTGSG T TE D D E E
KRP-180     109IM P P VF V AA VF AV II V F IFA F MHS TY H T NTTQ S T G SC GG NGT YGQTGSG T TK K KR KE D E E
KLP-18   91   T T NGS Y HH SSSSQ GT C GYNGT YGQTGSG THTI L IF VF VA IV V VFA ME D E D ED ED EKR KK K
Hklp2      -  178M P F L VIP F LF LI A A FL FI I I LLG S S N SHN G S Y S G G S C CS YN Q YE D E D E E E E DR R R K K K K
KIF15      -  178M P F L VIP F LF LI A A FL FI V I LLG S S N SHN G S Y S G G S C CS YN Q YD D E D E E E E DR R R K K K K
Xklp2      -  179L P F L VIP F LFFLI A FL FI I IF LLG S S N THN G S Y N G G S C CS YN QE D E E E E E E DR R R K K K K
KRP-180     169L P F M VIP F LF LV FL FL I I LLG C G N HH G S Y S N HG Y C CS YN Q YED D E E E E D E E E DR R R R K R R
KLP-18     -- -  148L P W LM LIP V VF L A L F V V FV L VI LLG C S T Q G S H QH T CQ T S S YN YD D E E D E E E E DR K K K
Hklp2      238 D E E E ES S G Y H G G Q TS YQ SGG N STS N SS SHA A L L I VFVV AV VV AA A VL W VA M AR KK R RR R R
KIF15       238D E E E ES S G Y H G G Q S YQ S G N STS N SS SHA V L L I VFVV AV VVA AA A VL W VA M AR KK R R RR R R
Xklp2       239D E E E ES S G H G G Q TS YQ S G N STS N SS SHA A LFL I VFVV AV VV AA A VL M W VA M AR KK R RR R R
KRP-180     229D E D E E EPA L L L M VFV LI AVA A A VL A W VAA M AS G H N G G S S YG Q G HN TS N SS SHR KK R RR R R
KLP-18    - -  206 N N Q SG Q G S N N H Q G Q STGST N SS SHA V L I LV AL V PL LM LV W AM A AK K R K K K R RD D D D E E
Hklp2       298VF I I M IV I LL LV LA A M L A I L L VT T S SN N TS N GS Q TH G GN N S SC GQE E E D E D E EK R R K R K R
KIF15       298VF I I M AV I LL LV LA A M L A I L L VT T S SS N TS N GS Q TH G GN N S SC GQE E E D E D E EK R R K R K R
Xklp2       299VF V I M LV I L LV LA V L A I L L VT T S TN N SSQ N GS Q TQT G GS N S SC GQE E D D E D E EK R R K R K R
KRP-180     289VF V I A V I V L LV LA AI V L A I L IL VT S S G SN SQ H GS Q T G GS N S S GNE E D E D EK KK R R K K R K K
KLP-18      266LLII I LV IL LV LA L A I L VLR K R K R R K R K RTQ TG SS N GS QTHT SSG TN NSS T G CE E E D E D E
Hklp2      358 I ALV V V L FLL L A AIIA V P F L L FAT GNG Q H CY S T S GGN T N H GS C G T ST N QD D D EK R R K R K R
KIF15       358I ALV V V L FLL L A AIIA V P F L L FAT GNG Q H CY S T S GGN T N H GS C G T ST N QD D D EK R R K R K R
Xklp2       359I ALV VA I L FLL L A F IA V P F L L FAT NG Q H CY S T S GGN T Y N H GS C G T ST Q QD D D ER R R K R K K
KRP-180   349  IMALV IA VP L FLL L A IIA V P A F L L FAD D D D EHG Q H Y S S S GGN TY N H C G T STK R R K R K K K R
KLP-18     -  325I LLA P A VP L IL L AVIV M P FA LMFAR K K R K K RD D D D ES G H Y SH TH NS GGNS T N H Q SNST Q
Hklp2       376R K K KA LI AVVN N TQGNED
KIF15       376R K K KA LI AVVN N TQGNED
Xklp2      377 R K K KA LI AVVN N TQGNED
KRP-180     367R K K RA MI AVVN N TQGNED
KLP-18      343SCT N T N TGMIM IA VMR E D
Figure 1.20: Motor domain sequence alignment of Kif15 homologues. Human Hklp2 (Sueishi
et al., 2000), rat KIF15 (Buster et al., 2003), Xenopus laevis Xklp2 (Vernos et al., 1993), sea
urchin KRP180 (Rogers et al., 2000) and KLP-18 in Caenorhabditis elegans (Segbert et al.,
2003). The alignment was generated using the ClustalW2 multiple alignment tool (Larkin
et al., 2007). Small and hydrophobic residues are shown in red, acidic residues in blue and
basic residues are shown in magenta. Glycine and residues containing hydroxyl, sulfhydryl
or amine groups are shown in green.
In several proceeding studies, representatives of other Kif15 homologues have been described;
KRP180 in sea urchin (Rogers et al., 2000), Hklp2 in human (Sueishi et al., 2000), KIF15 in
rat (Buster et al., 2003) and KLP-18 in Caenorhabditis elegans (Segbert et al., 2003). All
of these share high sequence homology within the motor domain (50–60%), and contain a
rod-like stalk with a leucine zipper at the carboxy-terminus of the protein. The overall Kif15
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architecture is presented in Figure 1.19. The sequence alignment of Kif15 motor domain
homologues is shown in Figure 1.20.
The oligomeric state of the Kif15 protein was assessed by gel filtration and sucrose gradient
centrifugation which indicated that it forms dimers (Wittmann et al., 1998). Moreover the
experiments confirmed that the protein is asymmetric, as expected for such a long protein
with a predominant rod-like shaped domain. The dimeric state of the protein was also
established in case of KRP180 (Rogers et al., 2000) and rat KIF15 (Liu et al., 2011).
1.2.1 Kif15 cellular localisation, functions and partner proteins
In the original paper by Boleti et al. (1996) Xklp2 was implicated as a centrosome associated
protein that was mainly detected in dividing cells. Immunofluorescent staining performed
in the Xenopus egg extract revealed its centrosomal localisation, from prometaphase and
throughout mitotic cell division. In addition, a fraction of the protein could be detected on
the spindle MTs, especially in close proximity to spindle poles. A portion of the protein
could also be visualised in the cytoplasm in interphase. The centrosomal staining could not
be abolished upon MT depolymerisation: after nocodazole (a MT depolymerisation agent)
treatment of the Xenopus egg extract, Xklp2 staining was still visible on the centrosomes.
This led to the belief that Xklp2 can co-localise with centrosomes in a MT independent
manner. The effort to establish which part of the protein is in fact crucial for Xklp2 targeting
to MTs pointed to the critical role of the protein C-terminus. It has also been established
that, in order to perform movement, Xklp2 requires both N-terminal motor and C-terminals
tail domains. Protein localisation on the bipolar spindle was further investigated and Xklp2
was believed to be required for its formation and maintenance, as well as for initial centrosome
separation (Boleti et al., 1996).
This range of functions is highly similar to the role played in mitosis by Eg5. This kinesin is
able to link antiparallel MTs due to its homotetrameric structure, and by performing plus-
end directed movement, to slide them apart, and in doing so, to separate sister chromatids
(Saunders and Hoyt, 1992; Sawin et al., 1992). Obviously, Kif15 would have to employ
a somewhat different mechanism to promote spindle separation, because it does not have
the ability to form tetramers. The necessity of Kif15 activity for proper mitotic spindle
assembly and maintenance was initially somewhat controversial, pointing to its role in spindle
preservation and elongation rather than initiation (Walczak et al., 1998).
New light was shed on the mechanism of Xklp2 action when it was recognised that it does
not associate with centrosomes, and the centrosomal staining was due to Xklp2 presence
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on minus-end MTs. But how can a plus-end directed motor accumulate at the MT minus-
end? It has been shown that a cytoplasmic motor — dynein — can take part in Xklp2
localisation, together with the dynactin complex. Inhibition of dynein function (antibody
addition), caused Xklp2 dissociation from the MTs (Wittmann et al., 1998).
MD Coiled Coil Tail
19 375 1149 1388
Actin
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Ki-67
1017 1237 TPX2
1359 1388
Figure 1.21: Bar diagram of Kif15 and its putative partner proteins. Black bars represent re-
gions involved in the interactions. The numbering relates to human Kif15 residues. Colouring
is as for Figure 1.19.
Furthermore a novel protein was identified — TPX2 (Targeting protein for Xklp2) that
mediates the Xklp2 tail interaction with MTs. TPX2 is a highly basic 82.4 kDa MT-associated
protein (MAP) that is located to the mitotic spindle after nuclear envelope breakdown (NEB)
in a dynein-dynactin dependent manner (Wittmann et al., 2000). A human TPX2 homolog
has also been described (Heidebrecht et al., 2003). The interaction between Xklp2 and TPX2
occurs through the Xklp2 leucine zipper (Figure 1.21), and even a single amino acid mutation
in this region eradicates the ability of Xklp2 to bind MTs. Further analysis of the tail
domain unveiled the function of the N-terminal tail part in supporting protein dimerisation.
Occurrence of dimerisation seems to be important because of low endogenous Xklp2 affinity
to MTs observed in Xenopus egg extract (Boleti et al., 1996), and it is possible that creation
of a higher oligomeric state stabilises the interaction with MTs. Another interesting finding
was the fact that the Xklp2 tail and TPX2 do not seem to bind at all when MTs are absent
(Wittmann et al., 1998).
A similar cellular distribution could be observed for KRP180 in sea urchin, providing the
first verification of Kif15 motor action in vivo. Moreover, the experiments in this setting
further proved that KRP180 is not essential for primary events during mitosis, but it is
crucial for maintenance and elongation of an already initiated spindle (Rogers et al., 2000).
Additionally, a specific time point during mitosis has been pinpointed, when blocking KRP180
activity caused dramatic collapse of the spindles — just after NEB. This is in agreement with
the notion that this class of proteins is targeted to MTs by TPX2, which co-localises with
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MTs in NEB (Wittmann et al., 1998).
A separate study looked into KLP-18, a C. elegans homolog of Kif15, and its role in mitosis
and meiosis. Its mitotic localisation resembled these described previously. In addition Kif15
was enriched in the interzone throughout late anaphase and telophase. C. elegans meiotic
spindles lack centrosomes and KLP-18 was found to localise to the acentrosomal spindle. The
protein was detected on disorganised MTs and remained on them upon spindle polarisation,
concentrated mainly at the poles, but also between poles and chromosomes. Once cells entered
anaphase, KLP-18 was concentrated in the interzone. It has been shown that KLP-18 activity
is not essential in mitotic spindle centrosome dependent separation, but it is crucial for proper
MT sorting and spindle assembly in the acentrosomal setting (Segbert et al., 2003).
Human Kif15 was detected in rather striking circumstances. Two-hybrid screening in yeast,
utilising the forkhead-associated (FHA) domain of Ki-67 as bait, resulted in the pulling down
of a novel human kinesin-like protein that shared 53% amino acid identity with Xklp2 (Sueishi
et al., 2000).
Ki-67 is well known as a proliferation marker. It was first identified when Ki-67 antibody was
generated by injecting mice with nuclei of Hodgkin lymphoma cells. Ki-67 is very effective
as an indicator of cell division, because it is present during active stages of the cell cycle,
but absent when cells are in the resting period. Although its existence has been known for
30 years, the exact function of Ki-67 is still not clear (Scholzen and Gerdes, 2000), though
it has been implicated in the process of higher chromatin organisation and association with
chromosomes (Takagi et al., 1999; Verheijen et al., 1989). The best-characterised part of Ki-
67 is its N-terminal FHA domain. This is quite a common protein motif that has been shown
to specifically recognise phosphorylated threonine residues, which often triggers assembly of
protein complexes (Durocher and Jackson, 2002).
Interaction of Kif15 and Ki-67 led to the hypothesis that Kif15 can associate with chromo-
somes, through its interaction with the FHA domain. Regions required for interaction were
further narrowed to residues 1–99 of Ki-67 and residues 1017–1237 of Kif15 (Figure 1.21).
This interaction has been shown to occur both in yeast and in vitro, using recombinant
protein expressed in E. coli (Sueishi et al., 2000).
Examination of the cellular distribution of Kif15 revealed its association with centrosomes
at interphase, as shown in previous studies. In prometaphase and metaphase, Kif15 co-
localises to the spindle. A novel observation was that a pool of Kif15 was detected in the
equatorial region of the spindle. This localisation could not be abolished by depolymerisation
of MTs, which resulted in the creation of a punctuate staining pattern of Kif15 bound to the
chromosomes. These dots were in close proximity to centromeres although not centrally
on them. Furthermore, it has been shown that mitotic full-length Kif15 presented a lower
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electrophoresis velocity, than the one from interphase cells. It is tempting to assign this
feature to protein phosphorylation, though it has never been tested. This hypothesis is
appealing, as this could be a mechanism of protein modification that enables changes in its
localisation during a cell cycle (Sueishi et al., 2000).
Another study looked at KIF15 from a different angle. Buster et al. (2003) reported ex-
pression of KIF15 in rat post-mitotic neurons and its effect on neuronal migration. The rat
homologue of KIF15 shared all common features of this protein family, including N-terminal
motor and a rod-shaped C-terminal domain. Their study emphasised the presence of a
myosin tail homology domain in the stalk extending from amino acids 740 to 1333. Over-
all, the reported localisation in the mitotic cell for KIF15 stayed in line with all previous
reports. A novel reported compartment of KIF15 association was suggested, located on the
actomyosin ring upon cytokinesis and localisation with actin during interphase (Buster et
al., 2003). A similar distribution was reported once before in sea urchin, but it has not been
further investigated (Rogers et al., 2000). A closer look at the KIF15 mode of action in
neurons showed that they perform an analogous function to that observed in mitosis, sorting
and controlling MT movement (Buster et al., 2003). It has been further demonstrated that
removing KIF15 activity makes axonal growth over two times faster and affects proper growth
cone turning. Similar events occur after Eg5 depletion (Ferhat et al., 1998a). Nonetheless
there were several differences in neuron phenotype upon deletion of these proteins. Lack of
KIF15 caused a decrease in axonal branching while Eg5 activity elimination led to exactly the
opposite effect. Co-immunoprecipitation of KIF15 with actin confirmed possibility of their
co-localisation (Eg5 did not immunoprecipitate with actin) (Liu et al., 2011). Potentially,
KIF15 could utilise its myosin tail homology domain located in the coiled-coil to associate
with an actin-based motor and through this interaction contact actin (Figure 1.21), though
this theory has not yet been diligently investigated.
1.2.2 Kif15 activity and possible clinical implications
Kif15 exerts only a fraction of the forces important for bipolar spindle vitality and its func-
tioning is not necessary for spindle formation. Kif15 depleted cells can successfully execute
mitotic division, although it has been noted that without its activity the assembled spindles
are shorter (in comparison with control cells) (Vanneste et al., 2009). A different effect of
Kif15 loss was observed when it was tested in cells treated with monastrol (an Eg5 inhibitor
(Mayer et al., 1999)), in the context of inhibited Eg5 activity, where creation of monopolar
spindles rose to 95% from 61% in control cells. Subsequent monastrol washout caused cells
to recover 15% faster if Kif15 activity was present. The localisation of Kif15 and Eg5 dur-
ing metaphase has also been shown to differ. Eg5 was visualised mostly on spindle MTs in
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close proximity to the spindle poles, while Kif15 was enriched mostly in the central part of
the spindle, close to chromosomes. Also, the time of their association to MTs was different,
with Eg5 gathering around the centrosome at the origin of mitosis, and Kif15 appearing
on spindles after NEB. Cells with fully assembled spindles, blocked in the metaphase, did
not collapse upon Eg5 inhibition as long as Kif15 activity was retained. And when it was
depleted, monopolar spindle percentage rose dramatically. Additionally, overexpression of
Eg5 did not lead to any spindle defects, whilst Kif15 overexpression led to multipolar spindle
formation and major MT formation abnormalities. All this strongly points to a role for Kif15
in spindle elongation and maintenance (Vanneste et al., 2009).
A distinct Kif15 quality is its chromosomal localisation via interaction with Ki-67. The inter-
action has been further supported by the observation that Ki-67 silenced cells did not disrupt
Kif15 MT localisation but caused a chromosome association loss. Moreover, the spindles were
about 12% longer than these in control cells, showing that once Kif15-chromosome interaction
is blocked, it contributes more towards spindle elongation (Vanneste et al., 2009).
An independent study identified Kif15 as the motor protein responsible for the maintenance
of the bipolar spindle in metaphase from the pool of all human kinesins, utilising a siRNA
approach. This work led to conclusions similar to these of Vanneste et al. (2009), depicting
Kif15 as crucial for rapid spindle elongation, but not for its assembly. Also, the interaction
between TPX2 and Kif15 was verified in human cells. This study went one step further,
showing that overexpression of Kif15 can rescue formation of the spindle when Eg5 activity
is blocked by its inhibitor (Tanenbaum et al., 2009).
Overall, Kif15 and Eg5 seem to work together to assure bipolar spindle wellbeing. Co-
inhibition of both of Kif15 andf Eg5, might be of value from a clinical point of view. Especially
since it is suspected that Eg5 inhibition can be overcome by upregulating Kif15 expression
levels. A patent for Kif15 inhibitors was deposited in 2004 (McDonald et al., 2004), although
no biochemical or structural data were published since to validate these compounds as potent
Kif15 targeting drugs. Until now, knowledge about Kif15 deregulation in cancer or other
proliferative-related diseases is poor (Scanlan et al., 2001).
A more recent study showed that interfering with MT dynamics upon Eg5 inhibition enables
Kif15 to bypass the role of Eg5 in initial centrosome separation, to establish the bipolar
spindle, and progress successfully through mitosis (Florian and Mayer, 2011). This is in-
teresting, particularly in the context of targeting Eg5 and MTs in cancer treatment that
could be bypassed by employing an acentrosomal nucleation pathway (in a manner similar
to the one described in C. elegans meiosis (Segbert et al., 2003)). It is worth noting that
this effect varies depending on the MT-targeting drug deployed: it was observed when using
vinblastine, but not paclitaxel. These results emphasise the need for careful consideration
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when combining Eg5 and MT-targeting drugs (Florian and Mayer, 2011).
1.3 Kif7 and Kif27, Kinesin-4 family representatives
Human Kif7 and Kif27, members of the Kinesin-4 family (Katoh and Katoh, 2004a, b) are
paralogues, presenting the typical kinesin fold. Overall, they share 44% sequence identity,
and even more in the motor domains (61%).
1.3.1 Kif7 and Kif27 structural organisation
Kif7 and Kif27 possess an N-terminal, globular motor domain, containing a nucleotide binding
and MT-interacting region, followed by a stalk domain predicted to form a discontinuous
coiled-coil, and C-terminal tail domain (Figure 1.22).
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Figure 1.22: General architecture of Kif7 (top) and Kif27 (bottom). The globular motor
domain (MD, blue) is followed by the neck linker (violet), a stalk predicted to form a discon-
tinuous coiled-coil (red), followed by a C-terminal tail domain (grey).
Both proteins are orthologues of the Drosophila melanogaster kinesin-like protein called
Costal-2 (Cos2) that plays a key role in Hedgehog (Hh) signalling. The Hh ligands (Sonic
hedgehog — SHh, Indian hedgehog — IHh and Desert hedgehog — DHh) are glycoproteins
that have a crucial role during embryogenesis (Bijlsma et al., 2004) and tumorigenesis (Pasca
di Magliano and Hebrok, 2003). Their signals are transduced through the transmembrane
proteins Patched 1 (Ptch 1), Patched 2 (Ptch 2) and Smoothened (Smo). In the absence of
Hh proteins, Ptch family members suppress Smo activity, which becomes activated upon Hh
ligand binding to the Ptch protein. These events lead to the activation of the transcription
factors Gli 1, Gli 2 and Gli 3. The direct interaction of the MT-bound protein Cos2 with
Cubitus interruptus (Ci) in the cytoplasm is believed to be essential for its sequential phos-
phorylation by three distinct kinases: Protein Kinase A (PKA), Glycogen Synthase Kinase
β (GSKβ) and Casein Kinase 1 (CK1), and subsequent proteasome-dependent cleavage. The
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generated fragment, CiR, diffuses into the nucleus, where it corepresses Hh target genes (Tay
et al., 2005; Wang et al., 2000).
1.3.2 Kif7 and Kif27 role in primary cilia
Human Kif7 and Kif27 function in the primary cilium, a sensory organelle (Verhey et al.,
2011), where they have been shown to interact with Gli transcription factors, and are believed
to fulfil distinct functions in regulating Gli proteins. Kif7, a critical regulator of mammalian
Hh signalling, acts as both positive and negative regulator in the Hh signalling pathway, but
it performs this role differently from Cos2, as it does not interact with Smo or Fu (Endoh-
Yamagami et al., 2009). The current hypothesis suggests that Kif7 is a plus-end directed
motor, transporting Gli2 from the cilium, thus preventing its activation (Goetz and Anderson,
2012). In contrast, Kif27 interacts with Fu, which takes part in the construction of the
primary cilium (Wilson et al., 2009). Kif7 and Kif27 seem to work together in vertebrates to
fulfil the role of the single Cos2 gene in D. melanogaster. There are several reports describing
Kif7 mutant alleles in mouse embryos and their characterisation has highlighted the critical
role of Kif7 in primary cilium formation and Hh signalling (Cheung et al., 2009; Endoh-
Yamagami et al., 2009; Liem et al., 2009). One of these alleles carried a L130P mutation,
and caused the death of mouse embryos at the end of gestation.
1.3.3 Kif7 associated diseases
In humans, various Kif7 mutations have been linked to a range of neurodegenerative diseases
including Joubert (Dafinger et al., 2011), Hydrolethalus and Acrocallosal syndromes (Putoux
et al., 2011). In addition, since inappropriate activation of Hh signalling can lead to the
formation of medulloblastomas, rhabdomyosarcomas, basal carcinomas and other tumour
types (Goetz and Anderson, 2012), and given Kif7’s role in human primary cilium formations
and Hh signalling (Liem et al., 2009), Kif7 might also be linked to other diseases such as
cancer.
1.4 Objectives
The objectives of this project were:
– to create a kinesin motor domain expression panel;
– to obtain biochemical, kinetic and structural insight into a poorly described motor — Kif15;
– to structurally characterise Kinesin-4 family members.
Chapter 2
Materials and methods
2.1 Materials
cDNAs, codon-optimised for expression in E. coli, were purchased from GenScript. DTT,
glutathione, IPTG, imidazole, NaCl, Na-EGTA, MgCl2, meso-erythtritol, methanol, PIPES,
PMSF, primers for subcloning, taxol, TB medium, TBS-T, Tris-HCl and urea were bought
from Sigma. All restriction enzymes and Quick Ligase were purchased from New England
Biolabs. The accessories for the QiaCube robot, such as nickel columns and the HotStar
HiFidelity PCR kit were obtained from Qiagen. 1 and 5 ml HisTrap FF, 1 and 5 ml HiTrapQ
FF, 1 and 5 ml HiTrapSP FF, HiPrep 26/10 desalting, Superose 12, HiLoad Superdex S30,
HiLoad Superdex S75, HiLoad Superdex S200 columns and nickel beads were purchased from
GE Healthcare. A Vibra-Cell VCX 750 sonicator was purchased from Sonics & Materials,
Inc. GS-800 Calibrated Densitometer was purchased from Bio-Rad. Amicon Ultra-15 cen-
trifugal filter units were purchased from Millipore. Crystallisation screens were purchased
from Qiagen and Hampton Research. Crystallisation reagents, additives, detergents, dialysis
buttons and Fluorinert solution were purchased from Hampton Research. BL21(DE3)pLysS,
Rosetta-gami(DE3)pLysS and Origami 2(DE3)pLysS cells, Bug Buster and Benzonase nucle-
ase were bought from Novagen. NuPAGE system SDS-PAGE gels, WB membranes, running
and transfer buffers were obtained from Invitrogen. QuikChange kit, BL21-CodonPlus(DE3)-
RIPL and ArcticExpress cells were purchased from Agilent Technologies. 6xHis mAb-HRP
conjugate was bought from Clontech and BM Chemiluminescence Western Blotting Substrate
from Roche. All expression vectors were obtained from previous lab members. The proteins
were purified utilising A¨KTA purification systems from GE Healthcare. Bovine brains were
obtained from the University of Glasgow’s School of Veterinary Medicine. The Beatson Pro-
teomics group performed mass spectroscopy. Beatson Sequencing Services carried out DNA
sequencing.
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2.2 Kinesin expression panel methods
2.2.1 Subcloning into expression vectors
The protein sequences of the human kinesins were aligned with the motor domain sequence
of human Kif5B, for which the crystal structure is known (PDB ID: 1BG2), to define the
boundaries of the motor domain, using the ClustalW2 multiple alignment program from the
European Bioinformatics Institute (Larkin et al., 2007). Figure 2.1 present an exemplary
alignment of Kif5B, Kif6 and Kif9 motor domain sequences.
Kif5B - ------- ----  48    MA LA I VM F PL V IA F VVIA P AFD E E E D EDCN C N S N G Y QG T S YK R R R K K K
Kif3B   -  59 M L V VVV PM AA VV V V L V V P A MP F FS SS S C NG SY GQ S N GT H T TK K R R R K K K K K K KE E D D D E
Kif9     ---  57M V AFV V P FA MI I I L VV W F LGT Q T H YG N S H T G NNQQT SRKK R R K K KK RR KDD E ED D D D
Kif5B    108 D E D D E E D ER KK K K KVF V A IV VL IFA M L P M IIQSSTSQ Q YN C GYNGT YGQTSSG THT G H G G
Kif3B    119 D D E DE D E D EAV W A F L F PLV VL F IFA M I P VIY N Q Y T S QG NGT YGQTGTG TYT G G GK R K R KR
Kif9    -  116 D D E D D EG HN SQ Y T SQ GYNGT CYGQTG G TYT TG T NY H GVL A LV VA AV AL IM A M A ILK K K R
Kif5B    ---- -  163P IV IF I M L F I V F I L I LL V L V VPR K K R K K RQ NY YS N H SY Y S TN S H ND DE E E D D D ED
Kif3B    - ----  174P F IF I LV A L I I LL L L P VNS H TH S SQNQQY SY YQ S QT TGD E EE D D E E DR R R K KR K R
Kif9     -  175P AL VF MI P AI V V L I LF LL LP V P V PM IV P IR R R RQQ TH T SY YN N ST Y G S T T N QGE E E E D E
Kif5B    - 222Y GCT CS T G SN H TN N HSS SHS N Q NTQT QV FV P VM I VAV M IFLI VK R K R R K KE DE D DE E E E
Kif3B     234Y SS T S H N GNQN S G TN N HSS SH T CS G G NV L FV V I VM V V A M AIFVI I V LK K K R RD E E E E E D E
Kif9      235FI L V L AF LLF IIA M IF I M A LK R K R R KG S H TSQ S G TN SHT N NSS SHC T Y HS T SEED E E E DE
Kif5B    -- -  279L L LV LA V A AVL A I L AL VI ALA VPSG Y GS S TG G N N S S GN S G STY YK K K K K RD E E DE E D
Kif3B     294H G N GS Q TG QG T N S S GN S G STH YI V L LV LA A A L A I L L AL VI ALV IPR K R K R K K K RD E E E D D
Kif9     -  294Y TS N GS S TGS G TY N S S Q G QN H QI I LV LA L VL A I L FL AIIAL VPFK R K R K K R RD E E E E D D
Kif5B     337S T Q S GGNC TT CCS SSYN S T ST GQ T NT C N TK R R K R K KM IL L IVI P LLF A I V V V L AD E E E
Kif3B     352S T Q S GGN T N G SYN T TT Y N N N NK R K R R K K K R KL LL L A VMVA V PA V L L A A I P V PD EE ED D
Kif9      352S TH S GGNCN TN YG Q T SS S TT N YK K R R K KL AL L MVLV I AA L L L FA M LV PAI AD E DE E E D
Figure 2.1: Alignment of Kif5B, Kif6 and Kif9 motor domain sequences. The alignment
was generated using ClustalW2 multiple alignment tool (Larkin et al., 2007). Small and
hydrophobic residues are shown in red, acidic residues in blue and basic residues are shown
in magenta. Glycine and residues containing hydroxyl, sulfhydryl or amine groups are shown
in green.
Codon-optimised cDNAs encoding human kinesin motor domains were purchased in vec-
tor pUC57 for the following kinesins: Kif1A1´355 (coding for residues 1–355, naming sys-
tem is kept for all constructs), Kif1B1´354, Kif4B1´337, Kif6103´351, Kif78´361, Kif121´361,
Kif131´353, Kif14366´713, Kif1519´375, Kif1710´347, Kif24216´546, Kif26A386´737, Kif26B462´813
and Kif271´341. Additional constructs were cloned from full-length DNA for a set of kinesins
using the HotStar HiFidelity PCR kit. The primers were designed by introducing a required
restriction site in the middle of the oligonucleotide, with an overhang of at least 9 nucleotides
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on each site. Efforts were made to keep primer GC content above 50% and melting tempera-
ture above 75˝C. The PCR reaction was conducted with following cycling parameters: initial
denaturation — 95˝C, 5 min; 45 extension cycles (95˝C, 15 sec; 55˝C, 1 min; 72˝C, 1 min);
final extension — 72˝C, 10 min. The created constructs and used PCR primers are shown in
Table 2.1.
Construct Forward primer Reverse primer
Kif2B208´555 5’ C AGC AAG ATC TCA
GTC ATG AAG CCC CCG
CAA GAA 3’
5’ G TGC CTC ATG TCC CTC GAG
ATA GTG GCC ACG ATG 3’
Kif3A7´360 5’ ATG CCG ATC ATC ATG
ACA GAG AAG CCA GAA
AGC 3’
5’ CTG GAA CTG CTC GAG CAA
AGC ATC CTT TGG ATC 3’
Kif3B1´354 5’ G ACT GGA TCA GAG
TTC ATC ATG ACA AAG
TTG AAA AGC TCA GAG 3’
5’ TTC CTG GAA TTC TCG CTC
GAG GGC ATC CTT 3’
Kif5A1´339 5’ CCG GCT ACC ATC ATG
ACG GAG ACC AAC 3’
5’ CTT CTC ATA TTT CTT CTT
CCA CTG CTC GAG AGT CAA CTC
CAA ATT 3’
Kif5C1´339 5’ CG GCC GTC ATG ACG
GAT CCA GCC GAA 3’
5’ CTC TTT TTC ATA TTT CTT
CTT CTC GAG TTC TGC TGT CAG
TTC TAG G 3’
Kif91´351 5’ CTG GTG AAC GCT ACC
ATG GGT ACT AGG AAA
AAA GTT CAT GCA TTT 3’
5’ CTC CAG GTT CTT GAC CAT
TCT CTC GAG ATC ATA CTT TTC
ATT GAT 3’
Table 2.1: Kinesins constructs cloned from the full-length DNA. The construct length, for-
ward and reverse primers are presented.
Expression co
n
s
tru
c
t
H
xrT
TEV
NcoI
XhoI
BspHI
STOP
pET-M20
 con noi ss trs ue cr tpx
E H
NcoI XhoI
BspHI
STOP
pET-28a
Figure 2.2: E. coli expression vectors used in the kinesin motor domain study. A modified
pET-M20 possesses N-terminal Trx fusion protein, His-tag and TEV cleavage site. TEV
cleaved kinesin construct carries additional glycine and alanine residues at the N-terminus.
A pET-28a contains C-terminal uncleavable His-tag. The plasmid-mediated resistance and
used restriction sites are indicated.
Subsequently, all amplified genes were double-restricted with NcoI or BspHI and XhoI and
cloned into two E. coli expression vectors using standard methods: a modified pET-M20
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(N-terminal Trx fusion protein (thioredoxin, 12 kDa fusion protein, promotes solubility and
folding), His-tag and TEV cleavage site) and pET-28a (C-terminal His-tag) (Figure 2.2).
Both vectors contain an engineered stop codon (pET-M20 after XhoI site, pET-28a after
His-tag). After cloning into expression vectors, the sequence of the constructs was verified
by DNA sequencing.
2.2.2 Small-scale expression and semi-automated purification
The kinesin motor domain constructs were transformed into the following E. coli expres-
sion strains: BL21-CodonPlus(DE3)-RIPL, BL21(DE3), BL21(DE3)pLysS (pLysS plasmid
suppress pre-induction protein expression by producing inhibitor of T7 RNA polymerase
(T7 lysozyme)), Origami 2(DE3)pLysS (strain carries mutations in the thioredoxin reduc-
tase and glutathione reductase genes, which enhance disulfide bond formation), Rosetta-
gami(DE3)pLysS (strain contains codons rarely used in E. coli) and ArcticExpress (strain
promotes soluble protein expression). All competent cells were thawed on ice. For each trans-
formation 50 µl of cells were mixed with 1 µl of mini-prepped DNA and incubated on ice for
30 min. After incubation transformation reactions were incubated in a 42˝C water bath for
30 sec, then cooled on ice for 5 min. Subsequently, the reactions were supplemented with
200 µl of LB medium (no antibiotic) and incubated for 1 h at 37˝C. Then, about 100 µl of the
resulting cultures were spread on LB plates (with appropriate antibiotic added, ampicillin
for pET-M20 clones, or kanamycin for pET-28a). Plates were incubated overnight at 37˝C.
A single colony was picked from each plate for expression test. 20 ml cultures were grown in
Falcon 50 ml tubes in TB medium at 37˝C to an OD600 of approximately 0.7 and subsequently
induced overnight with 0.5 mM IPTG at 18˝C. The cultures were centrifuged (15 min, 4˝C,
3300g), the pellets transferred into 2 ml QiaCube safe-lock tubes, frozen in liquid nitrogen and
stored at ´80˝C. Small-scale purifications were performed using a QiaCube robot with the
following buffers: 20 mM Tris-HCl, 300 mM NaCl, 1mM MgCl2, containing 10 mM imidazole
in the equilibration buffer, 50 mM in the washing buffer and 250 mM in the elution buffer.
To assure protein solubility, the pH of the buffers was adjusted depending on the pI of the
protein and kept by one pH unit away from the pI of the construct. QiaCube robot enables
automated purification of 12 small-scale expressed samples, by utilising small immobilized
metal afnity chromatography (IMAC) spin-columns. IMAC is a highly efficient method used
for purification of polyhistidine-tagged (His-tagged) proteins. The divalent metal ions, for
example nickel or cobalt, have propensity to bind histidine. The metals immobilized on the
resin by chelation facilitate purification of the overexpressed protein from the crude E. coli
lysate. Prior to purification buffers were kept at 4˝C. The pI of prepped constructs are pre-
sented in Table 2.2 along with their systematic and trivial names, construct lengths, pH of
the buffers used in the purifications and extinction coefficients.
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Systematic
name
Other names Construct pI of
construct
pH
of buffer
Extinction coeff.
[M´1cm´1]
Kif1A ATSV, MRD9 Kif1A1´355 8.92 7.0 33600
Kif1B KLP, CMT2 Kif1B1´354 8.87 7.0 33725
Kif2B FLJ53902 Kif2B208´555 10.30 7.0 24005
Kif3A KRP85, Klp64D Kif3A1´354 8.98 7.0 18130
Kif3B KRP95, Klp68D Kif3B1´354 9.04 7.0 23505
Kif4B Chromokinesin Kif4B1´337 6.85 7.9 13910
Kif5A nKHC Kif5A1´339 6.33 7.5 16765
Kif5C uKHC Kif5C1´339 6.38 7.5 15275
Kif6 C6orf102 Kif6103´351 6.46 7.5 19620
Kif7 ACLS, HLS2 Kif78´361 5.98 7.0 16180
Kif9 MGC104186 Kif91´351 6.87 7.9 26610
Kif12 RP11-56P10.3 Kif121´361 9.60 7.0 20315
Kif13 GAKIN Kif131´353 9.08 7.0 30620
Kif14 MGC142302 Kif14366´713 6.40 7.5 36120
Kif15 Hklp2, Xklp2 Kif1519´375 8.68 7.0 17608
Kif17 Kif17b Kif1710´347 8.19 7.0 23880
Kif24 C9orf48 Kif24216´546 8.18 7.0 26275
Kif26A FLJ22753 Kif26A386´737 9.59 7.0 18048
Kif26B FLJ10157 Kif26B462´813 9.45 7.0 23545
Kif27 RP11-575L7.3 Kif271´341 6.85 7.9 13910
Table 2.2: Kinesins tested in a motor domain expression trial. Systematic and trivial names,
construct lengths, pI of the constructs, pH of the buffers used in the purifications and extinc-
tion coefficients of twenty tested human kinesin motor domains.
Before purification, samples were re-suspended in 50 µl of 50% Bug Buster in equilibration
buffer supplemented with 1 µl of Benzonase nuclease. Subsequently, cells were lysed by three
cycles of freezing on dry ice and thawing at 25˝C (six cycles for BL21-CodonPlus(DE3)-RIPL
and ArcticExpress cells). Samples were purified using nickel pull down of His-tagged proteins
and eluents were analysed by SDS-PAGE. Bands of the expected size were excised from the
gel and analysed by mass spectrometry fingerprint analysis.
2.2.3 Western blot
Following small-scale purification, samples which did not reveal any significant protein over-
expression by SDS-PAGE, were further examined by western blot. Supernatants and pellets
were analysed separately. Supernatants were diluted 20-fold with equilibration buffer. 20 µl
of pellet was re-suspended and boiled in 1 ml of 6 M urea and diluted 20-fold with equili-
bration buffer. SDS-PAGE was run with the following volumes: 10 µl of the sample, 8 µl
loading buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, 0.125M Tris-HCl pH 7.0)
and 2 µl reducing agent (10% 2-mercaptoethanol). Next, proteins were transferred onto a
nitrocellulose membrane (30 V, 400 mA, 1 h 20 min) in transfer buffer supplemented with
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20% methanol. Afterwards the membrane was blocked overnight at 4˝C in a solution of 5%
milk solution in TBS-T. After blocking, the membrane was incubated in 1% milk solution,
containing the 6xHis mAb-HRP conjugate for 1 h at room temperature. After incubation
the conjugate excess was removed by three washes with TBS-T (5 min each) and a final
rinse (5 min) in water. Finally, the membrane was developed with BM Chemiluminescence
Western Blotting Substrate.
2.2.4 Large-scale expression and purification
12 l of bacterial cultures were grown and harvested as described for the small-scale expression
test and re-suspended in lysis buffer (affinity wash buffer supplemented with 1 mM PMSF,
0.1 mg/ml lysozyme, 50–60 ml). Cells were lysed by sonication (8 cycles of 8 sec on/off, 20 ml
lysate fractions) and centrifuged (1 h, 4˝C, 31,400g). Supernatants were pooled and proteins
were purified by affinity chromatography (1 ml HisTrap FF; wash buffer: 50 mM PIPES,
250 mM NaCl, 2 mM MgCl2, 40 mM imidazole; elution buffer: 50 mM PIPES, 250 mM
NaCl, 2 mM MgCl2, 500 mM imidazole). After elution, protein solutions were supplemented
with 1 mM Mg2`ATP (repeated after each purification step). Subsequently, they were cleaved
overnight with His-tagged TEV protease (0.05 mg TEV / 1 mg protein). Before TEV cleavage,
the buffer was exchanged to eliminate imidazole (HiPrep 26/10 desalting; 50 mM PIPES,
250 mM NaCl, 2 mM MgCl2). Afterwards, His-tagged Trx and TEV were removed by a
second run of the HisTrap column. The final purification step for all kinesins consisted of
gel filtration chromatography (HiLoad Superdex S75) in gel filtration buffer (50 mM PIPES,
250 mM NaCl, 2 mM MgCl2, 1 mM DTT).
2.2.5 Expression and purification of His-tagged TEV protease
The expression construct for TEV (Tobacco etch virus) protease consisted of full-length
cDNA cloned into the pET-15b expression vector (C-terminal His-tag) with NcoI at the 5’
and BamHI at the 3’ end. The plasmid was transformed into BL21(DE3)pLysS competent
cells and bacteria were grown in 12 l of TB medium at 37˝C, until an OD600 of 0.4, then
temperature was reduced to 18˝C. Once the temperature reached 18˝C, and the OD600 was
close to 0.6–0.8, the cultures were induced with 0.5 mM IPTG and grown for another 16 h.
Cells were harvested and lysed by sonication as previously described. After centrifugation
the supernatant was applied to an affinity column (1 ml HisTrap FF; wash buffer: 50 mM
Tris-HCl pH 8.0, 250 mM NaCl, 40 mM imidazole; elution buffer: 50 mM Tris-HCl pH 8.0,
250 mM NaCl, 500 mM imidazole). The TEV protease was then applied to a HiPrep 26/10
desalting column equilibrated in 50 mM Tris-HCl pH 8.0, 250 mM NaCl and 10% sucrose
(cryoprotectant). Finally, TEV was concentrated to 2 mg/ml (Amicon Ultra-15, 10 kDa),
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aliquoted, frozen in liquid nitrogen and stored at ´80˝C. On average, 12 l of bacterial culture
yielded 30–50 mg of 80–90% pure TEV. The identity of the protease was confirmed by mass
spectrometry fingerprint with coverage of 75%.
2.2.6 Determination of protein concentration
Protein concentrations were determined using either the Beer-Lambert law, with absorbance
measured under native conditions, taking bound ADP into consideration (extinction coeffi-
cient = 2500 M´1cm´1), or by employing the Bradford method. The extinction coefficient for
each kinesin was calculated using the ProtParam software from the Bioinformatics Resource
Portal (Wilkins et al., 1999). Both methods yielded similar protein concentrations with dif-
ferences of 10–20% and the concentration obtained by applying the Beer-Lambert law was
used in further calculations.
2.2.7 Analytical gel filtration
The oligomeric state of the proteins was determined using a Superose 12 10/300 GL analytic
gel filtration column with a flow rate of 0.5 ml/min. This chromatographic method enables
molecular weight estimation of a test protein by calibrating the column with proteins of
known molecular weights. The major limitation of the method is that it works reliably
only for compact and globular molecules. Kinesin motor domains are known to be globular
making them ideal candidates for assigning molecular weight by analytical gel filtration.
Prior to running test proteins, the column was calibrated with proteins of known molecular
mass (ribonuclease A — 13.7 kDa, carbonic anhydrase — 29 kDa, ovalbumin — 43 kDa,
conalbumin — 75 kDa) and dextran blue to determine the column void volume. The Kav
values were calculated for the calibration proteins from the following equation:
Kav “ Ve ´ V0
Vc ´ V0
(where Ve is the elution volume, V0 is the void volume, Vc is the column volume), and plotted
against the logarithm of the molecular weights of the standards. The molecular weight for
each kinesin motor domain was calculated from the resulting equation.
2.2.8 Tubulin purification and polymerisation into MTs
Tubulin was purified from bovine brains, by a series of polymerisation and depolymerisation
steps as described previously (Castoldi and Popov, 2003). Two fresh bovine brains were
obtained on ice and homogenised in cold depolymerisation buffer (50 mM MES pH 6.8,
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1 mM CaCl2), then centrifuged at 29,000g, 4
˝C for 60 min. The pellet was discarded and
the supernatant was supplemented with equal volumes of warm polymerisation buffer (1 M
PIPES pH 6.9, 10 mM MgCl2, 20 mM EGTA) and glycerol, 1.5 mM ATP (final) and 0.5 mM
GTP (final). Tubulin was polymerised at 37˝C for 60 min. Subsequently, the sample was
centrifuged at 151,000g, 37˝C for 30 min. The supernatant was discarded, the pellet was
resuspended in 100 ml of cold depolymerisation buffer and incubated on ice for 30 min. Post
incubation tubulin was centrifuged at 70,000g, 4˝C for 30 min. The pellet was discarded,
the supernatant was supplemented with an equal volume of warm polymerisation buffer and
glycerol, 1.5 mM ATP and 0.5 mM GTP, incubated at 37˝C for 60 min, then centrifuged
at 151,000g, 37˝C for 30 min. In the next step, the obtained MT-pellet was resuspended
in 15 ml of cold BRB80 buffer (80 mM PIPES pH 6.8, 1 mM MgCl2, 1 mM EGTA) and
incubated on ice for 10 min. In a final step, tubulin was centrifuged at 104,000g, 4˝C for
30 min. The pellet was discarded and the supernatant contained purified protein. The purity
of the tubulin obtained is presented in Figure 2.3.
Figure 2.3: SDS-PAGE presenting purity of tubulin extracted from bovine brain.
Subsequently, tubulin was aliquoted at 18.5 mg/ml, snap frozen and stored in liquid nitrogen.
MTs were prepared at 60 µM (heterodimer). Tubulin was gently mixed with pre-warmed (to
37˝C) G-PEM buffer (100 mM PIPES pH 6.9, 1 mM EDTA, 1 mM MgCl2, 1 mM GTP)
supplemented with 20 µM of taxol. Polymerisation was carried out overnight at 37˝C.
2.3 Kif15 methods
2.3.1 Kif15 cloning and expression
Several codon-optimised cDNAs (Kif1519´375, Kif15376´743, Kif15744´1333, Kif151017´1237,
Kif151149´1388), covering the entire length of Kif15, were cloned into expression vectors (a
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modified pET-M20 and pET-28a) and screened for expression conditions in several E. coli
strains (as described previously in Chapter 2.2.2). An additional construct — Kif151´375 was
created, extending the Kif1519´375 construct by PCR, with four forward primers (5’ CA AAT
GGT CAG TCT AAC CAG CCG AGC AAC GAA G 3’, 5’ GAG TTA CGC AGC GTG
ACA AAT GGT CAG TCT AAC C 3’, 5’ GGC TGC AAA ACT GAG TTA CGC AGC GTG
3’, 5’ GAA CC ATG GCT CCT GGC TGC AAA ACT G 3’), and a single reverse primer
(5’ GAT CTC GAG TTA ACC CTG GGT ATC TTC ATT CAC AAC C 3’). When ex-
pression conditions for each of the constructs were established, large-scale purifications were
performed in a manner analogous to these described in Chapter 2.2.4. The pI of constructs
tested and pH of buffers used are presented in Table 2.3.
Construct pI pH of
PIPES
Extinction coeff.
[M´1cm´1]
Kif151´375 8.35 7.0 17670
Kif1519´375 8.68 7.0 17608
Kif15376´743 6.52 7.6 9002
Kif15744´1333 4.76 7.0 23232
Kif151017´1237 5.09 7.0 10032
Kif151149´1388 5.39 7.0 10032
Table 2.3: Purification details for Kif15 construct expression trial. pI of constructs, pH of
buffers used in the purifications and protein extinction coefficients.
2.3.2 Kif15 motor domain crystallisation
Purified Kif1519´375 protein, concentrated to 10 mg/ml was used to set several crystallisation
screens at 4 and 19˝C, in the presence and absence of 1 mM Mg2`ATP. The following crys-
tallisation screens were used: ComPAS, JSCG+, PACT, ammonium sulphate grid screen,
sodium malonate grid screen, MPD grid screen, Crystal screen HT, Crystal screen Lite, PEG
Ion, PEG 6000 and PEG LiCl. The various commercially available crystal screens contain
diverse precipitants, salts and buffers in a 96-well block format and allow high-throughput
crystallisation screening.
2.3.3 Kif15 motor domain crystals optimisation
Numerous optimisation attempts for Kif1519´375 crystals were tested. Various salts and PEGs
were tried. Several trays were set to investigate the influence of pH (Tris-HCl pH 7.5–9.0),
protein concentration (4–10 mg/ml), temperature (12 and 16˝C), protein to well solution
ratio (1:2, 2:1), seating versus hanging drop, micro-seeding, buffers (pH 7.0–9.0), additives
and detergents.
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2.3.4 X-ray crystallography
X-ray crystallography is an experimental technique exploiting the wave nature of X-rays to
determine the three-dimensional structure of crystalline solids. It enables insight into the
structure of biomolecules and facilitates the investigation of protein complexes. It is also a
key tool in structure-based drug design.
2.3.4.1 X-rays and diffraction
X-rays are electromagnetic waves characterised by wavelength, amplitude and phase, just
like visual light. The difference between them is the wavelength, much shorter for X-rays
(0.02–100 A˚) and their higher energy (inversely proportional to the wavelength). The range
between 0.5 A˚ and 1.6 A˚ (similar to the size of atoms and bonds within biomolecules) is
useful to provide high-resolution information about protein structures.
The determination of protein structure using X-rays requires obtaining a crystal, as diffraction
from a single protein molecule would be too weak to be measurable. Moreover the X-ray
beam is highly damaging to biological samples. In a single protein crystal the atoms are
periodically and systematically organised to create a crystal lattice. There are seven crystal
lattice systems (monoclinic, triclinic, orthorhombic, rhombohedral, tetragonal, hexagonal and
cubic). Each of them is characterised by a unit cell — the smallest component of the crystal
lattice determining the arrangement of atoms in a crystal and described by lattice parameters
(cell edge length and angles between edges). The orientation of each plane within a lattice is
uniquely identified by its Miller index.
Diffraction of an X-ray beam arises when the light interacts with the electron density sur-
rounding the atoms within the crystal. The periodic arrangement within the crystal lends
itself to a description in terms of series of equally separated planes. When X-ray beam hits
θ
θ
θ
θ
θ
• •
d
nλ=2d sinθ
Figure 2.4: Bragg diffraction. X-ray beams hit a set of crystal planes separated by a distance
d at an angle θ. For these two rays to produce a diffraction pattern, Bragg’s law has to be
satisfied.
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a crystal at a specific angle (θ), a fraction of it will be diffracted from it at the same an-
gle (Figure 2.4). The remaining beam penetrates the crystal and interacts with the second
crystal plane. As they travel different lengths before diffracting, the X-ray waves are not all
in the same phase and therefore some of them cancel each other out, while others add up.
This phenomenon is described by the Bragg’s law, which relates the distance between crystal
planes and the X-ray diffraction angle. In order to produce a diffraction spot (reflection) the
reflected waves need to be in phase (constructive interference) (Figure 2.4).
2.3.4.2 X-ray data processing
In order to gather enough data to solve the structure a crystal must be exposed to the X-ray
radiation at various orientations. The amount of required data depends on the level of crystal
symmetry. Data processing starts from indexing diffraction spots, identifying crystal lattice
and unit cell dimensions. Once the crystal symmetry is identified the data are integrated into
a single file containing the Miller index of each reflection from each diffraction image along
with its intensity. Typically a data set contains several records of a single reflection and in
the subsequent step these are identified, merged and scaled to ensure consistent intensity.
The processed data quality is assessed by the R-factor that compares the crystallographic
model and the experimental diffraction data.
Diffraction images (two-dimensional) from various crystal rotations are converted into an
electron density model using the mathematical method of Fourier transform. To solve an
X-ray structure, both amplitude and phase of the diffracted waves have to be known. The
information about amplitude can be recovered due to its dependency on the diffraction inten-
sity. The phase cannot be directly recorded during data collection but the information about
it can be retrieved in several ways, for example by molecular replacement. If the structure
of a homologous protein is known it can be used as a model to assign the orientation of the
molecules in the unit cell and to generate a three-dimensional electron density model.
2.3.4.3 Kif1519´375 data collection, processing and refinement
Data for optimised, cryo-protected (20% w/v meso-erythtritol) crystals were collected at the
European Synchrotron Radiation Facility (ESRF) to a resolution of 2.7 A˚. The structure
was solved by molecular replacement with MOLREP (Vagin and Teplyakov, 2000) using the
CENPE structure (PDB ID: 1T5C (Garcia-Saez et al., 2004)) as a search model. The model
for molecular replacement was picked by comparison of the Kif15 motor domain sequence
with the sequences of other kinesins for which X-ray structures were solved and deposited
in the PDB. CENPE is the most similar (42% identity) one and was used as a model. The
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asymmetric unit contains three copies of Kif1519´375 with Mg2`ATP bound in the catalytic
site positioned with REFMAC5 (Vagin et al., 2004) by rigid body and restrained refinement.
The structure model was improved using COOT (Emsley and Cowtan, 2004) and further
refined using PHENIX (Afonine et al., 2012) with non-crystallographic symmetry restraints.
2.3.5 Kif15 basal and MT-stimulated steady state kinetics
Steady-state basal and MT-stimulated ATPase rates of activity were measured using the
pyruvate kinase / lactate dehydrogenase linked assay (Hackney and Jiang, 2001). Kinetic
measurements were performed at 25˝C in 96-well micro-clear plates in a final volume of 100 µl
using a 96-well Tecan Sunrise photometer. The following reaction buffer was used: 25 mM
ACES, 2 mM Na-EGTA, 0.1 mM EDTA, 2 mM magnesium acetate, 1 mM 2-mercaptoethanol;
supplemented with: 2 mM PEP, 0.25 mM NADH, 5 µg/ml PK and 3 µg/ml LDH. The
reaction course is depicted in Figure 2.5.
PEP Pyruvate Lactate
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Figure 2.5: Course of coupled ATPase reaction. Pyruvate kinase (PK) catalyses transfer of
a phosphate group from phosphoenolopyruvate (PEP) to ADP, yielding one molecule of pyru-
vate and one molecule of ATP. Lactate dehydrogenase (LDH) catalyses the interconversion
of pyruvate and lactate with concomitant interconversion of NADH and NAD`. In the assay
absorbance at 340 nm is monitored, its decrease correlates with kinesin cycle progression.
Prior to the kinetic measurements, excess Mg2`ATP was removed by gel filtration. All
measurements were done at least in triplicate. The Michaelis-Menten curve was fitted using
Kaleidagraph 4.0 using the least squares method. Rates of activity were calculated using the
correlation between absorbance at 340 nm and kinesin activity (Hackney and Jiang, 2001)
using following equation:
Rate “ 2 ¨∆A340{min
εNADH ¨ 60 ¨ Ce
where εNADH signifies the molar extinction coefficient of NADH [M
´1cm´1], ∆A340{min
stands for the absorbance change per minute measured at 340 nm, Ce relates to the molar
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concentration of the tested enzyme. The factor of 2 in the equation is a correction factor,
normalising the optical path length in the 96-well Tecan plates to 1 cm. The salt dependence
of the basal Kif1519´375 and Kif151´375 ATPase activities was measured at NaCl concentra-
tions from 0 to 275 mM in the presence of 0.59 µM Kif1519´375 and 0.35 µM Kif151´375 and
1 mM Mg2`ATP. To determine the basal ATPase activity of Kif1519´375 and Kif151´375, their
activities were examined at ATP concentrations from 0 to 2 mM in the presence of 0.35 µM
Kif1519´375 and 0.35 µM Kif151´375 as well as 75 mM NaCl for Kif1519´375 and 50 mM NaCl
for Kif151´375. The salt dependence of the MT-stimulated ATPase activity of Kif1519´375
and Kif151´375 was determined by measuring rates of its activity at MT concentrations from
0 to 15 µM in the presence of 0.04 µM Kif1519´375 and 0.08 µM Kif151´375. Finally, the
MT-stimulated ATPase activity for both Kif15 constructs was measured in the presence of
increasing ATP concentrations from 0 to 0.75 mM in the presence of 0.04 µM Kif1519´375
and 0.04 µM Kif151´375, 3 mM MTs, in the absence of salt.
2.3.6 Kif15 inhibitor screening
Kif1519´375 enzymatic activity was tested in presence of various small molecules by employing
the in vitro coupled ATPase assay described in Chapter 2.3.5, using a 96-well Tecan Sunrise
photometer. First, the influence of the Eg5 inhibitors STLC and monastrol (up to a concen-
tration of 100 µM) was tested, both in the basal activity assay and in the presence of MTs.
The IC50 data were fitted with the following equation:
v
v0
“ 100´A ¨ rIsrIs ` IC50
where v is the reaction velocity at various inhibitor concentrations, v0 is the control velocity in
the absence of inhibitor (measured in the presensce of DMSO), A represents the amplitude,
rIs indicates the concentration of the inhibitor and IC50 indicates the median inhibitory
concentration (Skoufias et al., 2006). Moreover, twenty one compounds described as Kif15
inhibitors (McDonald et al., 2004) were synthesised by Sai Advantium Pharma Ltd (India)
and tested. Rates of ATPase activity were measured at 12 inhibitor concentrations from 0 to
200 µM. Since compounds were dissolved in DMSO, it was used as a control. The activity
was tested both under basal (1 mM ATP, 75 mM NaCl, 0.25 µM Kif1519´375) and under
MT-stimulated conditions (1 µM MTs, 1 mM ATP, 0 mM NaCl, 0.015 µM Kif1519´375).
The compounds were also tested at a lower ATP concentration (100 µM ATP, 75 mM NaCl,
0.25 µM Kif1519´375) to investigate the possibility of competitive inhibition.
In addition, other libraries were screened: 2452 small molecules from the National Cancer
Institute (Natural Inhibitor Set, Approved Oncology Set, Mechanistic Set and Structural
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Diversity Set), and 4000 natural product extracts (University of Strathclyde) were tested.
All of the libraries were obtained in the 96-well plate format and were tested using 96-well
micro-clear plates and a Tecan Sunrise photometer. Each compound was tested at a single
concentration of 200 µM in the presence and absence of MTs.
2.3.7 Kif15 motor domain pelleting assays
Pelleting assays were performed in 50 mM PIPES pH 6.9, 20 mM NaCl, 2 mM MgCl2 and
1 mM DTT. Kif1519´375 (1–12 µM) was gently mixed with taxol-polymerised MTs (5 µM,
prepared without GTP, 20 µM of taxol promotes MTs polymerisation) and supplemented
with buffer to a final volume of 40 µl. Binding assays were performed in the presence of
2 mM Mg2`ATP, 2 mM AMP-PNP or 4 mU of apyrase. Samples were incubated at room
temperature for 10 min and centrifuged in a Beckman TL100 ultracentrifuge at 100,000g, 25˝C
for 20 min. Supernatants were removed from the pellets. The pellets were re-suspended in
Laemmli reducing sample buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, 0.125 M
Tris-HCl pH 7.0, 10% 2-mercaptoethanol). Supernatants and pellet samples were run on
SDS-PAGE gels. On the gel for each experiment a standard of Kif1519´375 was run: 1, 2,
4 and 8 µl of the Kif15 motor domain at 0.5 mg/ml, along with the empty lane (for the
background correction). Gels were stained with Coomassie Brilliant Blue (Simply Blue Safe
Stain) and scanned using a GS-800 Calibrated Densitometer. Data were analysed using
ImageJ (Schneider et al., 2012), Microsoft Excel 2008 and Kaleidagraph 4.0. ImageJ soft-
ware enables the analysis of gel bands intensity with background subtraction. Additionally,
inclusion of a protein standard permits quantification of the proteins assayed. All assays
were run in triplicate. To calculate the dissociation constant (KD), the Michaelis-Menten
representation was used as follows:
rMT ¨Kif1519´375s “ Bmax ¨ rKif1519´375s
KD ¨ rKif1519´375s
with MT-bound Kif1519´375 (rMT ¨Kif1519´375s) plotted as a function of free Kif1519´375
(rKif1519´375s). Bmax corresponds to the maximal number of interacting sites.
2.3.8 Kif15 actin binding assay
The assay was conducted in F-actin buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2, 50 mM
KCl, 2 mM MgCl2, 1 mM ATP) in a reaction volume of 50 µl. F-actin was prepared at
a concentration of 18.4 µM by quickly thawing actin on ice and preparing G-actin at a con-
centration of 1 mg/ml in G-actin buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2). The G-actin
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was polymerised to F-actin by adding polymerisation buffer (5 mM Tris-HCl pH 8.0, 0.2 mM
CaCl2, 50 mM KCl, 2 mM MgCl2, 1 mM ATP) and incubation at room temperature for 1 h.
The F-actin stock was stable for 1 h after preparation. Negative and positive controls were
BSA (2 µM) and α-actinin (2 µM) (an actin-binding protein) respectively. Two constructs
were used in this test: Kif15740´1333, which contains a putative actin binding domain, and
the Kif15 tail — Kif151149´1388. The proteins were purified and subsequently eluted in a
buffer containing 50 mM PIPES pH 6.5, 20 mM NaCl, 2 mM MgCl2 (also tested at pH 7.5)
and used at 3 µM (Kif15740´1333) and 5 µM (Kif151149´1388), respectively. All assays were
performed in triplicate.
2.3.9 Purification of Kif15 partner proteins — FHA domain of Ki-67 and
TPX2
cDNAs, codon optimised for E. coli expression for Ki-67 FHA domain and full-length TPX2
were purchased, cloned and screened for expression conditions (both expressed in modified
pET-M20). The purification procedure for the FHA domain of Ki-67 (pI = 10.62) and TPX2
(pI = 9.77), followed that used for the kinesin motor domains purification protocol (Section
2.2.4), using PIPES pH 7.0 buffers.
2.3.10 Investigation of possibility of MT binding site in Kif15 tail domain
The possibility of an MT-binding site in the Kif15 tail was investigated in vitro. Direct binding
of Kif151149´1388 with MTs was tested, with the procedure analogous to the pelleting assays
for Kif1519´375 with various nucleotides (Chapter 2.3.7). Increasing amounts of Kif151149´1388
(1–10 µM) were incubated with MTs (5 µM), supernatants and pellets were analysed by SDS-
PAGE.
2.3.11 TPX2 interaction with MTs
Binding between TPX2 and MTs was tested using a pelleting assay (Chapter 2.3.7). The
amounts used for the assay were 4 µM MTs and a gradient of TPX2 from 1 to 4 µM.
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2.4 Kif7 and Kif27 methods
2.4.1 Kif7 and Kif27 cloning, protein expression and purification
Codon-optimised cDNAs of Kif78´361 and Kif271´341 were cloned previously (Chapter 2.2.1).
Additional shorter constructs in a modified pET-M20 expression vector were created using
the following primers. Kif78´347: 5’ CGT GCC CAG TAA ATC CGC AAC CGC GCC AC 3’;
Kif271´339: 5’ GCG AAC CGC GCG CGT TAG ATT CTC GAG TAA TCG 3’; Kif276´341:
5’ CT ATG GAA GCC ATG GCG GTG AAA GTT GCG 3’, 5’ GT GGT GCT CGA TTA
CTC GAG AAT GTT ACG C 3’; Kif2717´341: 5’ GT ATT CGT CCC ATG GTG TGC AAA
GAA GCG 3’, 5’ GT GGT GCT CGA TTA CTC GAG AAT GTT ACG C 3’. The Kif7
point mutation (Kif78´347 L130P) was introduced using a QuikChange kit with the following
mutagenic primer: 5’ C GAA GCC TTC AAA CCG ATC GAT GAA AAC GAC C 3’. The
PCR reaction was conducted with the following cycling parameters: initial denaturation —
95˝C, 30 sec; 18 extension cycles (95˝C, 30 sec; 55˝C, 1 min; 68˝C, 2 min); final extension
— 68˝C, 5 min. After PCR the reaction was treated with DpnI at 37˝C for 30 min. Post
digestion of template DNA, 10% of the reaction was used for a transformation into DH5α
competent cells. All obtained proteins were expressed in E. coli BL21(DE3)pLysS expression
cells. The purification procedure was analogous to the one for the originally created Kif7 and
Kif27 constructs (Section 2.2.4).
2.4.2 Kif7 and Kif27 crystallisation
All Kif7 and Kif27 constructs described above were used for crystallisation trials at 10 mg/ml,
at 4 and 19˝C, in the presence and absence of 1 mM Mg2`ATP. The set of crystallisation
screens used for Kif15 crystallisation screening was employed (Chapter 2.3.2).
2.4.3 Kif78´347 data collection, structure determination and refinement
Data for Kif78´347 crystals were collected at beamline I04-1 at Diamond Light Source and
processed with XDS (Kabsch, 2010) to 1.6 A˚ resolution. The structure was solved by molec-
ular replacement with MOLREP (Vagin and Teplyakov, 2000) using the Kif3B structure as a
search model (PDB ID: 3B6V) (39% identity with Kif7). The asymmetric unit contains one
copy of Kif78´347 with bound Mg2`ADP, positioned with REFMAC5 (Vagin et al., 2004) by
rigid body and restrained refinement. The model was subsequently improved with COOT
(Emsley and Cowtan, 2004) and further refined using PHENIX with TLS restraints (Afonine
et al., 2012).
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2.4.4 Kif7 and Kif27 oligomeric states
The oligomeric state of all constructs of Kif7 and Kif27 was determined as described in
Chapter 2.2.7. The identities of the proteins were confirmed by mass spectroscopy finger
print analyses.
2.4.5 Kif78´347 and Kif78´347 L130P western blot
One-litre cultures of native Kif78´347 and mutant Kif78´347 L130P were grown, harvested
and lysed as described previously. Subsequently, a procedure described in Chapter 2.2.3 was
performed to analyse their soluble and insoluble fractions.
Chapter 3
Results
3.1 Kinesin expression panel
Kinesins transport cellular cargoes and play key roles during cell division, in particular in
mitosis and cytokinesis. Because of their implication in a broad range of cellular processes,
they have been related to various diseases. The first CENPE inhibitor and a variety of
Eg5 targeting agents are currently in phase I and multiple phase II clinical trials. In this
chapter, in an effort to provide tools to test anti-mitotic inhibitor specificity, a description
is given of the cloning motor domains of nearly half of the kinesin superfamily. Expression
conditions were screened, the oligomeric state was established and purification procedures
were developed.
3.1.1 Cloning, small-scale expression and purification
Twenty kinesin motor domains, from eleven different subfamilies (almost half of the forty-
five kinesins identified in the human genome) were chosen as a first batch in the expression
trial (it was planned to test expression of all family members). They were subcloned into
two E. coli expression vectors: modified pET-M20 and pET-28a. The systematic and trivial
names, lengths of the constructs, pI, pH of buffers used in the purification and the molar
extinction coefficients are summarised in Table 2.2.
Six constructs were obtained by PCR (Chapter 2.2.1) and thirteen were purchased, as gene
synthesised, codon-optimised cDNA fragments. Post cloning, expression constructs were se-
quenced, and two verified clones for each kinesin (in each expression vector) were transformed,
into six different E. coli expression strains (Chapter 2.2.2). Subsequently, small-scale, semi-
automated purifications were performed using a Qiacube robot. This established purification
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conditions for nine different kinesin motor domains. The expected molecular weight is 52–
55 kDa for the constructs expressed in modified pET-M20 (Trx-fused constructs) and 39–42
when using pET-28a. An example of SDS-PAGE after small-scale purification is shown in
Figure 3.1. The summary of the expression trial is presented in Table 3.1. An average yield
from 12 l culture for each of the expressed protein is shown in (Table 3.2).
Figure 3.1: SDS-PAGE of small-scale purified kinesin motor domains, expressed in E. coli
BL21(DE3)pLysS cells. Lane 1 shows molecular weight markers (in kDa). Kif5A1´339 and
Kif78´361 overexpressed in modified pET-M20 (with an N-terminal Trx fusion protein) are
indicated with an arrow.
Construct BL21(DE3)
pLysS
BL21
(DE3)
BL21Codon
Plus(DE3)
Arctic
Express
Rosetta
(DE3)
pLysS
Origami2
(DE3)
pLysS
Kif3B1´354 pET-M20 pET-M20
Kif4B1´337 pET-M20
Kif5A1´339 pET-M20 pET-M20
Kif5C1´339 pET-M20 pET-M20
Kif78´361 pET-M20 pET-M20 pET-M20 pET-M20
Kif91´351 pET-M20 pET-M20 pET-M20 pET-M20 pET-M20 pET-M20
Kif1519´375 pET-M20
Kif24216´546 pET-M20
Kif271´341 pET-M20 pET-M20
pET-28a
pET-M20 pET-M20 pET-M20
Table 3.1: Summary of the human kinesin motor domain expression trial.
The identities of the kinesin motor domains were confirmed by mass spectroscopy fingerprint
analyses (Table 3.2).
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3.1.2 Determination of soluble kinesin oligomeric state and western blot
analysis of the remaining constructs
The majority of positive results (protein expression) were obtained in the modified pET-M20
vector, indicating a significant role of the TEV-cleavable, Trx fusion protein, in improving
protein solubility. This is in agreement with the performed western blot analysis on super-
natants and pellets of samples, for which no soluble protein was obtained. The experiment,
performed using pET-M20 constructs revealed, that the majority of constructs were in fact
expressed, but insoluble (Figure 3.2). The only non-expressed proteins were: Kif121´361,
Kif1710´347, Kif26A386´737 and Kif26B462´813. These were crosschecked, by re-verifying the
DNA sequence. All of the tested E. coli cultures grew to the comparable cell density.
Figure 3.2: Western blot analysis of soluble (S, supernatant) and insoluble (P, pellet) frac-
tions of kinesin cultures (pET-M20 constructs), that did not yield protein in the expression
trial: Kif1A1´355, Kif1B1´354, Kif2B208´555, Kif3A1´354, Kif6103´351, Kif121´361, Kif131´353,
Kif14366´713, Kif1710´347, Kif26A386´737 and Kif26B462´813. The antibody for His-tagged
proteins and His-tagged protein standard were used. The arrow points to the Trx-fused
constructs (expected molecular weight: 52–55 kDa) visualised with His-tag antibody.
Figure 3.3: Analytical gel filtration profile of Kif1519´375. The experiment was conducted
using a Superose 12 10/300 GL column with a flow rate of 0.5 ml/min.
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Soluble proteins were subjected to analytical gel filtration (Figure 3.3). As expected, all tested
kinesin motor domains appear to be monomers in solution, as shown by their calculated and
measured molecular weights (Table 3.2).
Construct Sequence
coverage [%]
Theoretical
molecular
weight [kDa]
Determined
molecular
weight [kDa]
Average yield
from 12 l E. coli
culture [mg]
Kif3B1´354 57 39.2 35 18
Kif4B1´337 55 37.0 40 12
Kif5A1´339 62 37.8 38 35
Kif5C1´339 71 37.7 38 32
Kif78´361 56 38.7 38 26
Kif91´351 80 39.5 36 24
Kif1519´375 65 39.0 37 31
Kif24216´546 59 37.7 39 15
Kif271´341 49 38.3 36 21
Table 3.2: Expressed kinesin mass spectroscopy fingerprint analysis, their theoretical and
determined by analytical gel filtration molecular weights and an average yield from 12 l
E. coli culture.
3.1.3 Large-scale protein production and purification
All soluble proteins were produced in large-scale (12 l) E. coli culture using the modified
pET-M20 vector constructs and a three-step purification procedure (Chapter 2.2.4). An
average yield from 12 l culture for each of the expressed proteins is shown in (Table 3.2).
In the first step cell lysate was applied to a 1 ml HisTrap FF column equilibrated with
Figure 3.4: Purification of Trx-fused, His-tagged Kif1519´375 using a 1 ml HisTrap FF column.
Post binding and washing the protein was eluted with a gradient of imidazole (indicated by
a green line).
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wash buffer. Post binding, the column was washed with 50 ml of wash buffer and protein
was eluted with a gradient of elution buffer (imidazole gradient, 40–500 mM) (Figure 3.4).
After elution, protein sample was supplemented with 1 mM Mg2`ATP (repeated after each
purification step). The protein-containing fractions were pooled, buffer-exchanged on the
desalting column and cleaved overnight with His-tagged TEV protease at 4˝C (Figure 3.5).
Subsequently, sample was subjected to the second run of the affinity purification. Untagged
protein flowed through the nickel column, whereas His-tagged TEV and His-Trx remained
bound to the resin (Figure 3.6).
Figure 3.5: TEV cleavage of Trx-fused Kif1519´375. The protein was cleaved overnight with
His-tagged TEV protease. Lane 1 shows molecular weight markers (in kDa). Lane 2 shows
Trx-fused Kif1519´375 after affinity purification (theoretical molecular weight — 51 kDa).
Lane 3 shows Kif1519´375 (theoretical molecular weight — 39 kDa) and His-tagged Trx (the-
oretical molecular weight — 12 kDa) post TEV cleavage.
Figure 3.6: Chromatography profile of Kif1519´375 second affinity purification. Post TEV
cleavage, untagged Kif1519´375 was flowed through a nickel column. His-tagged TEV and
His-Trx bound to the column and were removed by washing the column with elution buffer
(500 mM imidazole, indicated by a green line).
Once separated from His-tagged TEV and Trx, the protein sample was concentrated to 2.5 ml
and applied to a HiLoad Superdex S75 gel filtration column (Figure 3.7). All large-scale
produced kinesins were obtained with a purity close to 95% (Figure 3.8).
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Figure 3.7: Gel filtration profile of Kif1519´375. The final purification step, size exclusion
chromatography was performed using a HiLoad Superdex S75 column. Kif1519´375 eluted in
fractions B2–C5 (second peak).
Figure 3.8: SDS-PAGE of Kif1519´375 after the final purification step — size exclusion chro-
matography. Lane 1 shows molecular weight markers (in kDa). Subsequent lanes show
fractions from the gel filtration purification (Figure 3.7, fractions B2–C5). The theoretical
molecular weight of the construct is 39 kDa.
3.2 Kif15 characterisation
Kif15 functions in the early stages of mitosis, in the formation of the bipolar spindle, and it
possess partially overlapping function with Eg5 — a well-characterised mitotic motor. Drugs
targeting Eg5 have shown promise as anti-cancer agents. Kif15 has recently become interest-
ing because it can substitute the functions of Eg5, and may itself have potential as a prospec-
tive drug target. In this chapter initial biochemical, kinetic and structural characterisation
of Kif15 are presented and comparison to the functionally related motor — Eg5 is reported.
Additionally, the interaction of Kif15 with MTs, and attempt to probe its interaction with
other binding partners (actin, TPX2) are investigated.
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3.2.1 Biophysical characterisation of mammalian Kif15
Several constructs covering the entire length of Kif15 (Figure 3.9) were created. After se-
quence verification, positive clones were tested for expression conditions in E. coli, as de-
scribed previously (Chapters 2.2.1 and 2.2.2). The expression conditions were established for
all of them, apart from Kif15376´743. The summary of the expression trial is summarised in
Table 3.3.
19
1
375
375
376 743
744 1333
1017 1237
13881149
Figure 3.9: Bar diagram of cloned Kif15 constructs. Constructs presented in green cover the
motor domain. The blue constructs depict the disrupted (grey) coiled-coil. The C-terminal
leucine zipper is shown in yellow.
Construct Expression vector E. coli expression strain Avg. yield from 12 l
E. coli culture [mg]
Kif151´375 pET-M20 BL-21CodonPlus(DE3)-RIL 28
Kif1519´375 pET-M20 BL-21CodonPlus(DE3)-RIL 31
Kif15744´1333 pET-M20, pET-28a BL21(DE3)pLysS 11
Kif151017´1237 pET-M20 BL-21CodonPlus(DE3)-RIL 22
Kif151149´1388 pET-M20 BL21(DE3)pLysS 18
Table 3.3: Results of the Kif15 construct expression trial.
The identity of the purified proteins was verified by mass spectrometry fingerprint analysis
with a sequence coverage above 60% for all tested constructs. The molecular mass that were
determined for both motor domain constructs by gel filtration was 39 kDa for Kif151´375 and
37 kDa for Kif1519´375 (Figure 3.3), both close to their theoretical masses, indicating that the
Kif15 motor domain is monomeric, in agreement with other kinesins. The gel filtration profiles
for Kif15744´1333, Kif151017´1237 and Kif151149´1388 were heterogeneous, indicating possible
assembly into higher oligomers and/or partial aggregation. All Kif15 proteins were expressed
in large-scale culture. The protocol for large-scale expression and purification consisted of
nickel pull down of the His-tagged protein, buffer exchange to eliminate imidazole, overnight
cleavage of the tag with TEV protease, a second affinity purification to remove the His-
tagged protease and the cleaved tag, finally followed by gel filtration. The detailed procedure
is described in Sections 2.2.4, 2.3.1 and 3.1.3.
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3.2.2 Kif15 crystallisation and crystal optimisation
Crystallisation screening on the Kif15 motor domain (Kif1519´375) was performed and a single
crystallisation condition was identified. Crystals appeared after three days in the sitting drop
set at 19˝C in the presence of 1 mM Mg2`ATP, 25% PEG 3350, 0.2 M MgCl2 and 0.1 mM
Tris-HCl pH 8.5. They were small and difficult to handle (Figure 3.10), as drops were covered
with skin and precipitate. Additional difficulty arose from the fact that protein, snap-frozen
in the liquid nitrogen, failed to form crystals. Therefore, each optimisation attempt required
freshly purified protein (after purification, the protein stays soluble for up to 5–7 days at 4˝C).
Initial diffraction tests of small plate-shaped crystals revealed low crystal quality and poor
diffraction (14–10 A˚) (Figure 3.11). Several approaches to make the crystals bigger and more
three-dimensional were tested. Reducing the protein concentration from 10 to 6–7 mg/ml
and seeding promoted formation of larger and thicker crystals (Figure 3.10). Seeds were
prepared from initially obtained crystals, by crushing them with a thin needle and diluting
in 25% PEG 3350, 0.2 M MgCl2 and 0.1 mM Tris-HCl pH 8.5. Seeding was performed using
a cat whisker dipped into the seed stock and mixed into a freshly set crystallisation drop.
The other challenge presented by the Kif15 motor domain crystals was their high radiation
sensitivity, as the crystals decayed before a full data set could be collected. Radiation damage
is caused by the interactions of X-ray beam photons with electrons and creating photoelectric
electrons (primary radiation damage). This damage is proportional to the X-ray dose received
by the crystal. The created photoelectric electrons cause further crystal decay by creating
free radicals (secondary radiation damage). Their destructive influence can be reduced by
cryocooling. Various cryoprotectants that protect crystals from freezing damage and prohibit
ice formation were tested: meso-erythtritol, glycerol and ethylene glycol. Eventually several
hundreds of crystals were screened to obtain a single, full data set reaching 2.7 A˚. Figure 3.11
shows the diffraction quality of the Kif15 crystals before and after optimisation.
Figure 3.10: Kif1519´375 crystals, pre- (left) and post- (right) optimisation.
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Figure 3.11: Kif1519´375 crystals diffraction quality pre- (left) and post- (right) optimisation.
3.2.3 Crystal structure of the binary Kif1519´375-Mg2`ADP complex
The Kif15 motor domain structure was solved by molecular replacement and refined to a res-
olution of 2.7 A˚. Data collection and refinement statistics are shown in Table 3.4. Kif1519´375
crystallised in space group P3221 with three molecules in the asymmetric unit. Crystals had
a Matthews parameter of 2.4 and a solvent content of 49.1%. The rmsd from ideal geometry
was 0.013 A˚ for bond lengths and 1.60˝ for bond angles. The final model contains residues
24–375 for molecules A and B and residues 24–372 for molecule C. Due to missing or non-
interpretable electron density, several smaller loops that could not be built were deleted (loop
L1: Gly27–Glu32, loop L6: Glu148–Ala142, loop L11: Gln258–Gly272), and these are absent
Kif1519´375-Mg2`ADP
PDB ID 4BN2
Beamline / Detector ID23-1 / Q315R
Resolution range [A˚] 30–2.7
Space group P3221
Unit cell parameters [A˚; ˝] a “ b “ 90.24, c “ 251.39
α “ β “ 90, γ “ 120
Completeness [%] 89.7 (86.5)
Rmerge 9.8 (37.8)
Multiplicity 3.7 (3.5)
Mean I/σ 8.6 (3.1)
No. of total / unique reflections 108223 / 29592
No. of copies per AU 3
Rwork / Rfree [%] 21.2 / 26.3
No. of Mg2`ADP / water molecules 3 / 156
Bond length rmsd [A˚] 0.013
Bond angle rmsd [˝] 1.60
Table 3.4: Data collection and refinement statistics for Kif1519´375-Mg2`ADP complex. Val-
ues in parentheses are for the highest shell.
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from the model. Side chains, for which no density was observed, were deleted from the Cβ po-
sition onwards. The Ramachandran plot shows that 94.3% of residues are in favoured regions,
5.5% are in additionally allowed regions and 0.2% of residues are outliers. Since molecule A
presents better-defined electron density and a more complete model than molecules B and
C, it was used for further discussion of the structure. An exemplary electron density map of
Kif15 residues 89–96 is presented in Figure 3.12.
Figure 3.12: A model of Kif1519´375 residues 89–96 (β3, part of loop L4). The electron
density map (coloured in blue) is contoured at 1σ.
The Kif15 motor domain shows a typical kinesin fold with an 8-stranded β-sheet, surrounded
by three major α-helices on each side (Figure 3.13). The crystallised Kif15 construct con-
tains a neck linker, which aligns with the catalytic core, forming a small β-sheet. Although
Mg2`ADP is bound in the catalytic site, Kif15 is in the “ATP-like” conformation (see Fig-
ure 1.11). The switch II cluster (helix α4–loop L12–helix α5) is in the “upward” position
allowing the neck linker to dock to the motor domain (Figure 3.13, Figure 3.15).
3.2.4 Comparison of the Kif15 motor domain to the functionally related
motor Eg5
A comparison of the Kif15 motor domain to the functionally related motor Eg5 (Blangy et
al., 1995; Turner et al., 2001) was performed, using the AMP-PNP-Eg5 complex, representing
the “ATP-like” Eg5 state (PDB ID: 3HQD (Parke et al., 2009)). The sequence alignment of
Kif15 and Eg5 (Figure 3.14) shows the high similarity inside their motor domains, with 41.8%
identical, 15.5% strongly similar and 12.8% weakly similar residues, which is also reflected by
their structures (Figure 3.15). Outside their motor domains, the primary sequence is at best
only weakly conserved with 20.3% identical, 20.2% strongly similar and 9.8% weakly similar
residues. The Kif15 motor domain, compared with the Eg5 catalytic core, has a deletion
of two amino acids and a single insertion in the loop L1 region. Also, in the case of Eg5,
loop L1 is interrupted by helix α0, while in Kif15, loop L1 is longer. Loop L1 is part of the
L1-L3-L5 cluster that together with loop L9 mediates the entrance of the nucleotide (Song
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Figure 3.13: Stereo plots of the front and back view of the human Kif1519´375-Mg2`ADP
complex. α-helices are coloured in blue, β-strands in green and loops / turns in grey. The
switch II cluster (α4-L12-α5) is highlighted in claret. The neck linker, following the C-
terminal helix α6 is shown in cyan. Mg2`ADP is shown as a ball and stick model, indicated
with an arrow.
et al., 2001). In contrast to Eg5, three residues are missing in the Kif15 loop L2 region.
Four residues are missing in loop L5, five in loop L8 (loop L8 is implicated in MT-stimulated
ADP release (Fourniol and Moores, 2010)) and a single residue is missing in the surface loop
L10. There is a five-residue insertion in loop L6 of Kif15; this loop is believed to influence
nucleotide affinity (Kollmar and Glockner, 2003). Loop L5 is known to be important for
inhibitor binding in Eg5, in Kif15 this loop is shorter. In addition, several other key residues
involved in inhibitor binding in Eg5 such as Glu116, Arg119, Trp127 and Ala216 (Yan et al.,
2004) are not present in Kif15. All of these suggest that Kif15 could not be affected by Eg5
targeting drugs. Loop L11 is not visible in any of the three molecules of the asymmetric unit.
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Figure 3.14: Comparison of sequences and secondary structures of Kif15 and Eg5 motor
domains. Structural and sequence alignment of Eg5 (PDB ID: 3HQD (Parke et al., 2009)),
and Kif15 motor domains. Residue 16 of Eg5 is aligned with residue 24 of Kif15. Identical
residues are coloured in white on a red background and similar residues are shaded red. The
position of the ATP-binding pocket (N1 to N4), the switch I and II regions and the position of
the neck linker regions are underlined in black. The alignment was generated using ClustalW2
multiple alignment tool (Larkin et al., 2007). Figure was prepared using ESPript (Gouet et
al., 2003).
3.2.5 Steady state ATPase activity
Kinetic parameters for Kif151´375 and Kif1519´375 were measured (Table 3.5). To determine
the optimal salt concentration, rates of the basal ATPase activity were measured using NaCl
concentrations from 0 to 275 mM in buffer containing 1 mM ATP. The highest basal activity
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Figure 3.15: Structure overlay of Kif15 and Eg5-AMP-PNP complex. Front and back view
of overlaid Kif15 (green) and Eg5 (blue) (PDB ID: 3HQD (Parke et al., 2009)) structures.
Mg2` and AMP-PNP are shown as a ball and stick model.
was registered at 50 mM NaCl for the longer Kif15 construct and 75 mM NaCl for Kif1519´375
(Figure 3.16A). These salt concentrations were used in further basal activity tests. The differ-
ences in activity were rather minor and decreased only slowly at higher salt concentrations.
The basal ATPase activity was measured using ATP concentrations from 0 to 2 mM. At
1 mM Mg2`ATP the kcat for the basal ATPase activity of Kif151´375 was 0.028˘ 0.0004 s´1
with a KM,ATP of 23.0 ˘ 2 µM. In contrast, the shorter construct was more active with a
kcat of 0.054 ˘ 0.001 s´1 and a KM,ATP of 40 ˘ 6 µM (Figure 3.16B). Subsequently, the
salt dependence of the MT-stimulated ATPase activity of both constructs was determined,
by performing the reactions at MT concentrations from 0 to 10 µM in the presence of 0 or
Basal ATPase activity MT-stimulated ATPase activity
kcat [s
´1] KM,ATP
[µM]
kcat [s
´1]
(CKCl [mM])
K0.5,MT
[µM]
KM,ATP
[µM]
Kif151´375 0.028˘ 0.0004 23˘ 2 2.1˘ 0.1 (0)
0.050˘ 0.005 (50)
3.1˘ 0.3 109˘ 20
Kif1519´375 0.054˘ 0.001 40˘ 6 2.3˘ 0.1 (0)
0.50˘ 0.03 (50)
0.5˘ 0.1 (100)
0.4˘ 0.1 (150)
1.1˘ 0.1 33˘ 3
Table 3.5: Kinetic parameters determined for Kif151´375 and Kif1519´375. Kinetic parame-
ters were determined by fitting Michaelis-Menten curve by Kaleidagraph 4.0 using the least
squares method. The errors represent the standard error values of the curve parameters.
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Figure 3.16: Characterisation of the basal and MT-stimulated ATPase activities of Kif151´375
and Kif1519´375. (A) Influence of NaCl concentration on the basal ATPase activity of
Kif151´375 (blue) and Kif1519´375 (red), in the presence of 1 mM ATP. (B) Optimisation
of the basal ATPase activity in the presence of increasing ATP concentrations measured at
50 mM NaCl for Kif151´375 (blue) and 75 mM NaCl for Kif1519´375 (red). (C) Salt depen-
dence of the MT-stimulated Kif151´375 (blue) ATPase activity in the presence of 0 (˛) and
50 (ˆ) mM KCl; salt dependence of the MT-stimulated Kif1519´375 (red) ATPase activity in
the presence of 0 (‚), 50 (˝), 100 (˝) and 150 (‚) mM KCl; all measured at 1 mM ATP. (D)
Optimisation of the ATP concentration for the MT-stimulated ATPase activity of Kif151´375
(blue) and Kif1519´375 (red), in the presence of increasing ATP concentrations, measured at
3 µM MT in the absence of salt. The Michaelis-Menten curve was fitted by Kaleidagraph 4.0
using the least squares method (Chapter 2.3.5). Rates of activity were calculated using the
correlation between absorbance at 340 nm and kinesin activity. All measurements were done
at least in triplicate, error bars are indicated.
50 mM KCl for Kif151´375, and 0, 50, 100 or 150 mM KCl for Kif1519´375. With increasing
salt concentrations MT-stimulated ATPase activity decreased significantly, especially for the
Kif151´375 construct (Figure 3.16C). The kcat for the MT-stimulated ATPase activity was
2.1˘ 0.1 s´1 with a K0.5,MT of 3.1˘ 0.1 µM for Kif151´375 and 2.3˘ 0.1 s´1 with a K0.5,MT
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of 1.1˘ 0.1 µM for Kif1519´375. Finally, the MT-stimulated ATPase activity in the presence
of increasing ATP concentrations (from 0 to 2 µM) was determined, establishing a KM,ATP
of 109˘ 20 µM for Kif151´375 and a KM,ATP of 33˘ 3 µM for Kif1519´375 (Figure 3.16D).
3.2.6 Kif15 inhibitor screening
Initially, the effect of two potent Eg5 inhibitors, monastrol and STLC, on Kif15 ATPase activ-
ity was checked, both in the presence and absence of MTs (Figure 3.17), the more active Kif15
construct was used (Kif1519´375). As expected, Kif15 stayed fully active, even at the highest
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Figure 3.17: Inhibition of Kif15 (green) and Eg5 (blue) by monastrol and STLC. (A) Inhi-
bition of the basal ATPase activity in the presence of increasing monastrol concentrations.
(B) Inhibition of the MT-stimulated ATPase activity in the presence of increasing monastrol
concentrations. (C) Inhibition of the basal ATPase activity in the presence of increasing
STLC concentrations. (D) Inhibition of the MT-stimulated ATPase activity in the presence
of increasing STLC concentrations. The IC50 curve was fitted using Kaleidagraph 4.0 using
the least squares method (Chapter 2.3.6). All measurements were done at least in triplicate,
error bars are indicated.
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inhibitor concentration, up to 100 µM, while Eg5 was inhibited. In an effort to identify small
molecules inhibiting Kif15 ATPase activity, nearly 2500 compounds and 4000 natural product
Figure 3.18: Structures of twenty-one small molecules from the Kif15 inhibitors patent (Mc-
Donald et al., 2004) tested in the Kif15 ATPase assay.
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extracts were tested. The libraries were obtained in the 96-well plate format and were tested
using 96-well micro-clear plates and a Tecan Sunrise photometer. Each compound was tested
at a single concentration of 200 µM in the presence and absence of MTs. Unfortunately, none
of them inhibited Kif15 activity. Upon encountering a patent for Kif15 inhibitors (McDonald
et al., 2004), another approach to obtain a Kif15 inhibitor was undertaken. Twenty-one of
the small molecules from the Kif15 inhibitors patent (Figure 3.18) were purchased and their
influence on Kif15 activity, under basal and MT-stimulated conditions was tested. Addition-
ally, the possibility of the competitive inhibition was investigated, by measuring rates of Kif15
activity at a low ATP concentration, up to 100 µM. In all of these conditions Kif15 activity
was unaffected up to 200 µM of each compound. The patent does not provide any information
about the mechanism of action of the described compounds (quinazolinedione derivatives),
it only points to their inhibitory effect on Kif15 activity. Compounds were soluble in DMSO
and prepared as described in Section 2.3.6. DMSO was used as a control and did not have
any effect on Kif15 ATPase activity. In the used experimental setting (in vitro ATPase assay)
the possibility of the compound binding to the protein could not be ruled out (this could
possibly be investigated by NMR), but the possibility of inhibiting Kif15 enzymatic activity
was eliminated. Due to limited information presented in the patent it is difficult to speculate
as to why none of the inhibitors was effective.
3.2.7 Kif15 nucleotide-dependent MT-binding site
The affinity of Kif1519´375 for MTs in the presence of 2 mM Mg2`ATP, 2 mM AMP-PNP
and 4 mU apyrase (thus establishing the “nucleotide-free” state) was determined, using the
MT-pelleting assay. Increasing amounts of Kif1519´375 (1–12 µM) were incubated with MTs
(5 µM) and supplemented with nucleotide or apyrase. Post incubation and centrifugation
samples of supernatants and pellets were analysed by SDS-PAGE. The results are shown in
Figure 3.19. The KD values, as well as the stoichiometry of binding of Kif15 to MTs, are
summarised in Table 3.6. A portion of depolymerised MTs is visible in the supernatant.
Although MTs were prepared in the presence of taxol, polymerisation was not complete and
some of tubulin heterodimer is present in the soluble fraction of the sample. A comparable
amount of unpolymerised tubulin heterodimer was recovered from the supernatant in the
AMP-PNP Apyrase
KD [µM] 0.5˘ 0.2 0.4˘ 0.2
Bmax [µM] 3.5˘ 0.2 3.2˘ 0.2
Stoichiometry
(Kif1519´375 : MT)
1 : 1.1 1 : 1.3
Table 3.6: Dissociation constants, maximum binding capacity and the stoichiometry of bind-
ing of Kif1519´375 to MTs measured in the presence of 2 mM AMP-PNP or 4 mU apyrase.
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Figure 3.19: MT-pelleting assays in the presence of the Kif15 motor domain. (A) MT-
pelleting assays of the Kif15 motor domain in the presence of various nucleotides. Increasing
amounts of Kif1519´375 (1–12 µM) were incubated with MTs (5 µM) in the presence of 2 mM
Mg2`ATP, 2 mM AMP-PNP or 4 mU apyrase. Samples of supernatants and pellets were
analysed by SDS-PAGE. (B) MT-binding of Kif1519´375 in the presence of 2 mM Mg2`ATP,
2 mM AMP-PNP or 4 mU apyrase. The Michaelis-Menten curve was fitted by Kaleida-
graph 4.0 using the least squares method.
control experiment, where no Kif15 was added. In the presence of the slowly-hydrolysable
ATP analogue AMP-PNP or apyrase, Kif1519´375 shows comparable affinities for MT with
KD values of 0.5 ˘ 0.2 and 0.4 ˘ 0.2 µM, respectively, with a stoichiometry (Kif1519´375
to MTs) of close to one (1.1 and 1.3, respectively) indicating that one Kif15 motor domain
binds to one αβ-tubulin heterodimer, in agreement with results reported for other kinesins.
Under conditions tested, the Kif15 motor domain shows no affinity for MTs in the presence
of Mg2`ATP (in the presence of MTs, ATP is rapidly hydrolysed, the ADP-state is known to
possess low affinity for MTs). In conclusion, human Kif15 contains a nucleotide-dependent
MT binding region in its motor domain.
3.2.8 Investigation of the possibility of a second MT-binding site within
the Kif15 tail domain
The possibility of a nucleotide-independent MT-binding region in the Kif15 tail domain was
also investigated. A second MT-binding site has been identified in a variety of kinesin tail
domains (Chandra et al., 1993; Echard et al., 1998; Germani et al., 2000; Karabay and
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Figure 3.20: MT-pelleting assays for the Kif15 tail domain. Increasing amounts of
Kif151149´1388 (1–10 µM) were incubated with MTs (5 µM). No nucleotide was added. Sam-
ples of supernatants and pellets were analysed by SDS-PAGE.
Walker, 1999; Kuriyama et al., 1994; Liao et al., 1994; Meluh and Rose, 1990; Narasimhulu
and Reddy, 1998) and has been shown, in some cases, to be physiologically important for
their biological function. The data for the Kif15 tail-MT interaction are shown in Figure 3.20.
Kif151149´1388 did not bind to MTs in the pelleting assay, suggesting that the tail does not
contain MT-binding site.
3.2.9 Kif15 and actin binding investigation
To investigate a possible, direct interaction between Kif15740´1333 (the myosin homology do-
main) and actin in vitro, an actin-binding assay was performed (Figure 3.21). No binding was
detected under conditions tested for Kif15, while the positive control (α-actinin, cytoskeletal
actin-binding protein) co-pelleted with actin. Although this experiment did not reveal any
interaction, it cannot be ruled out, because of the limitations of the used methodology. It
Figure 3.21: Actin-binding assay. Samples of supernatants and pellets were analysed by
SDS-PAGE. Lane 1: F-actin alone. Lane 2: α-actinin alone. Lane 3: F-actin and α-actinin.
Lane 4: F-actin and BSA. Lane 5: Kif15740´1333 alone. Lane 6: F-actin and Kif15740´1333.
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is possible that designed construct was not sufficient for actin binding. Another possibility
is that binding requires an additional molecule mediating the Kif15-actin interaction that
was present in the in vivo scenario for which the binding was reported (Buster et al., 2003).
Unfortunately no information about such a partner protein is available in the literature.
3.2.10 Kif15 partner protein investigation
In order to investigate interactions between Kif15 and its binding partners, full-length TPX2
and the FHA domain of Ki-67 were cloned and tested for expression, under a variety of
conditions. Both were expressed in BL21(DE3)pLysS and purified from large-scale culture
(Figure 3.22). Purified TPX2 was used to determine its affinity for MTs. The pelleting assay,
in which increasing amounts of TPX2 (1–4 µM) was incubated with MTs (4 µM), revealed
high TPX2 affinity for MTs (KD “ 50 nM). Results are presented in Figure 3.23.
Figure 3.22: SDS-PAGE of purified Ki-67 FHA domain (left) and TPX2 (right). Lane 1 on
each gel shows molecular weight markers (in kDa). The expected molecular weight of the
proteins are 14 kDa for FHA domain and 86 kDa for TPX2.
Figure 3.23: TPX2 MT-pelleting assays. Samples of supernatants and pellets were analysed
by SDS-PAGE. Increasing amounts of TPX2 (1–4 µM) were incubated with MTs (4 µM).
CHAPTER 3. RESULTS 63
3.3 Characterisation of Kif7 and Kif27, Kinesin-4 family mem-
bers
Members of the Kinesin-4 superfamily are implicated in a variety of diseases, including Jou-
bert, Hydrolethalus and Acrocallosal Syndromes. They also play a role in primary cilium
formation and the Hedgehog signalling pathway. In this chapter, attempts to crystallise
members of the Kinesin-4 family are reported. The obtained high-resolution structure of the
human Kif7 motor domain is described and compared to conventional kinesin. In addition
influence of one of the published Kif7 mutations is sampled.
3.3.1 Kif7 and Kif27 cloning, expression and purification
Following proteins were cloned, expressed and purified: Kif78´347, Kif78´361, Kif271´341,
Kif271´339, Kif276´341, Kif2717´341, as described in Sections 2.2.1–2.2.4 (cloning primers are
Figure 3.24: Analytical gel filtration profile of Kif78´347. The experiment was conducted a
using Superose 12 10/300 GL column with a flow rate of 0.5 ml/min.
Figure 3.25: Analytical gel filtration profile of Kif271´341. The experiment was conducted
using a Superose 12 10/300 GL column with a flow rate of 0.5 ml/min.
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presented in Sections 2.2.1 and 2.4.1). Performed analytical gel filtration runs showed that
all constructs were monomeric, as expected for kinesin motor domains. The exemplary gel
filtration profiles are shown in Figure 3.24 and Figure 3.25. The proteins were 90–95% pure
as judged by SDS-PAGE, presented in Figure 3.26.
Figure 3.26: SDS-PAGE of fractions from gel filtration runs of Kif78´347 (left) and Kif271´341
(right). Lane 1 on each gel shows molecular weight markers (in kDa). The expected molecular
weight of the proteins are 37 kDa for Kif78´347 motor domain and 38 kDa for Kif271´341.
3.3.2 Kif7 and Kif27 crystallisation
Of all Kif7 and Kif27 constructs used for crystallisation screening, only Kif78´347, which lacks
the neck linker region, yielded crystals. None of the Kif27 constructs crystallised. Kif78´347
crystals grew in 20%PEG 3350, in the presence of one of various salts (0.2 M ammonium
nitrate, 0.2 M lithium acetate, 0.1 M magnesium formate dihydrate, 0.2 M potassium sodium
tartrate, 0.1 M sodium acetate, 0.2 M sodium nitrate), however, the best quality crystals were
obtained in the presence of lithium acetate, and this condition was used to reproduce crystals
at the micro-scale for X-ray diffraction data collection.
3.3.3 Kif7 motor domain structure
Kif78´347 crystallised with one molecule per asymmetric unit. Data were collected to 1.6 A˚,
thus Kif7 belongs to a small group of kinesin motor domains with X-ray structure solved to
higher resolution. A higher resolution structure was reported for Saccharomyces cerevisiae
Kar3 mutant motor domain (1.3 A˚) (Yun et al., 2001). Figure 3.27 shows diffraction quality
of the Kif7 crystals. An exemplary electron density map for Kif7 model is presented in
Figure 3.32. Data collection and refinement statistics are summarised in Table 3.7. The
final structure includes residues 12–347 (missing regions: 107–114, 207–211, 230–241, 260–
273) with bound Mg2`ADP (octahedrically coordinated) in the catalytic site, and 328 water
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Figure 3.27: Kif78´347 crystal X-ray diffraction image.
molecules. The refined structure contains 98.7% of residues in the most favourable region,
1.3% in allowed regions and no outliers. Figure 3.28 presents the overall structure of the
front and the back view of the Kif7 motor domain. Kif7 contains an 8-stranded β-sheet core
with three solvent-exposed α-helices on each side, displaying the characteristic arrowhead-like
structure, typical for all members of the kinesin superfamily solved so far (Kull et al., 1996).
Subsequently, Kif7 structure was compared to that of conventional kinesin, the founding
member of the kinesin superfamily. The alignment of Kif78´347 with conventional kinesin
(Kif5B) revealed their high structural similarity (Figure 3.29, Figure 3.30). The sequence
identity between the Kif5B and Kif7 motor domains is 37%. There are two single insertions
in Kif7 loop L2. The P-loop is conserved in both proteins. In both structures, helix α2
Kif78´347-Mg2`ADP
PDB ID 4A14
Beamline / Detector I04-1 / Pilatus 2M
Resolution range [A˚] 30–1.6
Space group P212121
Unit cell parameters [A˚; ˝] a “ 45.99, b “ 79.80, c “ 95.05
α “ β “ γ “ 90
Completeness [%] 99.9 (100)
Rmerge 3.2 (43.1)
Multiplicity 7.5 (7.5)
Mean I/σ 30.1 (4.4)
No. of total / unique reflections 46998 / 6746
No. of copies per AU 1
Rwork / Rfree [%] 18.25 / 20.67
No. of Mg2`ADP / water molecules 1 / 348
Bond length rmsd [A˚] 0.011
Bond angle rmsd [˝] 1.547
Table 3.7: Data collection and refinement statistics for Kif78´347-Mg2`ADP complex. Values
in parentheses are for the highest shell.
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Figure 3.28: Overall structure of Kif78´347 in complex with Mg2`ADP. α-helices are shown in
blue, β-strands in red and loop regions are shaded in grey. The switch II cluster (α4-L12-α5)
and the end of helix α6 preceding the neck-linker region (not visible in this structure) are
coloured in orange. Mg2`ADP is presented as a ball and stick model.
is interrupted by loop L5, Kif7 contains a three-residue insertion in this loop. Although
some electron density was visible for loop L5, residues Ala107 to Glu114 are missing, due
to its increased length and high flexibility. Several attempts were undertaken to build this
Figure 3.29: Structure overlay of Kif7 and Kif5B motor domain. Front and back view of over-
laid Kif7 (blue) and Kif5B (red) (PDB ID: 1BG2 (Kull et al., 1996)) structures. Mg2`ADP
is shown as a ball and stick model.
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region but each attempt caused appearance of negative electron density after refinement.
Once this part of model was deleted, the structure was refined again and positive electron
density appeared indicating that this region may possess a dual conformation. In Kif7,
the end of the second part of helix α2 has a single residue deletion, compared with Kif5B.
Another two-residue insertion in Kif7 occurs in the loop L8 region, which is fully visible in
the structure. Only residues Val159–Thr161 have an unclear density, which may suggest a
variable conformation of this part of the loop. In Kif5B, the switch I region (residues 199
to 205) consists of a small helix (α3a), whereas in Kif7 it forms a loop (L9). The remaining
part of switch I region is highly conserved in both proteins. In Kif7, there is an eight-residue
long insertion in loop L10, this region is disordered and not visible in the structure. Switch II
Figure 3.30: Sequence and secondary structure element alignment of Kif7 and Kif5B. Sec-
ondary structure elements derived from the crystal structures of the Kif5B (PDB ID: 1BG2
(Kull et al., 1996)) and Kif7 motor domains. Identical residues are coloured in white on a
red background, similar residues are shaded in red. The ATP-binding pocket and the switch
regions elements (N1 to N4) are underlined in black. The alignment was generated using
ClustalW2 multiple alignment tool (Larkin et al., 2007). Figure was prepared using ESPript
(Gouet et al., 2003).
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(Asp251–Glu257), which is highly conserved in both proteins and typically disordered in
kinesins, is not fully visible in the Kif78´347 structure. The switch II cluster (α4-L12-α5) is
in the down position, and one would expect the neck linker (Arg350–Asn356) to be either
unstructured, or structured, but in an undocked position with respect to the motor domain.
However, the neck linker is not included in this structure, due to the short length of the
crystallised Kif7 construct. Kif78´361 contained the neck linker region, but did not crystallise,
whereas Kif78´347, lacking the neck linker, revealed that the C-terminal residue Gln347 shows
crystal contacts, indicating that there would not be space for a neck linker in this crystal
form. This might explain why the longer Kif7 construct did not yield crystals. The loop
L11 region (Leu260–Ile273) is missing, as in most other kinesin structures. Kif7 contains a
three-residue insertion in fully visible loop L12.
3.3.4 Influence of the L130P mutation on the Kif7 motor domain
In a mouse model, a single mutation in the Kif7 motor domain (L130P) caused early em-
bryonic lethality. This mutation was introduced through N-ethyl-N-nitrosourea induction, in
order to determine the impact on Hh signalling (Liem et al., 2009). To investigate how L130P
mutation could influence the structure, the mutation was introduced into the expression con-
struct of the motor domain (Kif78´347). Although the construct carrying the mutation was
expressed in E. coli, the protein was insoluble (Figure 3.31).
Figure 3.31: Western blot analysis of soluble (supernatant) and insoluble (pellet) fractions of
Kif78´347 and Kif78´347 L130P. The antibody for His-tagged proteins and His-tagged protein
standard were used. The expected molecular weight for Kif78´347 is 37.3 kDa
Nevertheless, the structure of native Kif7 reveals that the L130P mutation would be situated
at the end of the second half of the interrupted helix α2 (Figure 3.32). It is possible that the
mutation of leucine to proline, a known “helix breaker”, could cause a significant change to
the protein’s secondary structure in this region. Also, there is one C-H-pi interaction between
Leu130 and Phe83 that is lost when leucine is mutated to proline.
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Figure 3.32: Stereo-plot of Kif78´347 helix α2 residues 128–132. The electron density map
(coloured in blue) is contoured at 1 σ. A single mutation in this region (L130P) causes
embryonic lethality.
Chapter 4
Discussion
4.1 Kinesin expression panel
Kinesins are known to perform a wide range of key cellular functions. Several human ki-
nesins have been linked to various diseases (Mandelkow and Mandelkow, 2002). Certain
mitotic kinesins, like CENPE and Eg5, are potential targets for drug development in cancer
chemotherapy (Huszar et al., 2009). Therefore, it is desirable to establish protocol for kinesin
expression conditions for at least one representative of each subfamily, to test the selectivity
of specific kinesin inhibitors, or to facilitate inhibitor screening for these, which are potential
targets. Last but not least, it is important to investigate kinesins from different subfamilies
to correlate cellular functions with activity data. As the E. coli expression system is the
most accessible, fast and cheap for in vitro protein expression, and it is employed in many
laboratories, it would be most advantageous to use it for future studies on kinesins.
Kinesin panels play an important role in elucidating the specificity of kinesin inhibitors for
drug discovery and for chemical genetics (a method of using small molecules as tools for
basic biological research, analogous to classical genetics, it requires a library of compounds
(equivalent to a mutation in classical genetics) and an assay to screen for a phenotype change).
In particular, for chemical genetics it is crucial to know how specific the inhibitors are. Small
subfamily-specific panels have been reported for Eg5 and CENPE (Rath and Kozielski, 2012)
and larger multi-species panels have been reported (DeBonis et al., 2004). Lately, several
kinesin panels of different size have been reported for the development of kinesin-targeting
drugs for cancer chemotherapy (Sakowicz et al., 2004; Skoufias et al., 2006). A range of
GST-tagged kinesins from different species are commercially available (Cytoskeleton, USA).
A common feature of most of these panels is that the exact conditions (construct length,
expression E. coli strain and strategy, purification protocol) used to obtain active kinesins
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are not given.
In this study, motor domain expression of almost half of human kinesins was investigated. Of
these, nine could be expressed and purified. In addition there are a few other human kinesin
motor domain which have been previously investigated. These include as yet unpublished
crystal structures submitted to the PDB by the Canadian Structural Genomics Consortium:
Kif2A (PDB ID: 2GRY), Kif2C (PDB ID: 2HEH), Kif3B (PDB ID: 3B6U), Kif3C (PDB
ID: 3B6V), Kif13B (PDB ID: 3GBJ), Kif22 (PDB ID: 3BFN), KifC1 (PDB ID: 2REP) and
KifC3 (PDB ID: 2H58). Other groups published structures of Kif5B (PDB ID: 1BG2 (Kull
et al., 1996)), CENPE (PDB ID: 1T5C Garcia-Saez et al., 2004)) and Eg5 (PDB ID: 1II6
(Turner et al., 2001)). The structure of human Kif18A has also been solved (PDB ID: 3LRE
(Peters et al., 2010)). There is also reported expression for Kif1C and Kif14 (Tcherniuk et
al., 2010). Other lab members have successfully expressed motor domains of three Kinesin-6
family representatives (Mklp1, Mklp2 and Mpp1). Taken together with kinesins tested in this
study, twenty-four out of forty-five of the human kinesin motor domains can be produced in
E. coli, although final statistics can only be provided once the other untested kinesins have
been subjected to the screening procedure. The other approach that may increase the success
Figure 4.1: Phylogenetic analysis (Dereeper et al., 2008) of human kinesin motor domains,
expressed and purified in E. coli in this study, and from a literature survey. The following
kinesin motor domains were expressed in this study: Kif3B, Kif4B, Kif5A, Kif5C, Kif7, Kif9,
Kif15, Kif24 and Kif27.
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rate in the expression trial is usage of other fusion proteins (MBP, SUMO, GST), as solubility
is clearly an issue for this family representatives. A simplified phylogenetic tree (Figure 4.1)
reveals that kinesins from thirteen out of fourteen subfamilies can be expressed, purified and
investigated. The only family with no reported E. coli expression is Kinesin-11, members
of this family (Kif26A, Kif26B) are rather atypical kinesins. Although they possess a motor
domain and bind to MTs, they lack ATPase activity. Kinesin-11 family members play a role
in neuronal development (Zhou et al., 2009). In summary, this work provides information
about expression conditions for a panel of human kinesins, which can be useful for kinetic
characterisation of medically relevant motors, and for specificity assays on small molecules
targeting medically relevant kinesins.
4.2 Kif15 and Eg5 fulfil overlapping roles in a distinct manner
The role of Kif15 role during bipolar spindle elongation and maintenance reveals that it may
be, under certain conditions, a functional homologue of Eg5, a protein crucial for bipolar
spindle initiation and separation. Although their mechanism of action is clearly different, both
proteins are able to work redundantly to fulfil similar roles. Homotetrameric Eg5 performs its
function because of its unique quaternary structure, allowing it to crosslink antiparallel MTs,
and with its plus-ended directed motility, slides them apart, to form the bipolar spindle. In
Eg5 Kif15
TPX2 Ki-67
Figure 4.2: Model of Kif15 and Eg5 mode of action during bipolar spindle formation.
Tetrameric Eg5 binds and slides MT poles apart. Kif15 associates with MTs via TPX2
or to chromosomes through its interaction with the FHA domain of Ki-67.
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contrast, Kif15 works as a dimer (Wittmann et al., 1998) and, as demonstrated in this study,
it does not contain a MT-binding site within its tail domain. The function of the MT-linker
is carried out by TPX2 through the Kif15 C-terminal leucine zipper region (Wittmann et al.,
2000) (Figure 4.2).
4.2.1 Kif15 enzymatic activity
Kif15 ATPase activity characterisation provided initial insight into its enzymatic mode of
action. A specific Kif15 feature is its low affinity for MTs (compared with that of a con-
ventional kinesin), in the case of both of the motor domain constructs tested. Kif151´375
construct possesses the first 18 residues that are thought to include the cover strand, a short
nine-residue N-terminal region shown to interact with the C-terminal neck linker in the case
of several other kinesin family members. These two regions have been shown to fold into
the so-called neck-cover bundle by forming a small β-sheet and creating a force generating
element in several members of the kinesin superfamily (Hwang et al., 2008; Khalil et al.,
2008). In the case of Kif15 ATPase activity, with the exception of a threefold difference in
the KM,ATP and K0.5,MT values there was no significant difference between Kif151´375 and
Kif1519´375, indicating that the presence or absence of the cover strand does not significantly
change its ATPase characteristics.
4.2.2 Kif15 and partner proteins
Two reported partner proteins of Kif15 were cloned, expressed and purified — TPX2 and
the FHA domain of Ki-67. Due to project termination, only initial characterisation was
performed, confirming tight binding of TPX2 to MTs. The resultant production protocol for
both protein production will be useful for further studies.
4.2.3 Kif15 function and clinical implications
Due to their similar functions, Kif15 may be able to take over the role played by Eg5,
following anti-Eg5 chemotherapy, by simply up-regulating protein expression levels, at least
in cell culture (Tanenbaum et al., 2009). Such an interchange of abilities of the two motors
is supported by observations in neuronal cells (Liu et al., 2011), which are non-mitotic,
suggesting a broadly applicable theme, by which two structurally different motors can share
a function but not a mechanism of action. If this scenario of a possible resistance mechanism
were true for certain tumours, co-inhibition of both motors, Eg5 and Kif15, could be a vital
therapeutic approach. In light of recent studies it is apparent that Kif15 can overcome Eg5
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inhibition after nuclear envelope breakdown (the initial events of mitotic division), after the
centrosome separation is bypassed by nuclear envelope dynein (Raaijmakers et al., 2012;
Tanenbaum and Medema, 2010). The crystal structure of human Kif15 obtained in this work
will be a valuable asset for structure-guided drug design. The comparison of both of motors
revealed that despite overall similarity, Kif15 and Eg5 have important differences allowing
Kif15 to be impervious to Eg5 targeting drugs.
4.3 Kinesin-4 family members
The primary cilium, made of non-motile MTs, is a Hedgehog signalling transduction centre
in vertebrate cells, where Kif7 plays a significant role in Gli protein trafficking (Figure 4.3).
The Kif7 motor domain structure provides a first insight into Kinesin-4 family member struc-
ture. During investigation of the family representatives, several attempts to measure kinetic
parameters of Kif7 and Kif27 constructs were undertaken, yet none of these was successful
due to abnormal protein behaviour during the ATPase assay. Each attempt to measure the
activity resulted in random data with no obvious trend and the attempts to fit the Michaelis-
Menten curve were unsuccessful. The solved structure of Kif7 motor domain did not reveal
Gli
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Sufu
Kinases
IFT
GliA
GliA
GliA
Kif7
(+)
Dynein
motor
Basal body
Ptch1
Smo
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Figure 4.3: The Hedgehog signalling pathway in the primary cilium. (Left) When ligand is
not present, Ptch1 is localised to the cilium, inhibiting membrane internalising of Smo. Kif7
prevents Gli enrichment. (Right) Upon ligand binding, Smo localises to the membrane, Kif7
moves onto cilium MTs, therefore promoting Gli accumulation at the cilium tip. Addition-
ally, Kif7 can block Sufu activity. The reverse transport is accommodated by dynein and
intraflagellar transport (IFT) elements. Figure adapted from Goetz and Anderson (2012).
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any abnormal features of Kif7 catalytic core. On the contrary it shows its high similarity to
the conventional kinesin motor. Even though the purified protein seems pure as judged by
SDS-PAGE (Figure 3.26), it is possible that a minor contaminant is impeding the ATPase
assay. Although some information is available about the involvement of kinesins in the ver-
tebrate signalling centre, it still is vague and requires further investigation. The question
regarding Kif7 regulation is still open. Is there an autoinhibitory mechanism that the protein
undergoes? Does it require conformational change? How is its localisation regulated? From
available studies, it is justified to assume that Kif7 motoric activity is crucial for early stages
of development, and its lack or malfunction can lead to a set of neurodegenerative diseases
and cancers (Dafinger et al., 2011; Putoux et al., 2011). In the future, it will be interesting to
determine whether Kif7 and its closely related paralogue Kif27 are proteins worth targeting
in the Hedgehog signalling pathway (Sarangi et al., 2009).
Part II
Structural and biochemical insights
into members of the ubiquitin
ligase family
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Chapter 5
Introduction
5.1 Ubiquitin and ubiquitin-like proteins
Ubiquitin is an 8.5 kDa protein known for its ability to covalently modify other proteins
(either as monoubiquitin or polyubiquitin chain), and in so doing, changing their fate. This
protein is a prototype of ubiquitin-like modifiers (Ubls) family. The family members possess a
common globular fold with one α-helix and four major β-strands (Schwartz and Hochstrasser,
2003). An other typical quality of the mature form of Ubls is the possession of diglycine at
their flexible, carboxy-terminal end. Surprisingly, regardless of their high structural homol-
ogy, no apparent sequence similarity is observed. The presence of the diglycine motif at their
C-terminus is essential for their activation and subsequent formation of an isopeptide linkage
between the Ubl’s C-terminal carboxyl group and the amino group of the lysine side chain
of the substrate (see Section 5.2). The process of utilising a covalently bound protein as a
signalling event is unique for eukaryotes, although there are prokaryotic proteins exhibiting a
ubiquitin-like fold (probably due to a shared ancestor) (Dye and Schulman, 2007). The Ubl
family includes the following members: SUMO (three types in higher eukaryotes), which
Figure 5.1: Typical fold of ubiquitin-like modifiers. The overall structure is presented for
ubiquitin (A) (PDB ID: 1UBQ, (Vijay-Kumar et al., 1987)), SUMO-1 (B) (PDB ID: 1Y8R,
(Lois and Lima, 2005)) and NEDD8 (C) (PDB ID: 1NDD, (Whitby et al., 1998)).
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plays roles in DNA repair and transcription modification, nucleoplasmic transport and signal
transduction (Johnson, 2004); NEDD8, involved in cell cycle progression, cytoskeletal regula-
tion and signalling (Pan et al., 2004); ATG8 and ATG12, controlling autophagy by membrane
modulation (Geng and Klionsky, 2008). Examples of ubiquitin-like proteins structures are
presented in Figure 5.1.
Due to the presence of seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) within
the ubiquitin sequence, different types of chains can be created. This is achieved via the
formation of an isopeptide linkage between the C-terminus of incoming ubiquitin and the
lysine side chain of the growing ubiquitin chain. Different types of ubiquitin chain can lead to
distinct cellular signals (Pickart and Eddins, 2004). The best-studied K48-linked chain targets
protein for degradation by the proteasome (Finley et al., 1994), whereas the K63-linked chain
is associated with DNA repair and protein trafficking (Zhao and Ulrich, 2010). In addition,
substrates can also be monoubiquitinated or monoubiquitinated at multiple lysine sites. This
type of modification has been implicated in histone modification, subcellular localisation and
lysosome-dependent degradation (Pickart and Eddins, 2004). Creation of chains has been
reported in the case of SUMO as well, although its role is not clear (Bylebyl et al., 2003).
5.2 Ubiquitin conjugation cascade
The process of ubiquitin attachment to the target protein can be summarised as conjugation
of the C-terminal glycine to the amino-group, usually supplied by lysine (or the protein N-
terminus) through formation of an isopeptide bond. This process is driven in a cascade-like
manner and coordinated by a set of enzymes: E1 — activating enzyme, E2 — conjugating en-
zyme and E3 — ligase (Dye and Schulman, 2007). The ubiquitination pathway is summarised
in Figure 5.2.
The first step in the ubiquitination pathway is driven by E1. The process of activation
comprises two steps. The mature form of ubiquitin, with its C-terminal diglycine motif, is
activated by ubiquitin-specific E1 in the presence of Mg2`ATP, by forming an acyl-phosphate
linkage with AMP (E1 is known to have a low affinity for ubiquitin in the absence of ATP).
Subsequent attack by the E1 catalytic cysteine on the ubiquitin-AMP complex leads to the
formation of a thioester linkage and AMP release. Each of the ubiquitin-like proteins possesses
a dedicated E1 enzyme. E1 contains three distinct domains: an adenylation domain, a
catalytic cysteine-containing domain and the ubiquitin-fold domain involved in E2 binding
(Huang et al., 2004).
Ubiquitin is transferred from E1 onto E2, the conjugating enzyme, through a transthioesteri-
fication reaction to the E2 catalytic cysteine forming an E2„ubiquitin conjugate („ indicates
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Figure 5.2: The ubiquitination pathway. E1 activates ubiquitin in an ATP dependent manner.
Post-activation, ubiquitin is linked with the catalytic cysteine on E1, which in the next step is
transferred onto the catalytic cysteine of E2. Further ubiquitin is passed onto the specific E3
ligase and finally onto the substrate. Figure adapted from Nakayama and Nakayama (2006).
a thioester bond). Single E2s exist for SUMO (Ubc9) and NEDD8 (Ubc12). Ubiquitin pos-
sesses a large family of E2 enzymes (about 40 in humans). E2s provide an additional step of
ubiquitination control and their variety facilitates interactions with an even more abundant
group of E3 ligases. All E2s contain a globular domain with a typical fold („17 kDa), pos-
sessing a catalytic cysteine positioned in the conserved sequence presented on the E2 surface
(Pickart, 2001).
E3 ligases generally contain two domains: an E2 binding domain and a substrate recognition
domain. E3 functions by recruiting E2„ubiquitin and its specific substrate and promoting
ubiquitin transfer from E2 to the lysine or N-terminus of the substrate (Dye and Schulman,
2007). Hundreds of E3s present in the human genome confer distinct substrate specificity
and regulate diverse cellular processes (Peng et al., 2003). The ubiquitination system also
employs deubiquitinating enzymes that deconjugate ubiquitin, thereby fulfilling regulatory
functions (Reyes-Turcu et al., 2009).
The complexity of the system arises from the presence of two E1s, tens of E2 enzymes that can
contact hundreds of E3s, which then pass the ubiquitin chain onto thousands of substrates
(Hershko and Ciechanover, 1998). This setup is further complicated by the possibility of a
single substrate binding to various E3s (Figure 5.3).
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Figure 5.3: The E1-E2-E3 system and its complexity. A single E1 activating enzyme passes
ubiquitin to tens of E2 enzymes and further via hundreds of E3s to thousands of substrates.
Figure adapted from Nalepa et al. (2006).
5.3 Ubiquitin ligase family
The large family of ubiquitin ligases is divided into three groups (according to their E2„Ubl
binding domains): HECT (Homologous of E6AP Carboxy Terminus), RING (Really inter-
esting new gene) and those that could not be classified into either group (Deshaies, 1999;
Metzger et al., 2012). RING E3s are the largest family with approximately 600–700 mem-
bers in the human genome (Dye and Schulman, 2007). RING E3s generally bind to the
E2„ubiquitin complex via their RING domain and are responsible for activation of the
E2„ubiquitin thioester linkage to facilitate discharge onto the substrate. By forming different
E2-E3 pairs, both mono and polyubiquitination of different linkage types can be assembled.
Unlike HECT E3s, RING ligases do not involve an intermediate state of thioester bound
E3„ubiquitin (Deshaies and Joazeiro, 2009). Differences between HECT and RING ligase
modes of action are presented in Figure 5.4.
The RING domains are characterised by two zinc ligands with each coordinated by four
cysteine / histidine residues. The unique zinc ligand configurations create a platform for
E2„ubiquitin binding (Deshaies and Joazeiro, 2009). Often the RING domains dimerise,
thereby creating either homodimers (for examples RNF4 and BIRC7) or heterodimers (for
example Mdm2-MdmX). Some RING E3s function in a higher oligomeric state (for example
the Prp19 tetramer), while others form multi-subunit complexes such as the cullin RING
ligases. Very few function as monomers (e.g. Mindbomb) (Metzger et al., 2013).
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Figure 5.4: Differences in the course of action of two classes of E3 ligases, HECT and
RING. RING E3s transfer ubiquitin directly onto the substrate, whereas HECT E3s form an
E3„ubiquitin thioester intermediate via their conserved cysteine residues. Figure adapted
from Deshaies and Joazeiro (2009).
E3s are regulated, often-involving posttranslational modifications, for example phosphoryla-
tion (Metzger et al., 2013). The complexity of the system where most E2-E3 pairs are not
known, where one E3 can modify several substrates and a single substrate may be the target
of a number of E3s, is tremendous and not well ascertained (Metzger et al., 2013).
5.4 Significance of ubiquitination
It has been reported that mutations within RING E3s are associated with various diseases,
by impairing their ability to control DNA repair, malignancy and tumour suppression (Lip-
kowitz and Weissman, 2011; Metzger et al., 2013; Nakayama and Nakayama, 2006). The
importance of ubiquitination is not limited to the maintenance of genomic stability. It is also
important for successful cell cycle progression, subcellular localisation and signal transduc-
tion (Lipkowitz and Weissman, 2011). Due to the significance of implicit ubiquitin ligases
in cancer formation and malignancy, the ubiquitin system has become a drug target. Ap-
proaches to targeting varies. Some strategies are concentrated on specific E3s, others target
the proteosome. Bortezomib also known as Velcade is the first inhibitor of the 26S proteasome
used in cancer therapy (Adams and Kauffman, 2004; Bonvini et al., 2007). It is a dipeptide
and comprises of pyrazinoic acid, phenylalanine and leucine with a boronic acid instead of a
carboxylic acid. The boron atom of the peptide specifically binds to the proteasome with a
high affinity. Bortezomib is successfully used in the clinic, predominantly in the treatment of
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patients with multiple myeloma. Major treatment associated side effects are peripheral neu-
ropathy, neutropenia and thrombocytopenia (Field-Smith et al., 2006). Therapies targeting
specific E3 ligases are more challenging (Garber, 2005). Although one could speculate that
targeting a particular E3 ligase would allow high specificity, it is important to keep in mind
that many substrates of each E3 ligase are unknown and it is difficult to anticipate possible
side effects. Nonetheless E3 ligases are extensively studied and several reports have been pub-
lished focused on ubiquitin ligase targeting, either by precluding protein-protein interaction
like nutlins (cis-imidazoline analogues) in case of MDM2-p53 interaction (Vassilev, 2004), or
by allosteric inhibition as in a case of SCF ubiquitin ligase (Orlicky et al., 2010).
5.5 Trim28 — characteristic and architecture
Trim28 — tripartite motif-containing 28 (other names include KAP1 and TIF1β), a member
of the Trim family of proteins, is involved in various cellular processes such as cell growth,
differentiation and development. KAP1 (Kru¨ppel-associated protein 1) was first described
due to its interaction with KRAB domains (Kru¨ppel-associated box) of the zinc finger proteins
(ZFP), the largest family of transcriptional factors (Friedman et al., 1996). Trim28 is a
corepressor of zinc fingers, and is targeted to DNA by interacting with them. In doing so,
Trim28 creates a scaffold for chromatin modifiers. Trim28 possesses an N-terminal RING
domain, followed by two B-box domains (zinc finger domains) and a coiled-coil region. This
fragment is often termed RBCC, and is a hallmark of the Trim family of proteins. In RBCC
motif all of the components work together in order to oligomerise or bind to the ligand.
KRAB domains interact with the Trim28 RBCC with high affinity in a 1:3 ratio (KRAB
to RBCC). Furthermore, the protein contains a C-terminal PHD domain (resembles the
RING mechanism of metal binding) with an adjacent Bromo domain (BRD, which recognises
acetylated lysine residues) (Friedman et al., 1996; Peng et al., 2007; Zeng et al., 2008). The
Trim28 domain layout is depicted in Figure 5.5.
RING
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Figure 5.5: Schematic representation of Trim28 and its domains. N-terminal RING, two
B-box domains and coiled-coil create RBCC motif. Protein terminates with PHD-BRD tan-
dem. Figure adapted from Zeng et al. (2008).
5.5.1 Trim28 as a transcription corepressor
Trim28 is best characterised in the context of its function in gene silencing. The N-terminal
RBCC motif interacts with zinc finger KRAB domains enabling Trim28 to be presented in
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close proximity to DNA. The PHD and BRD domains are typical attributes found in chro-
matin associated proteins, both of them have been shown to be able to recognise histone tails,
in addition they have the ability to cooperate and recruit binding partners. The Trim28 PHD-
BRD tandem has been shown to influence chromatin state by engaging histone deacetylase
and methylase. Deacetylation and methylation lead to transcription repression (Figure 5.6).
Histone acetyl group
Histone methyl group
SUMO
Ubc9HP1
HMTHDAC
DNADNA
Trim28
KRAB
Zn ﬁnger protein
Figure 5.6: Scheme of Trim28 action mode in gene silencing. Trim28 binds to KRAB domains
of the zinc finger proteins and recruits deacetylation and methylation machineries. It also
recruits HP1 proteins. The process of gene silencing is controlled by sumoylation of the BRD
domain mediated by the PHD motif. The PHD domain acts as a SUMO E3 ligase. Figure
adapted from Friedman et al. (1996).
It has been reported that the ability of Trim28 to act as a scaffold for the binding of other
proteins is controlled by sumoylation. The PHD domain serves as an intramolecular SUMO
E3 ligase and recruits SUMO E2 — Ubc9 to modify the adjacent BRD domain (Peng and
Wysocka, 2008). The addition of SUMO serves as a signal for the recruitment of deacetylation
and methylation machineries. Although sumoylation has been detected on multiple sites
within the Trim28 sequence, the majority of the modifications were present on the Lys779
and Lys804 of the BRD domain (Ivanov et al., 2007). The NMR spectroscopy structure of
the Trim28 PHD-BRD domain provided an insight into their overall fold (Figure 5.7) (Zeng
et al., 2008). Like the RING domain, the PHD domain binds to two zinc ligands coordinated
by four cysteine / histidine residues. The zinc ligand binding supports a globular fold of the
domain.
Intriguingly, other posttranslational modification such as phosphorylation on the unique
Ser824 residue, by nuclear ATM protein kinase, in response to DNA damage, inhibits Trim28
sumoylation and prevents gene silencing (Li et al., 2007). Ser824 phosphorylation has also
been shown to promote chromatin relaxation (Ziv et al., 2006). Trim28 deficient cells have
been shown to by highly sensitivity to radiation (Ivanov et al., 2007).
Trim28 has also been shown to recruit HP1 protein family members (non-histone, hetero-
chromatin-associated protein with a function in gene silencing) while being associated with
KRAB domains. The region of the direct interaction has been assigned to involve residues
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Figure 5.7: Overall fold of the Trim28 carboxy-terminal fragment. The PHD-BRD tandem,
with the PHD domain (lime) and BRD domain (blue). Zinc ions are depicted as pink spheres
(PDB ID: 2RO1) (Zeng et al., 2008).
located between coiled-coil and PHD domains. Existence of such an interaction pointed to the
possibility of a more elaborate Trim28 function in chromatin organisation, beyond the histone
tail modifications (Ryan et al., 1999). Furthermore, a study showed that Trim28 interacts
with the acidic domain of Mdm2 via its coiled-coil region. This interaction promotes p53
ubiquitination and degradation (Wang et al., 2005).
5.5.2 Trim28 as a RING E3 ligase
Although Trim28 contains an N-terminal RING domain, its ubiquitin ligase activity remains
elusive. A recent study investigated the ubiquitin ligase activity of Trim28. It was shown
that Trim28 does not function efficiently as a ubiquitin ligase on its own. A Mage-C2 protein
has been identified as a partner protein that enhances the Trim28 ligase activity (Doyle et
al., 2010). Mage family members were initially considered as tumour-specific antigens. They
possess a conserved MHG (Mage homology) domain and are involved in the interaction with
RING E3s, though the interaction itself does not occur via the RING domain. How Mage-C2
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Figure 5.8: A model of Mage-C2 interactions with the Trim28 RING and an E2 enzyme. This
protein-protein interactions were reported to promote the ligase activity of Trim28. Figure
adapted from Espantman and O’Shea (2010).
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stimulates Trim28 ubiquitin ligase activity is not clear (Figure 5.8) (Doyle et al., 2010; Feng
et al., 2011).
5.5.3 Trim28 and diseases
Trim28 is overexpressed in many cancers and contributes to p53 inactivation. Its upregulation
has been linked to poor prognosis for patients with gastric cancers (Hatakeyama, 2011; Iyen-
gar et al., 2011). Trim28 has also been shown to highly express in the central nervous system
and its loss is linked to anxiety-like behaviour in mice, consistent with a role in chromatin
regulation during brain development (Alter and Hen, 2008).
5.6 Objectives
The objectives of this project were:
– to obtain structural information about Trim28;
– to elucidate how Trim28 functions as an E3 ligase;
– to investigate the interactions of Trim28 with partner proteins.
Chapter 6
Materials and methods
The majority of materials and methods used in the Trim28 study were equivalent to those
described in the first part of the thesis. All additional techniques and reagents are described
below.
6.1 Materials
cDNAs were purchased from Life Sciences. GSH-Sepharose resin and glutathione were pur-
chased from GE Healthcare. Platinum Taq DNA polymerase was bought from Invitrogen.
A 10 ml SourceQ and a 10 ml SourceS columns were prepared by Dr. Danny Huang using
GE Healthcare resin. Dr. Gary Sibbet generated DH5α and BL21(DE3) competent cells.
All produced proteins were expressed using BL21(DE3) E. coli strain. All expression vectors
were obtained from previous lab members. Dr. Gary Sibbet performed all SPR experiments.
6.2 Methods
6.2.1 Trim28 cloning, expression and purification
Two constructs were obtained from Dr. Danny Huang — full-length Trim28 and Trim2833´412,
both in pGEX-4T1-TEV (N-terminal GST fusion protein, TEV cleavage site) (Figure 6.1).
The constructs carry GST-fusion protein. GST — glutathione S-transferase is a 26 kDa pro-
tein which has a potential to improve the solubility of the expressed protein. Additionally
once fused to a protein of interest, it can be used to pull-down from a lysate as GST has
a strong binding affinity for GSH. Once bound to the resin the protein is washed and then
eluted with free GSH excess.
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Thereafter additional constructs were created using Platinum Taq DNA polymerase. De-
signed primers included STOP codon. The PCR reaction was conducted with following
cycling parameters: initial denaturation — 94˝C, 2 min; 35 extension cycles (94˝C, 30 sec;
55˝C, 30 sec; 68˝C, 1 min); final extension — 68˝C, 10 min. The PCR primers are shown in
Table 6.1. PCR products were restricted with BamHI or BglII and EcoRI and ligated with
Quick Ligase into modified pGEX vector — pGEX-4T1-His-TEV (His-tag followed by a GST
and TEV cleavage site, engineered by Dr. Lori Buetow) (Figure 6.1). Verified clones were
transformed into BL21(DE3) cells.
Construct Forward primer Reverse primer
Trim2861´241 5’ CCG GGA TCC ATG CTG
CTG GAG CAC TGC 3’
5’ GGG GAA TTC TTA CTG GTG
GTC CTT GTG GGC 3’
Trim2833´149 5’ CG AGA TCT TCC ACC
GCC CCT TCG GC 3’
5’ CG GAA TTC TTA CGC ATC
CTG GGC GTC GG 3’
Trim28625´685 5’ CCG GGA TCC ATG GCC
ACC ATT TGC CG 3’
5’ GGG GAA TTC TTA ATC CAG
GCT GAG GCT GCC ATC C 3’
Trim28695´801 5’ CCG GGA TCC AAG CTC
TCA CCA GCC AAC CAG 3’
5’ GGG GAA TTC TTA ACC GAA
GGC CTC GTT CAT GCT 3’
Trim28625´801 5’ CCG GGA TCC ATG GCC
ACC ATT TGC CG 3’
5’ GGG GAA TTC TTA ACC GAA
GGC CTC GTT CAT GCT 3’
Table 6.1: Trim28 constructs cloned from the full-length DNA. The construct boundaries,
forward and reverse primers are presented.
12 l cultures in LB media were grown, harvested and lysed as described before (Section 2.2.4).
The purification protocol consisted of a GST pull-down on a 10 ml GSH-Sepharose column
at 4˝C (wash buffer: 150 mM NaCl, 50 mM Tris-HCl pH 7.6, 1 mM DTT; elution buffer:
150 mM NaCl, 50 mM Tris-HCl pH 7.6, 5 mM DTT, 10 mM glutathione). After applying
lysate through the column, resin was washed with 5 ml of wash buffer for each 1 ml of the
lysate. Once eluted proteins were desalted (150 mM NaCl, 50 mM Tris-HCl pH 7.6) and
cleaved with TEV overnight at 4˝C (0.05 mg TEV / 1 mg protein). Post cleavage proteins
were applied back through a 10 ml GSH-Sepharose or 5 ml HisTrap FF for proteins bearing
His-tag to remove GST (or His-GST). Afterwards samples were diluted with 50 mM Tris-
HCl pH 7.6 to reduce salt (NaCl) concentration in the sample to 20 mM and applied to
ion exchange column — a 10 ml SourceQ column (anion exchange). Only Trim2833´412 was
applied to the 10 ml SourceS (cation exchange), due to its basic pI. Following buffers were
used: wash buffer: 10 mM NaCl, 50 mM Tris-HCl pH 8.6 (Q column)/ MES pH 6.0 (S
column), 1 mM DTT; elution buffer: 500 mM NaCl, 50 mM Tris-HCl pH 8.6 (Q column)
/ MES pH 6.0 (S column), 1 mM DTT. Ion exchange chromatography enables proteins
separation according to their charge (affinity to the ion exchanger). Changing the pH of the
buffer changes the net charge of the protein and its ability to bind to the ion-exchanger. For
cation exchangers (S), a buffer must have a pH at least 1 pH unit below the pI of protein
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Figure 6.1: E. coli expression vectors used in the Trim28 study. A pGEX-4T1-TEV possesses
N-terminal GST fusion protein and TEV cleavage site. A pGEX-4T1-His-TEV possesses
N-terminal His-tag followed by a GST and TEV cleavage site. A pRSF-Duet possesses N-
terminal His-tag followed by TEV cleavage site. A pRSF-MBP-Duet possesses N-terminal
His-tag followed by an MBP fusion protein and TEV cleavage site. Post TEV cleavage all
constructs carry additional glycine and alanine residues on the N-terminus. The plasmid-
mediated resistance and used restriction sites are indicated.
to be bound and for anion exchangers (Q), at least 1 pH unit above the pI of protein to be
bound. Proteins were eluted with a salt gradient (ionic strength). The final step involved
size exclusion (150 mM NaCl, 50 mM Tris-HCl pH 7.6, 1 mM DTT) on a HiLoad Superdex
S200 for full length Trim28 and Trim2833´412, and a HiLoad Superdex S75 for the rest of the
proteins. Pure proteins were concentrated using an Amicon system.
6.2.2 Trim28 crystallisation, crystal optimisation and testing
Purified proteins were used for crystallisation screening (Trim28, Trim2833´412, Trim2833´149,
Trim2861´241 — 6 mg/ml; Trim28625´685 — 8 mg/ml; Trim28625´801 — 11 mg/ml), us-
ing screens specified in Section 2.3.2. Crystals were obtained in the first instance for the
full-length protein (19˝C; 1.2 M ammonium sulphate, 0.1 M Hepes pH 7.0). Optimisation
attempts were undertaken to improve the initial crystal form. Besides those described in
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Section 2.3.3, other approaches were applied, like growing crystals on top of Fluorinert solu-
tion (used for floating crystallisation, has viscosity similar to water and 75% greater density,
not miscible with most crystallisation reagents, crystals grown using Fluorinert do not stick
to the crystallisation plate), addition of 0.1% high purity agarose (crystallisation in agarose
gel, reduce nucleation) and utilising dialysis buttons (crystallisation by dialysis). The second
crystallised construct was Trim2833´412 (19˝C; 1.1 M ammonium tartrate dibasic pH 7.0;
5% Tacsimate pH 7.0, 0.1 M Hepes pH 7.0, 10% PEG MME). Trim2833´412 crystals were
improved by addition of detergents and additives (10% TRITON X-100, 10% CYMAL-1) in
the crystallisation solution. Various cryoprotectants were tested: 10–20% glycerol, 10–20%
ethylene glycol, 10–20% MPD, all of them protected crystals from freezing damage equally
well. The Trim2833´412 protein sequence was analysed using the UCLA MBI-SERp Server
(Goldschmidt et al., 2007) (which predicts mutation clusters with a potential of enhancing
crystallisation / changing crystal contacts). One of the mutants Trim2833´412 K365A, K366A
was created using a QuikChange kit (5’ GCC CTT TTG CTT TCT GCG GCG TTG ATC
TAC TTC CAG C 3’). The PCR reaction was conducted with following cycling parameters:
initial denaturation — 95˝C, 30 sec; 18 extension cycles (95˝C, 30 sec; 55˝C, 1 min; 68˝C, 2
min); final extension — 68˝C, 5 min. After PCR the reaction was treated with DpnI at 37˝C
for 30 min. Post digestion of template DNA 10% of the reaction was used for a transfor-
mation into DH5α competent cells. Plasmid DNA was miniprep-purified and sequenced. A
verified clone was transformed, expressed, purified and screened for crystallisation conditions
as described previously.
6.2.3 E2 enzymes expression and purification
cDNA from three representatives of the UbcH2 family: H. sapiens UbcE2A, M. musculus
UbcE2B, S. cerevisiae Rad6, and SUMO E2 enzyme — Ubc9, were obtained from Dr. Danny
Huang, all in a pRSF-Duet vector (N-terminal His-tag) (Figure 6.1). Proteins were produced
as described for Trim28 constructs (Section 6.2.1). A 10 ml SourceQ column (anion ex-
change) was used in the ion exchange step of the purification. Sixteen additional expression
constructs generated by Dr. Huang were expressed and purified in a small-scale: UbcH5A,
UbcH5B, UbcH5C, UbcH6, UbcH643´C , UbcH4/545´C , UbcH7, UbcH8, UbcH10, UbcE2Z,
CDC34, UbcH2gI, UbcH2C, UbcH2-25k, UbcH2W, UbcH2T (pGEX-4T1-TEV, Figure 6.1).
1 l E. coli culture was grown, harvested and re-suspended in lysis buffer (affinity wash buffer
supplemented with 1 mM PMSF, 0.1 mg/ml lysozyme). Cells were lysed by sonication (8
cycles of 8 sec on/off) and centrifuged (1 h, 4˝C, 31,400g). The lysate was incubated (rocked
at 4˝C) with 0.5 ml of GSH-Sepharose beads for 2 h. Subsequently beads were washed 5 times
with 10 ml of wash buffer. Proteins were cleaved on the beads (0.05 mg TEV / 1 mg protein)
at 4˝C. The cleaved proteins were eluted, while tag (GST) remained bound to the resin.
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6.2.4 KRAB domain of zinc finger protein cloning, expression and purifi-
cation
cDNAs for five zinc finger proteins were purchased and several constructs of KRAB domains
were created using primers specified in Table 6.2 utilising Platinum Taq DNA polymerase.
Designed primers included STOP codon. The PCR reaction was conducted with following
cycling parameters: initial denaturation — 94˝C, 2 min; 35 extension cycles (94˝C, 30 sec;
55˝C, 30 sec; 68˝C, 30 sec); final extension — 68˝C, 10 min.
Construct Forward primer Reverse primer
ZnF3208´47 5’ CG GGA TCC CTG ACA
TTC AGG GAT GTG 3’
5’ CG CTC GAG TTA CAG
GGA GAC CAG GTT CCT ATA
ATT CTC C 3’
ZnF3208´80 5’ CG GGA TCC CTG ACA
TTC AGG GAT GTG 3’
5’ CG CTC GAG TTA ATA ACT
TGC TTG TCT CTG CAA TGT
CC 3’
ZnF10KOX14´53 5’ CG GGA TCC GTG ACC
TTC AAG GAT GTA TTT GTG
G 3’
5’ CG CTC GAG TTA CAA
GGA AAC CAG GTT CTT ATA
GTT CTC CAG CAT C 3’
ZnF10KOX14´85 5’ CG GGA TCC GTG ACC
TTC AAG GAT GTA TTT GTG
G 3’
5’ CG CTC GAG TTA AGG
ATG GGT CTC TTG GTG AAT
TTC TCT C 3’
MmZnF1194´43 5’ CG AGA TCT GTG ACC
TAT GAG GAT GTG CAT GTG
AAC TTC 3’
5’ CG CTC GAG TTA TAT ACA
AGT AAG GTT CCA GTA GGT
TTC CAG CAT CAC ATC 3’
MmZnF1194´76 5’ CG AGA TCT GTG ACC
TAT GAG GAT GTG CAT GTG
AAC TTC 3’
5’ CG CTC GAG TTA CTG
CTT CTT TCC ATA TGC AGA
GGG ACA G 3’
ZnF27414´53 5’ CG GGA TCC GTG ACC
TTT GAA GAT GTA ACA CTG
GG 3’
5’ CG CTC GAG TTA CAC
TGA GAC CAG GTT CCT GTA
GTT CTC C 3’
ZnF27414´85 5’ CG GGA TCC GTG ACC
TTT GAA GAT GTA ACA CTG
GG 3’
5’ CG CTC GAG TTA TGG
AAT GGT GTC TTG AGG AAT
TCC TC 3’
ZnF354C12´51 5’ CG AGA TCT GTG ACA
TTC AGG GAT GTG GCC G 3’
5’ CG CTC GAG TTA CAG
TGA GAC CAG GCT GCT GTA
GTT CTC 3’
ZnF354C12´83 5’ CG AGA TCT GTG ACA
TTC AGG GAT GTG GCC G 3’
5’ CG CTC GAG TTA TAG
ACG GGT ATC TGA AGG
GAC TTC TCT TTC C 3’
Table 6.2: KRAB domain constructs of zinc finger proteins cloned from the full-length DNA.
The construct length, forward and reverse primers are presented.
Double restricted DNA (BamHI or BglII and XhoI) was ligated into three expression vec-
tors: pGEX-4T1-His-TEV, pRSF-Duet and pRSF-MBP-Duet (N-terminal His-tag followed
by an MBP fusion protein and TEV cleavage site) (Figure 6.1). MBP — maltose-binding
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protein is a 43 kDa protein used to increase recombinant protein solubility. Expression con-
ditions were established after small-scale tests (proteins pooled from 1 l cultures, using 200 µl
nickel beads, the protocol for small-scale purification described in Section 6.2.3 was followed).
Proteins were then produced in large-scale using pRSF-MBP-Duet constructs. 12 l of bac-
terial cultures were grown, harvested and re-suspended in lysis buffer (affinity wash buffer
supplemented with 1 mM PMSF, 0.1 mg/ml lysozyme). Cells were lysed by sonication (8
cycles of 8 sec on/off, 20 ml lysate fractions) and centrifuged (1 h, 4˝C, 31,400g). Super-
natants were pooled and proteins were purified by affinity chromatography (5 ml HisTrap
FF; wash buffer: 50 mM Tris-HCl pH 7.6, 150 mM NaCl, 20 mM imidazole; elution buffer:
50 mM Tris-HCl pH 7.6, 150 mM NaCl, 500 mM imidazole). After elution the buffer was
exchanged to eliminate imidazole (HiPrep 26/10 desalting; Tris-HCl pH 7.6, 250 mM NaCl).
Subsequently, proteins were cleaved overnight with His-tagged TEV protease (0.05 mg TEV
/ 1 mg protein). Afterwards, His-MBP and His-tagged TEV were removed by a second run
of the HisTrap column. The final purification step for all KRAB domains consisted of gel
filtration chromatography (HiLoad Superdex S30) in gel filtration buffer (50 mM Tris-HCl
pH 7.6, 150 mM NaCl, 1 mM DTT). Proteins were concentrated using Amicon spin filters.
6.2.5 Native gel shift
4.5% native polyacrylamide gels were poured. Samples were prepared to a final volume of
5 µl and supplemented with 5% glycerol, loaded on a gel and run for 1.5 h at 130 V in a
Tris-base boric acid pH 9.0 at 4˝C. The assay enables detection of protein-protein interactions
by comparing electrophoretic velocity of the individual proteins with the migration speed of
the protein mixture. Small and negatively charged proteins migrate fast in the gel, while
large and basic proteins move more slowly. Proteins separate in the native gel according to
relation between their pI and the pH of the buffer used. In order to enter into the gel the
protein pI needs to be lower than the pH of the buffer. No molecular weight markers were
used for native gels.
6.2.6 Trim28 co-crystallisation attempts with partner proteins
Crystallisation trials were conducted for Trim2833´412 (7 mg/ml, 180 µM) with several part-
ner proteins: HsE2A, MmE2B, Rad6, HsE2AC88A„ubiquitin, Rad6C88A„ubiquitin (ubiqui-
tin conjugated E2 enzymes were generated by Dr. Danny Huang), ZnF3208´80, ZnF27414´85,
ZnF10KOX14´85, MmZnF1194´76, ZnF354C12´83. All complexes with E2s and E2„ubiquitin
conjugates were prepared by mixing proteins in the following ratio: for 1 µM of Trim2833´412,
1.2 µM of E2s or E2„ubiquitin was added. The complexes with KRAB domains were pre-
pared by mixing proteins in the following ratio: for 1 µM of Trim2833´412, 0.4 µM of KRAB
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domain was added. All complexes were screened for crystallisation using screens specified in
Section 2.3.2 at 4 and 19˝C. Crystallisation drops were set immediately after proteins were
mixed.
6.2.7 Ubiquitination assay
Ubiquitination assays were performed at 37˝C in buffer containing 500 mM Tris-HCl pH 7.6,
5 mM MgCl2 and 5 mM ATP. Each reaction contained 100 nM MmE1 (mice E1 ubiquitin-
activating enzyme, purified by Dr. Danny Huang), 20 µM E2, 40 µM ubiquitin (non-labelled,
or γ-32P labelled) and 1 µM Trim2833´412. Reactions were stopped by mixing with SDS
loading dye. In the ubiquitination assay the ability of Trim28 to function as an E3 ligase was
probed in the presence of various E2 conjugating enzymes. The course of the ubiquitination
assay is depicted in Figure 6.2.
E2
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Ub
Ub
Ub
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Ub
Ub
Figure 6.2: Ubiquitination assay. If an E3 is catalytically competent in the presence of a
specific E2 enzyme (activated by an E1 ubiquitin-activating enzyme), it will autoubiquinate
itself attaching first a single ubiquitin and subsequently additional ubiquitin moieties, creating
a poly-ubiquitin chain.
6.2.8 Mage-C2 cloning, expression and purification
Three constructs were created from Mage-C2 cDNA utilising Platinum Taq DNA polymerase.
The PCR reaction was conducted with following cycling parameters: initial denaturation —
Construct Forward primer Reverse primer
Mage-C2 5’ CC GGA TCC ATG CCT
CCC GTT CCA GG 3’
5’ CG CTC GAG TCA CTC AGA
AAA GGA GAC GTT GCT GG 3’
Mage-C2131´C 5’ CC GGA TCC ATG CCT
CCC GTT CCA GG 3’
5’ CG GGA TCC CCA GAC AGT
GAG TCC TCT TTC ACA TAT
ACA CTA GAT G 3’
Mage-C2135´C 5’ CC GGA TCC ATG CCT
CCC GTT CCA GG 3’
5’ CG GGA TCC TCC TCT TTC
ACA TAT ACA CTA GAT GAA
AAG GTG GCC G 3’
Table 6.3: Mage-C2 constructs cloned from full-length DNA. The construct boundaries,
forward and reverse primers are presented.
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94˝C, 2 min; 35 extension cycles (94˝C, 30 sec; 55˝C, 30 sec; 68˝C, 30 sec); final extension —
68˝C, 10 min. The PCR primers are shown in Table 6.3 (included STOP codon). Expression
constructs, created in pGEX-4T1-His-TEV and pRSF-Duet (Figure 6.1), were tested for
expression conditions, expressed and purified as described in Sections 6.2.1 and 6.2.4.
6.2.9 Surface plasmon resonance
Binding between Trim28 and Ubc9 was assessed using Biacore. Biacore uses SPR (surface
plasmon resonance), a method of probing biomolecular interactions (protein-protein, protein-
ligand, DNA-protein, etc.) in real time, without labelling any of the assay components (Quinn
et al., 2000). SPR is the electron oscillation that occurrs when light is reflected from a
conducting film at the interface between two media of different refractive index. When using
Biacore system, these two media are: the test sample and the surface of the used sensor
chip. A thin layer of gold on the chip facilitates conductivity. SPR causes a reduction in
the intensity of reflected light at a specific angle of reflection. The angle is determined by
the mass of surface material, therefore it signals when biomolecules bind to the surface and
change the mass of the surface layer (Figure 6.3). In the performed experiments GST-tagged
Trim28 was immobilised on the chip surface, subsequently Ubc9 was injected across the chip
surface. The experiments were performed by Dr. Gary Sibbet.
Flow channel
Polarized light
Reﬂected light
Sensor chip with gold ﬁlm
Detector
Prism
Light source
Figure 6.3: Experimental set-up of an SPR experiment. SPR detects variations of the re-
fractive index in the near proximity of the sensor chip surface. It is observed as a sharp
shadow in the light reflected from the surface. The angle change is determined by the mass
of surface material, therefore it signals when biomolecules bind to the surface and change its
mass. Figure adapted from Cooper (2002).
Chapter 7
Results
Trim28 is best characterised as a transcription corepressor, but how it functions as an ubiq-
uitin ligase remains elusive. In this chapter, attempts to crystallise Trim28 to determine its
three-dimensional structure are described. A description is given of a Trim28 autoubiquitina-
tion assay to identify its E2 partner. Additionally investigation of Trim28 interactions with
Mage-C2 protein and KRAB domain-containing proteins is described.
7.1 Expression and purification of Trim28 constructs
Two constructs obtained from Dr. Danny Huang were tested for expression in BL21(DE3)
cells (see Section 2.2.2). Both constructs yielded soluble, stable proteins in a small-scale
expression test. Trim28 and Trim2833´412 were expressed and purified in a large-scale and
concentrated to 7 mg/ml for the full-length protein, and to 10 mg/ml for the construct
containing the RING domain, two B-box domains and a coiled-coil (RBCC, Trim2833´412).
The final purity of the proteins was higher for the shorter construct (Figure 7.1).
Figure 7.1: SDS-PAGE of purified full-length Trim28 (left) and Trim2833´412 (right). Lane 1
shows molecular weight markers (in kDa).
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Then additional constructs were created: Trim2833´149 — the RING domain, Trim2861´241
— containing the RING domain and the two B-box domains, Trim28625´685 — the PHD
domain, Trim28695´801 — BRD, Trim28625´801 — covering both PHD and BRD tandem.
All of the prepared constructs were expressed and purified from 12–24 l of E. coli culture.
Obtained pure proteins were concentrated to 6–10 mg/ml using Amicon system. The cloning
primers and purification details are described in Section 6.2.1. Trim28 constructs are depicted
in Figure 7.2. Their theoretical molecular weights, extinction coefficients, pI of the constructs
and an average yield from 12 l E. coli culture are presented in Table 7.1.
RING
60 153 241
B1 B2 C-C PHD BRD
1 381 625 800695
Figure 7.2: Cloned, expressed and purified Trim28 constructs: Trim2833´149 (RING),
Trim28625´685 (PHD), Trim28695´801 (BRD), Trim2861´241 (RING-B-box), Trim28625´801
(PHD-BRD), Trim2833´412 (RBCC) and the full-lenght Trim28.
Construct Theoretical molecu-
lar weight [kDa]
Extinction coeff.
[M´1cm´1]
pI Average yield from 12 l
E. coli culture [mg]
Trim28 89 42400 6.2 5.4
Trim2833´412 42 30940 8.4 6.5
Trim2861´241 19.7 5960 5.6 6
Trim2833´149 11.6 1490 4.8 5.8
Trim28625´685 6.8 5500 4.3 16
Trim28695´801 12.2 1490 7.9 20
Trim28625´801 19.8 6990 5.1 22
Table 7.1: Expressed Trim28 constructs, their theoretical molecular weights, extinction coef-
ficients, pI of the constructs and an average yield from 12 l E. coli culture.
7.2 Trim28 crystallisation attempts
Pure proteins were screened for crystallisation conditions as described in Section 6.2.2. The
first one to crystallise was the full-length construct, the crystals appeared in drops set at
19˝C in the presence of 1.2 M ammonium sulphate and 0.1 M Hepes pH 7.0 after 13 days.
They were small and spindle-shape (Figure 7.3). The initial harvesting attempts revealed an
unusual feature — they grew as a part of skin that covered the entire drop, making them
extremely difficult to manipulate and isolate. Moreover, upon attempts to crush, they did not
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shatter, as one would expect if they were protein crystals, instead, they presented “skin like”
behaviour. The series of attempts to optimise these crystals (additives, detergents, growing
with agarose, using dialysis buttons, Fluorinert reagent) did not improve their quality. Several
crystals tested in the Diamond Light Source synchrotron diffracted only to „20 A˚.
The next one to crystallise was the Trim2833´412 construct. Crystals appeared in the con-
ditions similar to those that produced full-length Trim28 crystals (19˝C; 1.1 M ammonium
tartrate dibasic pH 7.0; 5% Tacsimate pH 7.0, 0.1 M Hepes pH 7.0, 10% PEG MME) after 3
days. They had a shape similar to the full-length crystals, but unlike the full-length crystals,
they were easy to handle. However, they seemed unusually insensitive to poking or crushing.
Once poked, they broke into a few large pieces and did not shatter into fine pieces, as would
a typical protein crystal. Although early crystals were as small as full-length protein crys-
tals, growing in the presence of various detergents (10% TRITON X-100, 10% CYMAL-1)
made them grow bigger (Figure 7.3). Several crystals tested at the Diamond Light Source,
diffracted only to 15 A˚. Moreover, diffraction patterns were smeary (Figure 7.5), indicating
poor crystal quality and therefore it was not possible to assign a space group or gain any
additional information from these crystals.
Figure 7.3: Crystals of full-length Trim28 (left) and optimised Trim2833´412 crystals (right).
In an effort to further optimise Trim2833´412 crystals the protein sequence was analysed using
the UCLA MBI — Surface Entropy Reduction prediction Server (SERp). The SERp approach
has been developed for the prediction of sites on a protein construct that are most suitable for
mutation to enhance crystallisability (Goldschmidt et al., 2007). Three mutation clusters with
the potential of enhancing crystallisation / changing crystal contacts were identified. The
predicted mutant — Trim2833´412 K365A, K366A, containing two mutations in the coiled-coil
region was cloned, expressed and purified as the native protein. The protein expression level
was lower compared with the wild type. In addition, the mutant was unstable in 150 mM
NaCl, and successful purification required instead 300 mM NaCl in all buffers. Once purified
and concentrated to 6 mg/ml, the protein was used for crystallisation screening. The screen
yielded two new crystallisation conditions at 19˝C: 20% ethanol, 0.1 M Tris-HCl pH 8.5 and
10% MPD, 0.1 M Tris-HCl pH 8.0. The mutant crystals had a rod-like shape that resembled
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the native crystals (Figure 7.4). New hits were optimised by changing the pH and precipitant
concentration and obtained bigger crystals with classic protein crystal-type behaviour.
Figure 7.4: Crystals of Trim2833´412 K365A, K366A. Crystals on the left grew in the presence
of 10% MPD and 0.1 M Tris-HCl pH 8.5, on the right in the presence of 6% MPD and 0.1 M
Tris-HCl pH 7.5.
Although these crystals yielded a protein-like diffraction pattern with properly separated
diffraction spots (Figure 7.5), they did not diffract beyond 9 A˚. Additional optimisation
attempts, including crystal dehydration, did not improve diffraction quality. Nonetheless,
those crystals provided better quality data, and several of them were indexed using XDS
(Kabsch, 2010) giving invariably a P3 space group, with the following unit cell dimensions:
a “ b “ 310 A˚, c “ 240 A˚, α “ β “ 90˝, γ “ 120˝.
Figure 7.5: Trim28 crystal diffraction quality. On the left an X-ray diffraction image of a
Trim2833´412 crystal is shown, on the right a typical, higher quality Trim2833´412 K365A,
K366A crystal diffraction pattern is presented.
7.3 Identification of Trim28 E2 conjugating enzyme
Trim28 contains a RING domain at the N-terminus and a PHD domain at the C-terminus.
The RING domain is known for its ability to interact with an E2 ubiquitin conjugating
enzyme, though it is not clear whether the Trim28 RING domain has any ligase activity.
Interestingly, the Trim28 PHD domain has been reported to interact with the E2 SUMO
conjugating enzyme, Ubc9 (Peng and Wysocka, 2008). It is noteworthy that this is the only
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report that described the PHD domain interaction with an E2. It is still debatable whether
this interaction is real, since several other groups that studied SUMO E2 did not observe
this interaction. To investigate whether Trim28 and Ubc9 form a stable complex, a native
gel shift assay was performed at pH 9.0 by titrating full-length Trim28 (pI = 6.2), RING
(Trim2833´149, pI = 6.4) and PHD (Trim28625´685, pI = 4.3) domains with Ubc9 (pI = 9.4).
In the native gel, proteins are separated according to their molecular weight and charge. The
separation depends on the pI of the protein and the charge of the protein in the running
buffer. Negatively charged protein will enter the gel. In order to achieve this, the pI of the
protein needs to be lower than the pH of the running buffer. Small and negatively charged
proteins migrate fast in the gel, while large and basic proteins have lower electrophoretic
velocity. Formation of a protein complex can be monitored by comparing migration velocity
of the individual protein with that of the protein mixture. Unfortunately Ubc9 did not cause
any band shift when mixed with Trim28 constructs (Figure 7.6). Ubc9 did not enter the
gel because its pI is above the pH of the gel and running buffer. Due to the lack of a clear
shift, SPR (surface plasmon resonance) was used to investigate the binding (Section 6.2.9).
GST-tagged Trim28 was immobilised on the chip surface and Ubc9 (12 mg/ml) was injected
across the chip surface. Likewise, SPR experiments did not detect any binding.
Figure 7.6: Native gel shift of Trim28 constructs titrated with Ubc9. The gel on the left
shows the RING domain (Trim2833´149) titrated with Ubc9 (micromolar ratio: 1:0, 1:1, 1:2,
1:3, 0:3) and PHD domain (Trim28625´685) titrated with Ubc9 (micromolar ratio: 1:0, 1:1,
1:2, 1:3, 0:3). The gel on the right shows full-length Trim28 titrated with Ubc9 (micromolar
ratio: 1:0, 1:0.5, 1:1, 1:1.5, 1:2, 1:3, 1:4, 0:4).
In an effort to identify an E2 enzyme that functions with Trim28, a panel of nineteen E2 pro-
teins was expressed and purified. The following E2s were used: UbcH5A, UbcH5B, UbcH5C,
UbcH6, UbcH643´C , UbcH4/545´C , UbcH7, UbcH8, UbcH10, MmUbcE2B, Rad6, UbcE2Z,
UbcH2-25k, UbcH2gI, UbcH2C, CDC34, UbcE2A, UbcH2W, UbcH2T. All of the pure conju-
gating enzymes (3–6 mg protein obtained from 1 l culture) were used at 20 µM in the in vitro
autoubiquitination assay (Dou et al., 2012) with Trim2833´412. In the assay an ability of the
Trim2833´412 to function as an E3 ligase was probed (Figure 6.2). If an E3 is catalytically
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competent in the presence of a specific E2 enzyme (activated by an E1 ubiquitin-activating
enzyme), it will autoubiquinate itself attaching first a single ubiquitin and subsequently ad-
ditional ubiquitin moieties, creating a poly-ubiquitin chain. Surprisingly only UbcH2 family
members (Rad6, MmUbcE2B) displayed ubiquitination activity with Trim28. However, the
activity was rather low, with a single band corresponding to the Trim2833´412 modified with
a single ubiquitin molecule (Figure 7.7). Additionally, the reaction was performed at 37˝C
for 1 h. Usually under these conditions, one would expect to see a smeary band at the top
of the gel indicating poly-ubiquitinated products. A positive control was run using an E3
enzyme purified by Dr. Danny Huang — Ubr1. This enzyme is known to bind to Rad6 and
was poly-ubiquitinated under test conditions. All these factors suggested that Trim28 is not
an efficient ligase.
Figure 7.7: Ubiquitination assay of Trim2833´412 by various E2 conjugating enzymes. Ra-
diograms present results of the ubiquitination assay run for 1 h at 37˝C with 40 µM γ-32P
radiolabelled ubiquitin, 100 nM MmE1, 5 mM MgCl2, 5 mM ATP, testing 19 E2 (20 µM)
conjugating enzymes. For each of the E2s, a control with no E3 enzyme was run. The arrow
points to bands corresponding to Trim2833´412 modified with a single ubiquitin molecule.
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In order to validate the result, another assay using non-labelled ubiquitin was performed
and analysed by SDS-PAGE (Figure 7.8). In this case a faint ladder could be observed,
predominantly when the assay was run in the presence of Rad6 conjugating enzyme. Bands of
the ladder were analysed by mass spectroscopy. It was confirmed that Trim28 is ubiquitinated
at various lysine sites and, additionally, that ubiquitin also is conjugated to another ubiquitin,
suggesting the formation of poly-ubiquitin chain.
Figure 7.8: Ubiquitination assay of Trim2833´412 by MmUbcE2B and by Rad6 conjugating
enzymes. The ubiquitination assay was run for 1 h at 37˝C with 40 µM ubiquitin, 100 nM
MmE1, 5 mM MgCl2, 5 mM ATP and 20 µM E2, and analysed by SDS-PAGE. Lane 1 shows
molecular weight markers (in kDa).
To determine whether Trim2833´412 interacts with Rad6, a native gel shift assay was per-
formed. The experiment was run at pH 9.0. Trim2833´412 was titrated with Rad6, and a
stable conjugate of Rad6„ubiquitin, prepared by Dr. Danny Huang. Trim2833´412 has a pI
Figure 7.9: Native gel shift of Trim2833´412 titrated with Rad6 and Rad6„ubiquitin. The
left part of the gel shows Trim2833´412 titrated with Rad6 (micromolar ratio: 1:0, 1:1, 1:2,
1:3, 0:3), the right part shows Trim2833´412 titrated with Rad6„ubiquitin (micromolar ratio:
1:0, 1:1, 1:2, 1:3, 0:3).
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of 8.4 and only slightly enters the gel. Both Rad6 (pI = 4.0) and Rad6„ubiquitin conjugate
(pI = 4.3) enter the gel due to their highly acidic pIs. As shown in Figure 7.9, the band
corresponding to Trim28 (top) becomes more prominent with increasing amounts of Rad6 or
Rad6„ubiquitin, indicative of binding between Trim28 and Rad6.
7.4 Interaction of Trim28 and Mage-C2
Doyle et al. (2010) showed that in order for Trim28 to function efficiently as an E3 ligase, it
requires a partner protein, Mage-C2. Mage-C2 massively stimulated Trim28 ubiquitin ligase
activity with E2B by converting its ubiquitination pattern from mono-ubiquitinated product
to explicit poly-ubiquitin chain formation. In order to reproduce this result, Mage-C2 was
cloned, expressed and purified from the cDNA, according to procedures described before.
Three constructs were created based on data presented in Doyle et al. (2010) paper: the
full length Mage-C2 (pI = 4.1), Mage-C2131´C (pI = 4.4) and Mage-C2135´C (pI = 4.5). All
three proteins could be expressed both in the GST-bearing construct and in the pRSF-Duet
vector, resulting in His-tagged proteins. His-tagged constructs were selected for large-scale
expression and purification and pure proteins were produced, concentrated up to 10 mg/ml for
the truncated constructs, and 8 mg/ml for the full-length protein. An average yield from 12 l
E. coli culture using pRSF-Duet construct was 3 mg for the full-length protein and 7–8 mg for
truncated constructs. Then a native gel shift assay was performed to verify binding between
purified Mage-C2 proteins and Trim2833´412 (Figure 7.10). The experiments were performed
similarly to the one described for the titration of Trim2833´412 with Rad6 and Rad6„ubiquitin
(Section 7.3). All of the tested constructs caused Trim2833´412 to migrate faster into the
Figure 7.10: Native gel shift of Trim2833´412 titrated with Mage-C2131´C and Mage-C2135´C .
The left part of the gel shows Trim2833´412 titrated with Mage-C2131´C (micromolar ratio:
1:0, 1:0.5, 1:1, 1:2, 0:2), the right part Trim2833´412 titrated with Mage-C2135´C (micromolar
ratio: 1:0, 1:0.5, 1:1, 1:2, 0:2).
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gel, indicating interactions between Mage-C2 and Trim2833´412. After confirming binding
between Trim28 and Mage-C2, all three constructs were used in the ubiquitination assay at
concentration of 50 µM, as used in Doyle et al. (2010). The rest of the assay components
were used as described in Section 7.3. Experiments performed using unlabelled ubiquitin or
γ-32P-labelled ubiquitin did not reveal stimulation of Trim28 ligase activity. Reanalysis of
the Doyle et al. data led to the conclusion that the only difference between their reaction
setup and the performed reaction was the protein expression strategy. In their study, Trim28
and Mage-C2 were co-expressed in E. coli rather than purified separately, as in this study.
Thereupon, Trim28 and Mage-C2 were co-expressed using the GST-tagged Trim2833´412 and
each of the His-tagged Mage-C2 constructs, in the same manner as Doyle et al. (2010).
All of the complexes could be expressed and purified, and were used in the ubiquitination
assay (Figure 7.11). Unfortunately this approach did not cause any change in the Trim28
ubiquitination. Addition of Mage-C2 did not stimulate Trim28 ligase activity.
Figure 7.11: Ubiquitination assay of Trim2833´412 by Rad6 conjugating enzyme in the pres-
ence of Mage-C2. The ubiquitination assay was run for 1 h at 37˝C with 40 µM ubiquitin,
100 nM MmE1, 50 µM Mage-C2131´C or Mage-C2135´C , 5 mM MgCl2, 5 mM ATP and
20 µM E2, and analysed by SDS-PAGE. Lane 1 shows molecular weight markers (in kDa).
7.5 Interaction with zinc finger KRAB domains
Trim28 was first identified due to its interaction with the KRAB domains of zinc finger
proteins. The KRAB domain is a transcriptional repression domain present in approximately
400 human zinc finger transcription factors (KRAB zinc finger proteins). They consist of
about 75 amino acids and are made of two modules: A (highly conserved) and B (more
diverse). The KRAB domain is followed by a zinc finger region, a small protein motif that
binds DNA (Figure 7.12). In order to investigate the interactions between Trim28 and the
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KRAB A KRAB B ZnF region
Figure 7.12: Schematic representation of KRAB zinc finger protein. The KRAB domain
made of A and B modules is followed by a zinc finger motif.
KRAB domains, and to check whether addition of the KRAB domain may alter Trim28
crystal packing thereby yielding crystals with improved diffraction quality, five representatives
of the ZnF family were selected and two KRAB domain constructs for each ZnF protein were
generated. All of them were cloned into three expression vectors (pGEX-4T1-His-TEV, pRSF-
Duet, pRSF-MBP-Duet) and tested for expression conditions (Section 6.4) The summary of
the expression trial is presented in Table 7.2.
Construct pGEX-4T1-
His-TEV
pRSF-Duet pRSF-MBP-
Duet
Average yield from 12 l
E. coli culture [mg]
ZnF3208´47 ´ ´ + 2
ZnF3208´80 ´ ´ + 1.5
ZnF10KOX14´53 ´ + + 6
ZnF10KOX14´85 + + + 4
MmZnF1194´43 ´ ´ + 3
MmZnF1194´76 ´ ´ + 1
ZnF27414´53 ´ ´ + 5
ZnF27414´85 + + + 4
ZnF354C12´51 ´ ´ + 2
ZnF354C12´83 ´ ´ + 2
Table 7.2: Results of the KRAB domains expression trial. An average yield from 12 l E. coli
culture using pRSF-MBP-Duet constructs is presented.
These proteins have been previously shown to bind Trim28 (Peng et al., 2007). All con-
structs could be expressed as MBP fusion proteins. Additionally, ZnF10KOX14´85 and
ZnF27414´85 also expressed in a GST-tagged version while ZnF10KOX14´53, ZnF10KOX14´85
and ZnF27414´85 also expressed in the pRSF-Duet vector. All proteins were produced in
a large-scale culture using pRSF-MBP-Duet constructs, purified and concentrated up to
3–4 mg/ml. Then a native gel shift assay was performed to investigate interactions be-
tween Trim2833´412 and various KRAB domains (Figure 7.13). All KRAB domains caused
Trim2833´412 to migrate into the gel. According to the literature data (Friedman et al., 1996),
three Trim2833´412 molecules bind one zinc finger KRAB domain. To investigate the stoi-
chiometry, a native gel shift assay with a finer titration of Trim2833´412 with ZnF27414´85 was
performed (Figure 7.14). At a 1:0.4 ratio, all Trim2833´412 migrated into the gel. This is indi-
cated by the intensity of the Trim2833´412 band, which remained unchanged with increasing
ZnF27414´85 concentration (Figure 7.14, lanes 2–8, upper band). This result is in agree-
ment with published data, and suggests that a single KRAB domain binds to 3 Trim2833´412
molecules.
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Figure 7.13: Native gel shift of Trim2833´412 titrated with ZnF27414´85 (pI = 4.2) and
ZnF354C12´83 (pI = 4.6). The left part of the gel shows Trim2833´412 titrated with
ZnF27414´85 (micromolar ratio: 1:0, 1:1, 1:2, 1:3, 0:3), the right part Trim2833´412 titrated
with ZnF354C12´83 (micromolar ratio: 1:0, 1:1, 1:2, 1:3, 0:3).
Figure 7.14: Native gel shift of Trim2833´412 titrated with ZnF27414´85 (left-to-right, micro-
molar ratio: 1:0.25, 1:0.4, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:4, 0:4).
7.6 Co-crystallisation of Trim2833´412 with binding proteins
Various Trim2833´412-KRAB domain complexes were assembled and crystallisation trials on
a nanoscale were set up as described in Section 6.2.6. Of the screened complexes, only
Trim2833´412-ZnF27414´85 crystallised (Figure 7.15). The complex crystallised in two condi-
tions (1.6 M Na/K hydrogen phosphate; 1 M lithium sulphate, 0.1 M MES pH 6.5) at 19˝C.
These crystals were optimised and their diffraction was tested at the Diamond Light Source
synchrotron. Unfortunately they did not diffract.
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Figure 7.15: Crystals obtained for the Trim2833´412-ZnF27414´85 complex. On the left in
1.6 M Na/K hydrogen phosphate, on the right in 1 M lithium sulphate, 0.1 M MES pH 6.5.
Chapter 8
Discussion
8.1 Trim28 structure
Trim28 protein crystallised but the crystals diffracted poorly. Several approaches were used
to optimise Trim28 crystals, but all failed to produce a useful dataset. The SERp approach
yielded crystals with low diffracting resolution but with a nice diffracting pattern that allowed
data indexing with the P3 space group.
The poor data quality may result from high oligomer formation, as Trim28 oligomerisation
has been reported (Friedman et al., 1996). It could be observed when purifying full-length
Trim28 and the N-terminal RBCC cluster. During size exclusion chromatography, both
proteins eluted much faster than indicated by their theoretical molecular weights, suggesting
protein oligomerisation. Additionally, high solvent content may impair diffraction quality.
It is possible that other Trim28 constructs or optimisation strategies may lead to further
refining of the crystal packing and diffraction. A vital optimisation approach may involve
more extreme dehydration methods (Hagelueken et al., 2012), or other mutation clusters that
may promote other crystal forms (Goldschmidt et al., 2007). Trim28 is known to have multiple
binding partners, for example the KRAB domains of various zinc finger proteins. Addition
of different binding partners may disrupt Trim28 oligomerisation and promote formation of
different crystal forms. Alternatively, inclusion of a fusion protein such as T4 lysozyme, may
facilitate crystallisation. Fusion of T4 lysozyme at the N-terminus of a G-coupled protein
receptor has been shown to facilitate crystallisation and to promote alternative crystal packing
(Zou et al., 2012).
Ultimately other approach could be used to obtain an insight into the structure of the Trim28
N-terminus, for example NMR spectroscopy. This method was used to determine RING
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domain structures of other members of the Trim protein family: Trim31 (PDB ID: 2YSJ),
Trim32 (PDB ID: 2CT2) and Trim39 (PDB ID: 2ECJ) for which coordinates were submitted
to PDB by the RIKEN Structural Genomics/Proteomics Initiative (Japan).
Information about the overall shape of the protein could be assessed by SAXS (Small-angle
X-ray scattering). SAXS uses soluble protein samples and therefore does not require protein
crystals. This method is useful in the characterisation of large and partially disordered pro-
teins. Although SAXS resolution (1-3 nm) is much lower than that of X-ray crystallography
it can provide information about the size and shape of a molecule (Lipfert and Doniach,
2007).
8.2 Trim28 ligase activity
Accessing Trim28 ligase activity and E2 interactions proved to be challenging. Despite litera-
ture reports pointing to interaction between the PHD domain and Ubc9 (Peng and Wysocka,
2008), the interaction was not detected in this study using a native gel shift assay or SPR anal-
ysis. Although autoubiquitination of Trim2833´412 in the presence of Rad6 and MmUbcE2B
was detected, the reaction was very inefficient, yielding only mono-ubiquitinated form of
Trim28. Addition of Mage-C2 did not stimulate Trim28 ligase activity, as reported previ-
ously (Doyle et al., 2010). The remaining possibility is that the difference in the system
used for protein co-expression may affect the assay outcome. In the published work proteins
were produced using a single bicistronic expression vector, while in this study they were ex-
pressed using individual plasmids. It is possible that simultaneous expression of two proteins
separately but from the same RNA transcript may influence their folding, hence affect the
activity of Trim28. It is possible that other crucial detail in the experimental procedure was
overlooked, though it was impossible to identify it from the published report. Moreover, it is
possible that Trim28 does not prefer to autoubiquitinate itself like other E3s and it becomes
catalytically competent only in the presence of a true substrate.
8.3 Trim28 and its binding partners
The ability of Trim28 to bind KRAB domains of various zinc finger proteins was confirmed.
Also it binds of Mage-C2 and two E2 conjugating enzymes (Rad6 and MmUbcE2B) both
without and with conjugated ubiquitin. From the native gel shift assays it appears that
KRAB domains are the strongest binding partners, nonetheless ascertaining this requires
using a more quantitative experimental method such as SPR.
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Kinesins constitute a superfamily of microtubule-based motor
proteins with important cellular functions ranging from
intracellular transport to cell division. Some kinesin family
members function during the mitotic phase of the eukaryotic
cell cycle and are crucial for the successful progression of cell
division. In the early stages of mitosis, during prometaphase,
certain kinesins are required for the formation of the bipolar
spindle, such as Eg5 and Kif15, which seem to possess partially
overlapping functions. Because kinesins transform the
chemical energy from ATP hydrolysis into mechanical work,
inhibition of their function is a tractable approach for drug
development. Drugs targeting Eg5 have shown promise as
anticancer agents. Kif15 has recently come to the fore because
it can substitute the functions of Eg5, and may itself have
potential as a prospective drug target. Here, the initial
biochemical, kinetic and structural characterization of Kif15
is reported and it is compared with the functionally related
motor Eg5. Although Kif15 contains ADP in the catalytic site,
its motor-domain structure was captured in the ‘ATP-like’
configuration, with the neck linker docked to the catalytic
core. The interaction of Kif15 with microtubules was also
investigated and structural differences between these two
motors were elucidated which indicate profound differences
in their mode of action, in agreement with current models of
microtubule cross-linking and sliding.
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1. Introduction
Kinesins form a superfamily of proteins that play important
roles in eukaryotic intracellular trafficking and cell division
(Hirokawa et al., 2009). The genomes of higher vertebrates
contain as many as 45 genes coding for different kinesins.
The majority of these molecular machines are implicated in
intracellular transport, whereas a third of the superfamily
members plays key roles in different stages of mitosis and
cytokinesis (Wordeman, 2010). Some kinesins fulfill dual
functions in both transport and cell division, such as Eg5 (KSP,
Kif11, kinesin-5 family; Ferhat, Cook et al., 1998), Kif15
(Hklp2, Xklp2, KRP180, KLP-18, kinesin-12 family; Buster et
al., 2003; Liu et al., 2010), Kif2A (kinesin-13 family; Ganem &
Compton, 2004; Zhu et al., 2005), MKLP-1 (kinesin-6 family;
Zhu et al., 2005) and Kif4A/Kif4B (kinesin-4 family;
Mazumdar et al., 2004; Zhu et al., 2005; Zhu & Jiang, 2005). A
few kinesins are involved in the assembly and/or maintenance
of the bipolar spindle (Tanenbaum & Medema, 2010), namely
the two N-terminal plus-end-directed motors Eg5 (Blangy
et al., 1995) and Kif15, as well as the C-terminal minus-end-
directed kinesin KifC1 (HSET, kinesin-13 family) and dynein,
which belongs to another class of microtubule (MT)-based
motor proteins (Vaisberg et al., 1993).
Kif15 has been identified in a variety of eukaryotes,
including Xenopus (Boleti et al., 1996), human (Sueishi et al.,
2000), sea urchin (Rogers et al., 2000), Caenorhabditis elegans
(Segbert et al., 2003) and rodents (Buster et al., 2003).
Although Kif15 and Eg5 appear to share some functional
similarities during bipolar spindle formation, they seem to
work through distinct mechanisms, adopting rather diverse
quaternary structures (Vanneste et al., 2009).
The involvement of Eg5 in the separation of the duplicated
centrosomes (Blangy et al., 1995) has made it a potential target
for drug development in cancer chemotherapy, with several
kinesin-5-specific inhibitors in multiple Phase I and II clinical
trials (Huszar et al., 2009; Rath & Kozielski, 2012). Interest-
ingly, Kif15 overexpression has been shown to be able to
restore functions of Eg5 under certain conditions, for example
when Eg5 is depleted (Tanenbaum et al., 2009). Subsequently,
it has been hypothesized (although not yet proven) that
tumours treated with Eg5-targeting drugs might acquire
resistance to these inhibitors by simply up-regulating Kif15.
This interesting hypothesis and the involvement of Kif15 in
bipolar spindle assembly makes it a potential target for drug
development in cancer chemotherapy, and the first inhibitor
scaffolds targeting Kif15 have been reported in the patent
literature (McDonald et al., 2004).
Although the role of Kif15 in bipolar spindle formation has
been investigated in a variety of organisms (Boleti et al., 1996;
Rogers et al., 2000; Segbert et al., 2003; Sueishi et al., 2000) and
has been compared with that of Eg5 in cellular assays, much
less is known about its biochemical, mechanochemical and
structural properties or its interactions with binding partners.
The recombinant expression of human Kif15 for inhibitor
screening, and the structure determination of its motor
domain for structure-based design, would be highly desirable
to facilitate the drug-development process. Here, we provide
the initial biochemical characterization of human Kif15 and
compare its properties with those of its functionally related
partner Eg5. We reveal that Kif15, in contrast to Eg5, does not
have a second nucleotide-independent MT-binding site in its
C-terminal tail domain. Furthermore, we determine the crystal
structure of the binary Kif15–ADP complex captured in the
‘ATP-like’ state adopted by the switch II cluster and neck-
linker region.
2. Materials and methods
2.1. Cloning, expression and purification of mammalian
Kif15 proteins
The Homo sapiens Kif15 motor domain and neck-linker
region (named Kif1519–375 throughout this manuscript) was
cloned, expressed and purified as described previously (Liu et
al., 2010). A longer construct including the first 19 residues
that contains the cover strand (named Kif151–375) was cloned
by extending the Kif1519–375 construct by PCR with four
forward primers (P1_F, 50-CA AAT GGT CAG TCT AAC
CAG CCG AGC AAC GAA G-30; P2_F, 50-GAG TTA CGC
AGC GTG ACA AAT GGT CAG TCT AAC C-30; P3_F, 50-
GGC TGC AAA ACT GAG TTA CGC AGC GTG-30; P4_F,
50-GAACC ATGGCT CCT GGC TGC AAA ACT G-30) and
a single reverse primer (50-GAT CTC GAG TTA ACC CTG
GGT ATC TTC ATT CAC AAC C-30). Kif151–375 was
expressed and purified as described for the shorter construct.
The Kif15 tail construct from Rattus norvegicus (Kif151149–1388)
was cloned, expressed and purified as Kif1519–375.
2.2. Determination of protein concentrations
Protein concentrations were determined either by using the
Lambert–Beer law measured under native conditions [for the
motor-domain constructs bound ADP was taken into account
(2500 M1 cm1)] or by applying the Bradford method. The
extinction coefficients for each Kif15 construct were
calculated (Kif151–375, 17 670 M
1 cm1; Kif1519–375,
17 608 M1 cm1; Kif151149–1388, 10 033 M
1 cm1) using
ProtParam from the Bioinformatics Resource Portal (Wilkins
et al., 1999).
2.3. Analytical gel filtration
Analytical gel filtrations were performed on a Superose 12
10/300 GL column (GE Healthcare). Experiments were
conducted at a flow rate of 0.5 ml min1 (50 mM PIPES pH
6.8, 250 mM NaCl, 2 mM MgCl2, 1 mM DTT; all from Sigma)
using an injection volume of 200 ml. Prior to running Kif15
expression constructs, the column was calibrated with proteins
of known molecular mass (ribonuclease A, 13.7 kDa; carbonic
anhydrase, 29 kDa; ovalbumin, 43 kDa; conalbumin, 75 kDa)
and blue dextran. The Kav values were calculated for the
calibration proteins [(Ve  V0)/(Vc  V0), where Ve is the
elution volume, V0 is the void volume and Vc is the column
volume] and were plotted against the log of the molecular
masses of the standards. The molecular masses were calculated
from the resulting equation.
2.4. Steady-state enzyme kinetics
Steady-state basal and MT-stimulated activities were
determined using the pyruvate kinase/lactate dehydrogenase
coupled assay described previously (Hackney & Jiang, 2001).
All measurements were carried out at 25C using a 96-well
Sunrise photometer (Tecan) in a final reaction volume of
100 ml at least in triplicate. Data were analysed using Microsoft
Excel 2008 and KaleidaGraph 4.0 (Synergy Software). The salt
dependence of the basal Kif1519–375 and Kif151–375 ATPase
activities was measured at NaCl concentrations from 0 to
275 mM in the presence of 0.59 mM Kif1519–375 and 0.35 mM
Kif151–375 and 1 mM Mg
2+-ATP. To determine the basal
ATPase activity of Kif1519–375 and Kif151–375, their activities
were examined at ATP concentrations from 0 to 2 mM in the
presence of 0.35 mM Kif1519–375 and 0.75 mM Kif151–375 as well
as 75 mM NaCl for Kif1519–375 and 50 mM NaCl for Kif151–375.
The salt dependence of the MT-stimulated ATPase activity of
Kif1519–375 and Kif151–375 was determined by measuring their
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rates of activity at MT concentrations from 0 to 10 mM in the
presence of 0.04 mM Kif1519–375 and 0.08 mM Kif151–375 (in the
presence of 0, 50, 100 and 150 mM KCl for Kif1519–375 and in
the presence of 0 and 50 mM KCl for Kif151–375). Finally, the
MT-stimulated ATPase activity for both Kif15 constructs was
measured in the presence of increasing ATP concentrations
from 0 to 2 mM in the presence of 0.04 mM Kif1519–375 and
0.04 mM Kif151–375, 3 mM MTs in the absence of salt.
2.5. Transient-state enzyme kinetics
Slow Mant-ATP [20/30-O-(N-methylanthraniloyl)adenosine-
50-triphosphate] turnovers were performed by making manual
additions to a 100 ml cuvette in a modified Cary Eclipse
fluorescence spectrophotometer at 25C. Reactions were
started by adding the motor to a 5 mM solution of Mant-ATP
(Jena Bioscience) in BRB80 (80 mM PIPES–KOH pH 6.9,
1 mM MgCl2, 1 mM EGTA) to a final active-site concentration
of 3.4 mM. After the plateau of fluorescence had been reached,
a 2.5 ml chase of unlabelled 100 mM Mg2+-ATP was added.
Mant fluorescence was excited at 350 nm and emission was
monitored at 450 nm. Stopped-flow experiments were
performed at 25C using a TgK SF-61DX2 stopped-flow
spectrofluorimeter. Syringe 1 contained the Kif1519–375 or
Kif151–375 single head–Mant-ADP complex, which was formed
by adding stock 5 mM Mant-ATP to 2 mM Kif15 in BRB80
buffer with rapid mixing and incubating on ice for 30 min.
Syringe 2 contained MTs at various concentrations plus 2 mM
Mg2+-ATP chasing nucleotide. MTs for these experiments
were assembled from pig brain tubulin in BRB80, stabilized
using 20 mM taxol and supplemented with 2 mM Mg2+-ATP
immediately prior to use. Tubulin was dissolved in BRB80
without nucleotide or taxol. Mant fluorescence was excited at
350 nm and emission was monitored at 450 nm. Data were
fitted to single exponentials to yield an apparent rate of Mant-
ADP release (koff in s
1) and an amplitude. Collected data for
MT activation and tubulin activation of Mant-ADP release
were fitted to rectangular hyperbolas using KaleidaGraph.
Data points represent the averages of at least three pushes on
at least two separate occasions.
2.6. Tubulin purification and polymerization into MTs
Tubulin was purified from bovine brain by cycles of poly-
merization and depolymerization as described previously
(Castoldi & Popov, 2003). Subsequently, tubulin was aliquoted
at 18.5 mg ml1, snap-frozen and stored in liquid nitrogen.
MTs were prepared at 60 mM. The MT concentration was
calculated as the heterodimer concentration (110 kDa),
assuming that all of the tubulin polymerized. Tubulin was
gently mixed with pre-warmed G-PEM buffer (100 mM PIPES
pH 6.9, 1 mM EDTA, 1 mM MgCl2, 1 mM GTP; all from
Sigma) supplemented with 20 mM taxol. Polymerization was
carried out overnight at 37C. For nucleotide binding and
ATPase assays MTs were used in the taxol-polymerized form
prepared without GTP.
2.7. Pelleting assays
Pelleting assays were performed in 50 mM PIPES pH 6.9,
20 mM NaCl, 2 mM MgCl2, 1 mM DTT. Kif1519–375 (1–12 mM)
was gently mixed with taxol-polymerized MTs (5 mM) and
supplemented with buffer to a final volume of 40 ml. Binding
assays were performed in the presence of 2 mM Mg2+-ATP,
2 mM AMP-PNP or 4 mU apyrase. Samples were incubated at
room temperature for 10 min and centrifuged in a Beckman
TL100 ultracentrifuge at 100 000g and 25C for 20 min.
Supernatants were removed from the pellets. The pellet was
resuspended in Laemmli reducing sample buffer. Super-
natants and pellet samples were run on gradient SDS–PAGE
gels (4–12%). All measurements were performed in triplicate.
Data were analyzed using ImageJ 143.u, Microsoft Excel 2008
and KaleidaGraph 4.0. To calculate the dissociation constant
(Kd), the Michaelis–Menten representation was used, with
MT-bound Kif1519–375 ([MTKif1519–375]) plotted as a function
of free Kif1519–375 ([Kif1519–375]),
½MT  Kif1519375 ¼
Bmax  ½Kif1519375
Kd þ ½Kif1519375
: ð1Þ
Bmax corresponds to the maximal number of interacting sites.
2.8. Protein crystallization, data collection, processing and
refinement
Initial nanodrop screening was performed with purified
Kif1519–375 at 10 mg ml
1 in the presence and absence of
Mg2+-ATP at 4 and 19C. The protein crystallized at 19C
in the presence of nucleotide and 200 mM MgCl2, 25% PEG
3350, 100 mM Tris–HCl pH 8.5. Seeding further optimized
the crystals, together with decreasing the protein concentra-
tion and the temperature. Improved crystals were immersed in
cryoprotectant solution [20%(w/v) meso-erythritol, 240 mM
MgCl2, 30% PEG 3350, 120 mM Tris–HCl pH 8.5] and flash-
cooled in liquid nitrogen. Data were collected to a resolution
of 2.7 A˚ at the European Synchrotron Radiation Facility
(ESRF). The structure was solved by molecular replacement
with MOLREP (Vagin & Teplyakov, 2010) using the CENP-E
structure (PDB entry 1t5c; Garcia-Saez et al., 2004) as a search
model. The asymmetric unit contained three copies of
Kif1519–375 with bound Mg
2+-ADP in the catalytic site posi-
tioned with REFMAC5 (Murshudov et al., 2011) by rigid-body
and restrained refinement. The structure model was improved
using Coot (Emsley & Cowtan, 2004) and further refined using
PHENIX (Adams et al., 2010) with noncrystallographic
symmetry (NCS) restraints.
2.9. In vitro assay for neuronal migration
We used a previously established in vitro culture system to
study the migration of rat cerebellar granule neurons (Bix &
Clark, 1998; Hirotsune et al., 1998). Cerebella were isolated
from 6–8-day-old rat pups, triturated to give a single-cell
suspension and then transfected with either control or Kif15
siRNA and control EGFP plasmid using an Amaxa electro-
porator and plated on polylysine-coated plastic dishes in
serum-containing medium. The next day, the cells were
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released by treatment with trypsin and were allowed to stand
in a solution overnight after removing the trypsin. During this
period the cells formed aggregates, which were plated on glass
cover slips coated with laminin in serum-free medium to
stimulate migration. For time-lapse imaging, the cover slips
were placed in an imaging station consisting of a Zeiss
environmental chamber and a Zeiss Observer microscope.
Serial images were captured every 2 min for a period of 4 h. To
quantify cell movement, the total displacement exhibited by
the cell body was measured using the AxioVision software and
was divided by the time taken for the displacement.
3. Results and discussion
3.1. Biophysical characterization of mammalian Kif15 motor
and tail domains
Human Kif15 is a protein of 1388 residues (Fig. 1a) with
an N-terminal motor domain (19–375) followed by a long
-helical rod-shaped stalk predicted to form an interrupted
coiled coil. A bar diagram of Eg5 is presented in Fig. 1(b).
Kif15 does not contain the conventional C-terminal globular
domain typical of many other kinesins (e.g. Eg5); it possesses
a C-terminal leucine zipper, a common dimerization motif
(residues 1359–1380). The C-terminal region has also been
shown to contain binding sites for the forkhead-associated
(FHA) domain of Ki-67 (Sueishi et al., 2000; Vanneste et al.,
2009) and for the nuclear protein TPX2 (targeting protein for
Xklp2; Tanenbaum et al., 2009) (Fig. 1a).
The internal region of Kif15 contains a
putative myosin tail homology domain,
which has been shown to enable Kif15
to co-localize with actin (Buster et al.,
2003).
We subcloned, expressed and purified
the Kif15 motor (Kif1519–375, coding
for residues 19–357) and Kif151–375
including the first 18 residues that are
thought to include the cover strand, a
short nine-residue N-terminal region
shown to interact with the C-terminal
neck-linker region. These two regions
have been shown to fold into the so-
called neck-cover bundle by forming a
small -sheet and represent a force-
generating element in several members
of the kinesin superfamily (Hwang et al.,
2008; Khalil et al., 2008). Finally, we
cloned the C-terminal tail construct
(named Kif151149–1388; Fig. 1c) using
Escherichia coli codon-optimized
cDNA. The identity of the purified
proteins was verified by mass-spectro-
metric fingerprint analysis, with a
sequence coverage of 65% for
Kif1519–375, 81% for Kif151–375 and 61%
for Kif151149–1388. The molecular masses
of Kif1519–375 and Kif151–375 determined by gel filtration were
37 and 39 kDa close to their theoretical masses of 37 and
39 kDa, respectively, indicating that the Kif15 motor domain
and the Kif15 motor including the cover-strand region are
monomeric, in agreement with other kinesins. The gel-
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Figure 1
Schematic representation of human Kif15 and Eg5. (a) The Kif15 motor domain shown in green is
followed by a discontinuous -helical region predicted to form a coiled-coil stalk domain (coloured
blue). The C-terminal leucine-zipper motif is shaded in yellow. The putative interacting regions for
actin (residues 743–1333), Ki-67 (residues 1017–1237) and TPX2 (residues 1359–1380) in the
C-terminal half of Kif15 are also indicated. (b) The Eg5 motor domain shown in green is followed by
a discontinuous -helical region forming a coiled-coil domain (coloured blue). The C-terminal
globular tail is marked in pink. (c) Bar diagrams of the Kif15 constructs used in this study.
Table 1
Data-collection and refinement statistics for the H. sapiens Kif1519–375–
Mg2+-ADP binary complex.
Values in parentheses are for the highest resolution shell.
PDB entry 4bn2
Data-collection statistics
Beamline ID23-1, ESRF
Detector ADSC Q315R
Resolution range 30–2.7
Space group P3221
Unit-cell parameters (A˚, ) a = b = 90.2, c = 251.4,
 =  = 90,  = 120
Completeness (%) 89.7 (86.5)
Rmerge (%) 9.8 (37.8)
Multiplicity 3.7 (3.5)
Mean I/(I) 8.6 (3.1)
Total No. of reflections 108223
No. of unique reflections 29592
No. of copies per asymmetric unit 3
Refinement statistics
Rwork/Rfree (%) 21.2/26.3
No. of Mg2+-ADP molecules 3
No. of water molecules 156
R.m.s.d. from ideal geometry
Bond lengths (A˚) 0.013
Bond angles () 1.60
filtration profile for Kif151149–1388 was heterogeneous, indi-
cating possible assembly into higher oligomers and/or partial
aggregation.
3.2. Crystal structure of the binary Kif1519–375–Mg
2+-ADP
complex
The structure of the Kif15 motor domain was solved by
molecular replacement and refined to a resolution of 2.7 A˚.
Data-collection and refinement statistics are shown in Table 1.
Kif1519–375 crystallized in space group P3221 with three
molecules in the asymmetric unit. The crystals have a
Matthews parameter of 2.4 A˚3 Da1 and a solvent content of
49.1%. The r.m.s. deviations from ideal geometry were
0.013 A˚ for bond lengths and 1.60 for bond angles for the
refined structure. The final model contains residues 24–375 for
molecules A and B and residues 24–372 for molecule C. Owing
to missing or non-interpretable electron density, several
smaller loops could not be built and are absent from the
model. Side chains for which no density was observed were
deleted from the C position onwards. The Ramachandran
plot shows that 94.3% of the residues are in favoured regions,
5.5% are in additionally allowed regions and 0.2% are outliers.
Since molecule A presented better defined electron density
and a more complete model than molecules B and C, we
subsequently use it for further descriptions of the structure.
The Kif15 motor domain shows the typical kinesin fold with
an eight-stranded -sheet surrounded by three major -helices
on each side (Fig. 2a). The crystallized Kif15 construct
contains the neck linker, which aligns with the catalytic core,
forming a small -sheet. Although Mg2+-
ADP is bound in the catalytic site, Kif15 is in
the so-called ‘ATP-like’ conformation. The
switch II cluster (helix 4–loop L12–helix
5) is in the so-called ‘upward’ position,
allowing the neck linker to dock to the
motor domain (Fig. 2a). We subsequently
compared the structure of the Kif15 motor
with that of the functionally related Eg5
(Blangy et al., 1995; Turner et al., 2001), using
the AMP-PNP-bound complex representing
the ‘ATP-like’ state of Eg5 (Parke et al.,
2009). Sequence alignment of Kif15 and Eg5
shows their high similarity inside their
motor domains, with 41.8% identical, 15.5%
strongly similar and 12.8% weakly similar
residues, which is also reflected by their
structures (Fig. 2b). Outside their motor
domains the primary sequence is at best
only weakly conserved, with 20.3% iden-
tical, 20.2% strongly similar and 9.8%
weakly similar residues. Kif15 has a deletion
of two amino acids and a single insertion in
the loop L1 region. In the case of Eg5 loop
L1 is interrupted by helix 0, while in Kif15
loop L1 is longer. Loop L1 is part of the L1–
L3–L5 cluster that together with loop L9
mediates the entrance of the nucleotide
(Song et al., 2001). In contrast to Eg5, three
residues are missing in the Kif15 loop L2
region. Four residues are missing in loop L5,
five in loop L8 (loop L8 is implicated in
MT-stimulated ADP release; Fourniol &
Moores, 2010) and a single residue is missing
in the surface loop L10. There is a five-
residue insertion in loop L6 of Kif15 which
is believed to influence the nucleotide affi-
nity (Kollmar & Glo¨ckner, 2003). In Eg5,
loop L5 is known to be important for inhi-
bitor binding, and differences in the length
of this motif in Kif15 (in Kif15 this loop is
shorter) explain why Eg5-targeting inhibi-
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Figure 2
Overall structure of the binary Kif1519–375–Mg
2+-ADP complex and comparison of the
sequence/secondary structure of the Kif15 and Eg5 motor domains. (a) Stereo plots of the front
and back view of the human Kif15 motor domain. -Helices are coloured blue, -strands green
and loops/turns grey. The switch II cluster (4–L12–5) is highlighted in claret and the neck
linker following the C-terminal helix 6 is shown in cyan. Mg2+-ADP is shown as a ball-and-
stick model.
tors do not inhibit Kif15 (Liu et al., 2010). In addition, several
other key residues involved in inhibitor binding in Eg5, such as
Glu116, Arg119, Trp127 and Ala216, are not present in Kif15.
Loop L11 is not visible in any of the three molecules in the
asymmetric unit.
3.3. Steady-state ATPase activity
We subsequently measured the kinetic parameters for
Kif1519–375 and Kif151–375 (Fig. 3 and Table 2). To determine
the optimal salt concentration, the rates of basal ATPase
activity were measured on varying the NaCl concentration
from 0 to 275 mM. The highest basal activity was measured
at 75 mM NaCl for Kif1519–375 and at 50 mM for Kif151–375
(Fig. 3a). The differences in activity were rather minor and
only decreased slowly at higher salt concentrations. The basal
ATPase activity was measured using ATP concentrations from
0 to 2 mM. The kcat for the basal ATPase activity of Kif1519–375
was 0.054  0.001 s1, with a Km,ATP of 40.5  5.4 mM (Fig. 3b,
red data points). The kcat for the basal ATPase activity of
Kif151–375 was 0.028  0.0004 s1, about twofold lower, with a
Km,ATP of 23.0  1.9 mM (Fig. 3b, blue data points), an almost
twofold difference but still similar to the construct without the
cover strand. Subsequently, the salt dependence of the MT-
stimulated ATPase activity of Kif1519–375 and Kif151–375 was
determined by measuring the rates at MT concentrations from
0 to 10 mM in the presence of
0, 50, 100 or 150 mM KCl for
Kif1519–375 and of 0 or 50 mM KCl
for Kif151–375. With increasing
salt concentrations the MT-
stimulated ATPase activity for
both Kif15 constructs decreased
significantly (Fig. 3c). The kcat
for the MT-stimulated ATPase
activity was 2.3  0.1 s1 with a
K0.5,MT of 1.1  0.1 mM for
Kif1519–375, and kcat was 2.1 
0.1 s1 with a K0.5,MT of 3.1 
0.3 mM for Kif151–375, indicating
that there are no differences in
the kcat values between these two
Kif15 constructs. Finally, the
MT-stimulated ATPase activity in
the presence of increasing ATP
concentrations (from 0 to 2 mM)
was determined (Fig. 3d). The
Km,ATP values were 33  3 mM for
Kif1519–375 and 109  20 mM for
Kif151–375. With the exception of
a threefold difference in the
K0.5,MT and Km,ATP values there
was no significant difference
between these two constructs,
indicating that the presence or
absence of the cover strand does
not significantly change the
ATPase characteristics.
3.4. Transient-state ATPase
activity
Mant-ATP is a fluorescent
analogue of ATP that for some
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Figure 2 (continued)
(b) Structural and sequence alignment of the Eg5 (PDB entry 3hqd; Parke et al., 2009) and Kif15 motor
domains. Residue 16 of Eg5 is aligned with residue 24 of Kif15. Identical residues are coloured white on a
red background and similar residues are shaded in red. The position of the ATP-binding pocket (N1–N4),
the switch I and II regions and the position of the neck-linker regions are underlined in black.
Table 2
Kinetic parameters determined for Kif1519–375 and Kif151–375.
Basal ATPase activity MT-stimulated ATPase activity
kcat (s
1)
Km,ATP
(mM)
kcat (s
1)
([KCl], mM)
K0.5,MT
(mM)
Km,ATP
(mM)
Kif1519–375 0.054  0.001 40.5  5.4 2.3  0.1 (0) 1.1  0.1 33  3
0.5  0.1 (50)
0.5  0.1 (100)
0.4  0.1 (150)
Kif151–375 0.028  0.0004 23.0  1.9 2.1  0.1 (0) 3.1  0.3 109  20
0.05  0.01 (50)
kinesins gives a fluorescent enhancement on binding at the
motor active site. Initial slow transient-state turnover assays of
Mant-ATP were performed by making manual additions to a
fluorimeter cuvette (Supplementary Fig. S1a1). As can be seen
in our crystal structure, Kif15, like other kinesins, purifies with
Mg2+-ADP in its active site (Fig. 2a). Addition of an excess
of Mg2+-Mant-ATP initiates replacement of this active-site
Mg2+-ADP with Mant-ADP at a rate limited by the basal rate
constant of Mg2+-ADP release from the Kif15 motor domain.
We estimate this rate constant to be 0.017 s1. Once a plateau
of enhanced fluorescence is reached, addition of a ‘chase’ of
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Figure 3
Characterization of the basal and MT-stimulated ATPase activities of Kif1519–375 and Kif151–375. (a) Influence of the NaCl concentration on the basal
ATPase activity of Kif1519–375 (red) and Kif151–375 (blue) in the presence of 1 mM ATP. (b) Optimization of the basal ATPase activity in the presence of
increasing ATP concentrations measured at 75 mM NaCl for Kif1519–375 (red) and 50 mM NaCl for Kif151–375 (blue). (c) Salt dependence of the MT-
stimulated Kif1519–375 ATPase activity (red) in the absence (circles) and in the presence of 50 mM (filled circles), 100 mM (squares) and 150 mM (filled
squares) KCl and salt dependence of the MT-stimulated Kif151–375 ATPase activity (blue) in the absence (filled diamonds) and the presence (squares) of
50 mM KCl. Data were measured at increasing MT concentrations ranging from 0 to 10 mM in the presence of 1 mM ATP. (d) Optimization of the ATP
concentration for the MT-stimulated ATPase activity of Kif1519–375 (red) and Kif151–375 (blue) in the presence of increasing ATP concentrations,
measured at 3 mM MTs, in the absence of salt.
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: DW5063).
nonfluorescent Mg2+-ATP (Supplementary Fig. S1a) initiates
the opposite reaction, in which active-site Mg2+-Mant-ADP is
replaced with chasing Mg2+-ADP. At 0.005 s1, the rate
constant for Mant-ADP release is approximately threefold
slower than that for Mg2+-ADP release, indicating that Mant-
ADP binds slightly tighter than Mg2+-ADP but is nonetheless
a reasonably faithful surrogate and reporter for Mg2+-ADP
release. Preliminary stopped-flow assays were performed to
examine the MT activation of Mant-ADP release (Supple-
mentary Fig. S1b). Kif15 was pre-incubated on ice to load the
active site with Mant-ATP. The complex was then rapidly
warmed to 25C, loaded into the stopped flow and rapidly
mixed with various concentrations of MTs in the presence of
an excess of unlabelled chasing MgATP. The stopped-flow
data are preliminary, but nonetheless show that MTs activate
MgADP release from Kif15 motor domains 1000-fold. The
research papers
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Figure 4
MT pelleting assays in the presence of Kif15 motor or tail domains. (a) MT pelleting assays of the Kif15 motor domain in the presence of various
nucleotides. Increasing amounts of Kif1519–375 (1–12 mM) were incubated with MTs (5 mM) in the presence of 2 mM Mg
2+-ATP, 2 mM AMP-PNP or
4 mU apyrase. Samples of supernatants and pellets were analysed by SDS–PAGE. (b) MT binding of Kif1519–375 in the presence of 2 mM Mg
2+-ATP,
2 mM AMP-PNP or 4 mU apyrase. The plotted data relate to the amounts (mM) of Kif1519–375 recovered from supernatant and pellet (pelleted with
MTs) fractions of reactions run in the presence of various nucleotides. Data were obtained by analysing the SDS–PAGE (ImageJ 143.u) presented in (a).
(c) MT pelleting assays of the Kif15 tail domain. Increasing amounts of Kif151149–1388 (1–10 mM) were incubated with MTs (5 mM). Samples of
supernatants and pellets were analysed by SDS–PAGE. The plotted data relate to the amounts (mM) of Kif151149–1388 recovered from supernatant and
pellet (pelleted with MTs) fractions. Data were obtained by analysing the SDS–PAGE (ImageJ 143.u) presented on the left side of the figure.
apparent affinity for MTs in the presence of ATP was
consistent with steady-state assays (Fig. 3c) and MT pull-down
experiments (Figs. 4a and 4b).
Comparison of the steady-state ATPase kinetic parameters
of Eg5 and Kif15 show that they exhibit optimal in vitro
activity at higher salt concentrations (Eg5, 150 mM; Kif15, 50–
75 mM). The two motors have similar Km and kcat values for
their basal activity, but the MT-activated ATPase activity is
higher in the case of Eg5 than of Kif15. The affinities of the
motor domains for MTs vary similarly according to the type of
bound nucleotide (Lockhart & Cross, 1996), but steady-state,
transient-state and direct binding measurements all indicate
that the K0.5,MT is considerably higher in the case of Kif15.
3.5. Kif15 contains a nucleotide-dependent MT-binding site
in its motor domain, but not in its tail domain
We then determined the affinity of Kif1519–375 for MTs in
the presence of Mg2+-ATP, AMP-PNP and apyrase (thus
establishing the ‘nucleotide-free’ state) using the MT pelleting
assay. The results for the Kif15 motor domain are shown in
Fig. 4 and the Kd values as well as the stoichiometry of the
Kif15–MT complex are summarized in Table 3. In the
presence of the slowly hydrolysable ATP analogue AMP-PNP
or apyrase, Kif1519–375 shows comparable affinities for MTs,
with Kd values of 0.5  0.2 and 0.4  0.2 mM, respectively, and
a stoichiometry close to one (1.1 and 1.3, respectively), indi-
cating that one Kif15 motor domain binds to one -tubulin
heterodimer, in agreement with the results reported for other
kinesins. Under the conditions tested the Kif15 motor domain
shows no affinity for MTs in the presence of Mg2+-ATP (in the
presence of MTs ATP is rapidly hydrolysed to ADP, which is
known to possess low affinity for MTs). In conclusion, human
Kif15 contains a nucleotide-dependent MT-binding region in
its motor domain.
We then investigated whether or not Kif15 contains a
nucleotide-independent MT-binding region in its tail domain
(Fig. 4c). A second MT-binding site has been identified in a
variety of kinesin tail domains (Liao et al., 1994; Germani et
al., 2000; Kuriyama et al., 1994; Echard et al., 1998; Chandra
et al., 1993; Karabay & Walker, 1999; Meluh & Rose, 1990;
Narasimhulu & Reddy, 1998; Jiang et al., 2007) and has been
shown in some cases to be physiologically important for their
biological functions. In our hands Kif151149–1388 does not bind
to MTs in pelleting assays, indicating that the tail does not
contain an MT-binding side. This in contrast to human Eg5,
which has recently been shown to contain a nucleotide-
independent MT-binding region in its tail which is implicated
in MT cross-linking and sliding (Weinger et al., 2011).
3.6. Functional comparison of Kif15 and Eg5 in a non-mitosis
scenario
Given that the mitotic spindle is a rather unique MT
apparatus, we wished to investigate whether these two
different motors could accomplish similar functions in a non-
mitosis scenario. It has previously been reported that Eg5 as
well as Kif15 are both enriched in the populations of neurons
undergoing migration in the developing brain (Ferhat,
Kuriyama et al., 1998; Buster et al., 2003). A role for Eg5 in
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Figure 5
Depletion of Kif15 results in faster moving migratory neurons, which
migrate less consistently. (a) Quantification of average speed of migration
for control siRNA and Kif15 siRNA-treated cells (n = 11 and n = 12 cells,
respectively). (b) Quantification of the time period for control siRNA and
Kif15 siRNA-treated neurons, during which they exhibited consistent
forward movement. (c) Tracing of movements of individual cell bodies.
Table 3
Binding of the Kif15 motor domain to MTs in two different nucleotide
states.
Dissociation constants (Kd) and the stoichiometry of binding of Kif1519–375 to
MTs measured in the presence of 20 mM NaCl. Values for Mg2+-ATP were not
determined.
AMP-PNP Apyrase
Kd (mM) 0.5  0.2 0.4  0.2
Stoichiometry 1:1.1 1:1.3
regulating neuronal migration has already been documented
such that depletion of Eg5 results in neurons that migrate
faster (Falnikar et al., 2011). Here, we tested whether Kif15
plays a similar role by depleting it from migrating cerebellar
granule neurons using siRNA followed by time-lapse imaging.
We found that neurons depleted of Kif15 typically migrated
faster but less consistently, such that after a period of vigorous
forward movement a cell either remained stationary or
underwent a temporary stationary phase before restarting the
next phase of forward movement. Quantification showed that
the average displacement exhibited by neurons transfected
with control siRNA was 24.3  2.5 mm h1, whereas that for
neurons transfected with Kif15 siRNA was 63.3  6.1 mm h1
(p < 0.0001; see Fig. 5a). The average time period during which
neurons exhibited consistent forward movement was 2.5 
0.32 h for the control siRNA group, whereas that for the Kif15
siRNA group was 0.46  0.09 h (p < 0.0001; see Fig. 5b). This
phenotype differs from the Eg5-depletion phenotype in terms
of the consistency of migration. For tracings of the movements
of individual cell bodies, see Fig. 5(c). These observations are
reminiscent of previous studies on axonal growth and
guidance, in which depleting each of the two motors produced
similar but not identical phenotypes (Liu et al., 2010).
3.7. Kif15 and Eg5 in mitosis
The role of Kif15 during bipolar spindle formation in early
prometaphase reveals that it may – under certain conditions –
be a functional homologue of Eg5. Although their mechanism
of action is clearly different (Fig. 6), both proteins are able to
work redundantly to fulfill their similar roles. Homotetrameric
Eg5 performs its function because of its unique quaternary
structure that allows it to cross-link antiparallel MTs and, with
its plus-ended directed motility, to slide them apart to form
the bipolar spindle. It has recently been suggested that the
mechanistics of Eg5 function are even more complex, with
additional MT binding sites located in the tail domains
(Weinger et al., 2011). In contrast, Kif15 works as a dimer
(Wittmann et al., 1998) by crosslinking parallel kinetochore-
MTs (Sturgill & Ohi, 2013) and we demonstrated that it does
not contain an MT-binding site within its tail domain. The
function of the MT linker is most likely carried out by TPX2
through the C-terminal leucine-zipper region of Kif15 (Witt-
mann et al., 2000). Owing to their similar functions, Kif15 may
be able to take over the role of Eg5 following anti-Eg5
chemotherapy by simply up-regulating protein-expression
levels, at least in cell culture (Tanenbaum et al., 2009). Such an
interchange ability of the two motors, albeit not perfect, is
supported by our observations on neurons, which are non-
mitotic, suggesting a broadly applicable theme by which two
structurally different motors can be made to work in very
similar ways. If the scenario of a possible resistance
mechanism were true for certain tumours, co-inhibition of
both of motors, Eg5 and Kif15, could be a vital therapeutic
approach.
This paper reports the crystal structure of human Kif15,
which will be a valuable asset for structure-guided design. The
comparison of both motors revealed that despite overall
functional similarity, Kif15 and Eg5 have important differ-
ences, allowing Kif15 to be impervious to Eg5-targeting drugs.
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Kif7, a member of the kinesin 4 superfamily, is implicated
in a variety of diseases including Joubert, hydrolethalus and
acrocallosal syndromes. It is also involved in primary cilium
formation and the Hedgehog signalling pathway and may
play a role in cancer. Its activity is crucial for embryonic
development. Kif7 and Kif27, a closely related kinesin in the
same subfamily, are orthologues of the Drosophila melano-
gaster kinesin-like protein Costal-2 (Cos2). In vertebrates,
they work together to fulfil the role of the single Cos2 gene in
Drosophila. Here, the high-resolution structure of the human
Kif7 motor domain is reported and is compared with that of
conventional kinesin, the founding member of the kinesin
superfamily. These data are a first step towards structural
characterization of a kinesin-4 family member and of this
interesting molecular motor of medical significance.
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1. Introduction
Members of the kinesin superfamily of motor proteins (Kifs)
move unidirectionally along microtubules (MTs) in an ATP-
dependent manner. They perform various functions and are
best known for their role in neuronal transport (Hirokawa et
al., 2009) and mitosis/cytokinesis. Kinesins have been impli-
cated in a range of diseases, usually related to their role in
cellular transport, transport of pathogens and cell division
(Mandelkow & Mandelkow, 2001).
Human Kif7 and Kif27, which are members of the kinesin-4
family (Katoh & Katoh, 2004a,b), are paralogues. They share
44% sequence identity overall and have even higher identity
in the motor domain (61%). They possess an N-terminal
globular motor domain that contains nucleotide-binding and
MT-interacting regions, followed by a stalk domain predicted
to form a discontinuous coiled coil and a globular C-terminal
tail domain (Fig. 1).
Figure 1
Bar diagrams of the human kinesin-4 family members (a) Kif7 and (b) Kif27. The globular motor domain
(MD, blue) is followed by the short neck linker (Neck, violet), a stalk predicted to form a discontinuous
coiled-coil region (red) and a C-terminal tail domain (grey).
Both proteins are orthologues of the Drosophila melano-
gaster kinesin-like protein called Costal-2 (Cos2) that plays a
key role in Hedgehog (Hh) signalling. The Hedgehog ligands
[Sonic hedgehog (SHh), Indian hedgehog (IHh) and Desert
hedgehog (DHh)] are glycoproteins that play a crucial role
during embryogenesis (Bijlsma et al., 2004) and tumourigen-
esis (Magliano & Hebrok, 2003). Their signals are transduced
through the transmembrane proteins Patched 1 (Ptch 1),
Patched 2 (Ptch 2) and Smoothened (Smo). In the absence
of Hh proteins, Ptch-family members suppress Smo activity,
which becomes activated upon Hh ligand binding to the Ptch
proteins. These events lead to the activation of the transcrip-
tion factors Gli 1, Gli 2 and Gli 3. Direct interaction of the
MT-bound protein Cos2 with Cubitus interruptus (Ci) in the
cytoplasm is believed to be essential for its sequential phos-
phorylation by three distinct kinases, PKA, GSK and CK1,
and subsequent proteosome-dependent cleavage. The gener-
ated fragment, CiR, diffuses into the nucleus, where it co-
represses Hh target genes (Tay et al., 2004; Wang et al., 2000).
Human Kif7 and Kif27, which are putative ciliary motors with
roles in the primary cilia, a sensory organelle (Verhey et al.,
2011), have been shown to interact with Gli transcription
factors and are believed to fulfil distinct functions in regulating
Gli proteins. Kif7, a critical regulator of mammalian Hh
signalling, acts as both a positive and negative regulator in the
Hh signalling pathway but performs this role differently from
Cos2 in that it does not interact with Smo or Fu (Endoh-
Yamagami et al., 2009). The current hypothesis suggests that
Kif7, as a plus-end-directed motor, transports Gli 2 away from
the cilium, thus preventing its activation (Goetz & Anderson,
2010). In contrast, Kif27 interacts with Fu, which takes part
in the construction of the primary cilium (Wilson et al., 2009).
Kif7 and Kif27 seem to work together in vertebrates to fulfil
the role of the single Cos2 gene in D. melanogaster.
There are several reports describing Kif7 mutant alleles in
mouse embryos and their characterization has shown the
critical role of Kif7 in primary cilia formation and Hh signal-
ling (Karel et al., 2009; Cheung et al., 2009; Endoh-Yamagami
et al., 2009). One of these alleles carried a Kif7L130P mutation
and caused death of mouse embryos at the end of gestation.
In humans, various Kif7 mutations have been linked to
a range of neurodegenerative diseases, including Joubert
(Dafinger et al., 2011), hydrolethalus and acrocallosal syn-
dromes (Putoux et al., 2011). In addition, since inappropriate
activation of Hh signalling can lead to the formation of
medulloblastomas, rhabdomyosarcomas, basal carcinomas and
other tumour types (Goetz & Anderson, 2010) and given
the role of Kif7 in human primary cilia formation and Hh
signalling (Karel et al., 2009), Kif7 might also be linked to
other diseases such as cancer.
In our effort to characterize human kinesins of medical
interest, we report here the crystal structure of the human Kif7
motor domain to 1.6 A˚ resolution. We compare this crystal
structure with that of the founding member of the kinesin
superfamily, conventional kinesin (kinesin-1 family). This
is the first step towards the structural characterization of a
kinesin-4 family member.
2. Materials and methods
2.1. Cloning, protein expression and purification
Codon-optimized cDNAs for Kif78–361 and Kif271–341 were
purchased from GenScript and cloned into a modified pET-
M20 Escherichia coli expression vector carrying an N-terminal
Trx-fusion protein, a His tag and a TEV (tobacco etch virus)
cleavage site. The sequences were verified by DNA sequen-
cing. Subsequently, we cloned shorter constructs using the
following forward and reverse primers: Kif78–347, 5
0-CGTGCC
CAG TAA* ATC CGC AAC CGC GCC AC-30; Kif271–339, 50-
GCG AAC CGC GCG CGT TAG* ATT CTC GAG TAA
TCG-30; Kif276–341, 50-CT ATG GAA GCC ATG GCG GTG
AAAGTT GCG-30, 50-GT GGT GCT CGA TTA CTC GAG
AAT GTTACG C-30; Kif2717–341, 50-GTATT CGT CCC ATG
GTG TGC AAAGAAGCG-30, 50-GT GGT GCT CGATTA
CTC GAG AAT GTT ACG C-30. The Kif7 single point
mutation (Kif78–347L130P) was cloned employing the Quik-
Change Kit (Roche) with the following mutagenesis primer:
50-C GAA GCC TTC AAA CCG ATC GAT GAA AAC
GAC C-30. All proteins were expressed in E. coli BL21 (DE3)
pLysS expression cells (Novagen). Bacteria were grown in
Terrific Broth (TB) medium (Sigma) at 310 K to an A600 of 0.7
and were subsequently induced with 0.5 mM isopropyl -d-1-
thiogalactopyranoside (IPTG; Sigma) at a temperature of
291 K. Overnight cultures were centrifuged (20 min, 277 K,
3300g) and resuspended in lysis buffer. Cells were lysed by
sonication (eight cycles of 8 s on/off as 20 ml lysate fractions)
and centrifuged (1 h, 277 K, 31 400g). Supernatants were
pooled and the proteins were purified by affinity chromato-
graphy [1 ml HisTrap FF (GE Healthcare); buffer A, 50 mM
piperazine-N,N0-bis(2-ethanesulfonic acid) (PIPES) pH 7.0,
250 mM NaCl, 2 mMMgCl2, 40 mM imidazole (Sigma); buffer
B, 50 mM PIPES pH 7.0, 250 mMNaCl, 2 mMMgCl2, 500 mM
imidazole], followed by overnight cleavage with TEV protease
(0.05 mg TEV per milligram of protein). Prior to TEV clea-
vage, the buffer was exchanged to eliminate imidazole from
the protein solution (HiPrep 26/10, GE Healthcare; 50 mM
PIPES pH 7.0, 250 mM NaCl, 2 mM MgCl2). Subsequently,
His-tagged Trx and TEV were removed by a second run on a
His-trap affinity column. The final step of purification
consisted of gel filtration (Superose S75; GE Healthcare) in
gel-filtration buffer [50 mM PIPES pH 7.0, 250 mM NaCl,
2 mM MgCl2, 1 mM dithiothreitol (DTT; Sigma)].
2.2. Crystallization
All Kif7 and Kif27 constructs described above were used
for crystallization trials at 10 mg ml1 at 277 and 292 K in the
presence and absence of 1 mM Mg2+ATP. The crystallization
screens used were ComPAS, JCSG+, PACT (all from Qiagen),
Ammonium Sulfate Grid Screen, Sodium Malonate Grid
Screen, MPD Grid Screen, Crystal Screen HT, Crystal Screen
Lite, PEG/Ion, PEG 6000 and PEG LiCl (all from Hampton
Research). Kif78–347 crystals grew in 20%(w/v) PEG 3350
in the presence of various salts (0.1M magnesium formate
dihydrate, 0.2M lithium acetate, 0.2M potassium sodium
tartrate tetrahydrate, 0.1M sodium acetate, 0.2M ammonium
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nitrate, 0.2M sodium nitrate). However, the best crystals were
obtained in the presence of lithium acetate. All other protein
constructs did not yield crystals under the conditions tested.
2.3. Analytical gel filtration
Analytical gel filtration was performed to determine the
oligomeric state of the proteins (Superose 12 10/300 GL, GE
Healthcare; buffer 50 mM PIPES pH 7.0, 250 mMNaCl, 2 mM
MgCl2, 1 mMDTT). Experiments were conducted using a flow
rate of 1 ml min1 and an injection volume of 250 ml. Prior
to running Kif78–347 and Kif271–341 constructs, the column was
calibrated with proteins of known molecular mass (ribo-
nuclease A, 16.7 kDa; carbonic anhydrase, 14.5 kDa; oval-
bumin, 13.5 kDa; conalbumin, 13.0 kDa) and dextran blue.
The Kav values were calculated for calibration proteins
[(Ve  V0)/(Vc V0), where Ve is the elution volume, V0 is the
void volume and Vc is the column volume)] and plotted
against the log of the molecular weights of the standards. The
molecular masses of Kif78–347 and Kif271–341 were calculated
from the resulting equation. The identities of the proteins
were confirmed by mass spectrometry fingerprint analyses.
2.4. Data collection, structure determination and model
refinement
Kif78–347 crystals grown in 0.2M lithium acetate, 20%(w/v)
PEG 3350 on a microscale in hanging drops consisting of a 1:1
ratio of protein and reservoir solutions were transferred to
cryoprotectant solution [20%(w/v) meso-erythritol (Sigma),
0.24M lithium acetate and 24%(w/v) PEG 3350, 0.06M Pipes,
0.3M NaCl, 2.4 mM MgCl2, 1.2 mM DTT, 2.4 mM Mg
2+ATP]
and flash-cooled in liquid nitrogen. Data were collected on
beamline I04-1 at Diamond Light Source and were processed
with XDS (Kabsch, 2010) to 1.6 A˚ resolution in space group
P212121. The structure was solved by molecular replacement
with MOLREP (Vagin & Teplyakov, 2010) using the Kif3B
structure (PDB entry 3b6v; Structural Genomics Consortium,
unpublished work) as a search model. The asymmetric unit
contained one copy of Kif78–347 with bound Mg
2+ADP posi-
tioned with REFMAC5 (Murshudov et al., 2011) by rigid-body
and restrained refinement. The model was subsequently
improved with Coot (Emsley et al., 2010) and further refined
using PHENIX with TLS restraints (Zwart et al., 2008).
2.5. Determination of protein concentrations
Protein concentrations were determined using the
Beer–Lambert law with molar extinction coefficients (")
of 10 430 mol cm1 for Kif78–347 and 18 910 mol cm
1
for Kif278–347, taking bound ADP into account
("ADP = 2500 mol cm
1), or by the Bradford method. Both
methods yielded very similar protein concentrations, with
differences of <10%.
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Figure 2
SDS–PAGE of gel-filtration profiles of (a) Kif78–347 and (b) Kif271–341.
The left lane contains molecular-weight markers (labelled in kDa).
Table 1
Data-collection and refinement statistics for human Kif78–347.
Values in parentheses are for the highest resolution shell.
PDB entry 4a14
Beamline/detector I04-1/Pilatus 2M
Resolution range (A˚) 30–1.6
Space group P212121
Unit-cell parameters (A˚, ) a = 45.99, b = 79.80, c = 95.05,
 =  =  = 90.0
Completeness (%) 99.9 (100)
Rmerge (%) 3.2 (43.1)
Multiplicity 7.5 (7.5)
Mean I/(I) 30.1 (4.4)
No. of unique reflections 46998 (6746)
No. of copies per asymmetric unit 1
Refinement statistics
Rwork/Rfree (%) 18.25/20.67
No. of Mg2+ADP/waters 1/328
R.m.s.d. from ideal geometry
Bond lengths (A˚) 0.011
Bond angles () 1.547
Average B factors (A˚2)
Protein 27.6
Solvent 39.9
Ramachandran plot
Residues in favoured regions (%) 98.7
Residues in allowed regions (%) 1.3
Outliers (%) 0.0
2.6. Western blot
1 l cultures of native Kif78–347 and of Kif78–347L130P were
grown, harvested and lysed as described previously. Subse-
quently, supernatants and pellets were analyzed separately.
Supernatants were diluted tenfold. 200 ml of pellets was
resuspended and boiled in 2 ml 6M urea and diluted tenfold.
SDS–PAGE was run with the following ratio: 10 ml sample,
8 ml loading buffer and 2 ml reducing agent. Proteins were then
transferred onto nitrocellulose membrane (30 V, 400 mA, 1 h
20 min) in NuPAGE transfer buffer (Invitrogen) supplied with
20% methanol. The membrane was subsequently blocked
overnight at 277 K using a solution of 5% milk powder in
TBS-T (Tris-buffered saline/Tween-20). The blocking solution
was washed out with three cycles of 5 min washes with TBS-T
and the membrane was incubated in 1% milk solution con-
taining the 6His mAb-HRP conjugate (Clontech) for 1 h at
room temperature. After incubation, the excess conjugate was
removed by three washes with TBS-T (5 min each) and a final
rinse (5 min) in water. Finally, the membrane was developed
with BM Chemiluminescence Western Blotting Substrate
(Roche).
3. Results and discussion
Human Kif7 and Kif27 possess an N-terminal motor domain
that contains nucleotide-binding and MT-interacting regions
followed by a discontinuous -helical
region predicted to form a coiled coil
responsible for oligomerization and a
C-terminal globular tail domain (Fig. 1).
Mass spectrometry fingerprint analysis
with coverage of 56 and 49% confirmed
that the recombinantly expressed and
purified proteins were in fact Kif7 and
Kif27. Analytical gel filtration showed
that both constructs were monomeric
(38 and 36 kDa), as expected for kinesin
motor domains. Both proteins were
>95% pure as judged by SDS–PAGE
(Fig. 2). Of the seven Kif7 and Kif27
constructs used for crystallization, only
Kif78–347, which lacks the neck linker
region, yielded crystals. Kif78–347 crys-
tallized as a monomer with one mole-
cule per asymmetric unit. Data were
collected to 1.6 A˚ resolution and the
structure thus belongs to a small group
of kinesins solved to a higher resolution.
Data-collection and refinement statis-
tics are summarized in Table 1. The final
structure included residues 12–347
(missing regions: 107–114, 207–211,
230–241, 260–273) with bound
Mg2+ADP (octahedrally coordinated)
in the catalytic site and 328 water
molecules. The refined structure
contained 98.7% of residues in the most
favourable region, 1.3% in allowed
regions and no outliers. Fig. 3(a)
presents the front and the back views of
the overall structure of the Kif7 motor
domain. Kif7 contains an eight-stranded
-sheet core with three major solvent-
exposed -helices on each side,
displaying the characteristic arrowhead-
like structure typical of all members of
the kinesin superfamily solved to date
(Kull et al., 1996).
Subsequently, we compared the Kif7
structure with that of conventional
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Figure 3
(a) Overall structure of Kif78–347 in complex with Mg
2+ADP (ball-and-stick model). -Helices are
shown in blue, -strands are coloured red and loop regions are shaded in grey. The switch II cluster
(helix 4/loop L12/helix 5) and the end of helix 6 preceding the neck linker region (not visible in
this structure), which are thought to be pivotal for force generation in kinesins, are coloured orange.
(b) Stereo-plot of helix 2 residues 128–132. The 2Fo  Fc map (coloured in blue) is contoured at
1. A single mutation in this region (L130P) causes embryonic lethality in mice.
kinesin, the founding member of the kinesin superfamily.
Alignment of Kif78–347 with conventional kinesin (Kif5b)
revealed their high structural similarity (Fig. 4). The sequence
identity between the motor domains of Kif5b and Kif7 is 37%.
There are two single insertions in the loop L2 region in the
small three-stranded antiparallel -sheet of Kif7. The P-loop
or Walker motif (phosphate-binding region) is conserved in
both proteins. In both structures, helix 2 is interrupted by
loop L5, a highly important region for inhibitor binding in the
mitotic kinesin Eg5. Kif7 contains a three-residue insertion
in this loop. Although we could see some electron density for
loop L5, residues Ala107–Glu114 are missing owing to its
increased length and higher flexibility. In Kif7, the end of the
second part of helix 2 has a single-residue deletion compared
with Kif5b. Another two-residue insertion in Kif7 occurs in the
loop L8 region, which is fully visible in the structure. Only
residues Val159–Thr161 have an unclear density, which may
suggest a dual conformation of this part of the loop. In Kif5b
the switch I region (residues 199–205) consists of a small helix
(3a), whereas in Kif7 it forms a loop (L9). In Kif7 there is an
eight-residue long insertion in loop L10; this region is disor-
dered and is not visible in our structure. Switch II (Asp251–
Glu257), which is highly conserved in both proteins and
typically disordered in kinesins, is not fully visible in our
Kif79–349 structure. The switch II cluster (helix 4/loop L12/
helix 5) is in the so-called ‘down’ or ‘obstructive’ position
and one would expect the neck linker (Arg350–Asn356) to be
either unstructured or structured but in an undocked position
with respect to the motor domain. However, the neck linker is
not included in our protein owing to the short length of the
Kif7 construct used for crystallization. Kif78–361 contained the
neck-linker region but did not crystallize, whereas Kif78–347
lacking the neck linker revealed that the C-terminal residue
Gln347 shows crystal contacts indicating that there would not
be space for a neck linker in this crystal form. This might
explain why the longer Kif7 construct did not yield crystals.
The loop L11 region (Leu260–Ile273) is missing as in most
other kinesin structures. Kif7 contains a three-residue inser-
tion in loop L12 which is fully visible.
We also solved a mutated Kif7 motor-domain structure
(PDB entry 2xt3). Despite four point mutations (Kif7E226K,
Kif7R268L, Kif7L269R and Kif7H295N), the overall structure of
the motor domain remained unchanged (data not shown).
In summary, the structure of human Kif7 resembles that of
human conventional kinesin.
As previously mentioned, mutations in Kif7 alleles can
disturb Hh signalling, leading to death of mouse embryos. For
example, in mouse models a single mutation in the Kif7 motor
domain (L130P) caused early embryonic lethality at
the gestation stage. This mutation was introduced through
N-ethyl-N-nitrosourea induction
in order to determine the impact
on Hh signalling (Karel et al.,
2009). To understand how a single
mutation in Kif7 can lead to such
a dramatic event, we wanted to
investigate the structure of the
mutant. The construct carrying
the mutation was expressed in E.
coli but was insoluble (Fig. 5).
Nevertheless, the structure of
native Kif7 reveals that the L130P
mutation would be situated at the
end of the second half of the
interrupted helix 2 (Fig. 3b). We
speculate that the mutation of
leucine to proline, a known ‘helix
breaker’, could cause a significant
change to the secondary structure
of the protein in this region.
Another possibility could be that
mutated Kif7 is degraded or
aggregates in vivo owing to its
misfolding. Also, there is one C—
H— interaction between
Leu130 and Phe83 that is lost
when leucine is mutated to
proline.
In conclusion, we have pro-
vided structural insights into the
human Kif7 motor domain, a
kinesin that is potentially impli-
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Figure 4
Sequence alignment and secondary-structure elements derived from the crystal structures of the Kif5b
(conventional kinesin, kinesin-1; PDB entry 1bg2; Kull et al., 1996) and Kif7 motor domains. The
numbering relates to residues of Kif5b. Identical residues are coloured in white on a red background;
similar residues are shaded in red. The ATP-binding pocket and the switch regions (N1–N4) are underlined
in black.
cated in several diseases. In the future, it will be interesting
to determine whether Kif7 and its closely related paralogue
Kif27 are proteins that are worth targeting in the Hedgehog
signalling pathway (Sarangi et al., 2009).
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Figure 5
Western blot of soluble and insoluble fractions of Kif78–347 and Kif78–
347L130P. Lanes M contain molecular-weight markers (labelled in kDa).
